var title_f4_57_5008="Primary ciliary dyskinesia CT";
var content_f4_57_5008=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54505&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary ciliary dyskinesia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 331px; height: 243px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-resolution computed tomography of a 26-year-old man with primary ciliary dyskinesia demonstrating extensive bilateral bronchiectasis. At 10 years of age he underwent a lobectomy of his left lower lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Sten-Erik Bergstr&ouml;m, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5008=[""].join("\n");
var outline_f4_57_5008=null;
var title_f4_57_5009="Unstable midshaft fracture 1";
var content_f4_57_5009=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F67071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F67071&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Unstable midshaft forearm fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 406px; height: 453px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This 9-year-old child sustained an unstable midforearm fracture of the radius and ulna. There is approximately 25 degrees of volar angulation of the greenstick fracture of the radius on the lateral view (A) with dorsal displacement and shortening of the completely fractured distal ulnar fragment on the AP view (B).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paula Schweich, MD",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5009=[""].join("\n");
var outline_f4_57_5009=null;
var title_f4_57_5010="Nocardial brain abscess MRI";
var content_f4_57_5010=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78604&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nocardial brain abscess on MRI",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 256px; height: 515px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This noncontrast T1-weighted magnetic resonance imaging (MRI) sequence shows peripherally enhancing necrotic masses in the right cerebellum measuring 18 mm (blue arrow) and left occipital lobe supratentorially measuring 11 mm (white arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nocardial brain abscesses mimicking metastatic lung cancer. Infections in Medicine 2008; 25(11):520. Copyright &copy;2008, Infections in Medicine, CMPMedica. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5010=[""].join("\n");
var outline_f4_57_5010=null;
var title_f4_57_5011="High grade cystic duct leak I";
var content_f4_57_5011=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F58317%7EGAST%2F70108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F58317%7EGAST%2F70108&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High grade cystic stump leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 250px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP demonstrating extravasation of contrast with minimal filling of the intraheptic bile ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    High grade cystic stump leak after cholecystectomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 249px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAPkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwB1rF5S8dMVoxsFAOc49KpRf3v59alDFB/dxQBoiQKeTg4z65qRJskY78VmB2wOcenHarEcgyDu5PagDVR+h3VMkx6HJx29qzPOz0xThNnknAxQBr/aCDxj1zipobiNmO4EAdx1FZUQZ8MFwo5yasJPHGMAmR+/HH0oA3POjvECRyneBwGFViJEcqxXIrPjvnDDbgfhWhBeRygLIuD7jigBYWOBznmpRKV4wcZ9KR7TOWgOG69f5UkTMhxOSAOx70AdL4TtXuJJZdvyLx9a2dSillhdYmCnOMms3RtReGyAWNF3cjnpVK5u5JrsRbyAPmYZoA0SFtYCpfnbjI5rDlnCkMhY/XpT765JKxjGW5I61QcgMygjaf0oAuNqE+ODjJ4wBSLdylDmTPaqgzzjlu2R1qxHEwj+csBjoTz+VAD/ADjjDOSTUscbspYce7dKZboq4Y8tjqasE5yc84z6igAIjiGAQ0mM5I/pR9oYAckHpjNVpG+b7wB96j8wF8A9+tAGmrbupwSM4p6Oq4LHB6ispboRJncB7VA9yJH5Y47e9AGtNqGwkR+nUdTUD3LzfLKSQfTqKolvwB5pwdVHpQBJIpQbs7lPQipLX5iB0zzVPzWDHBPJyQecVZs5oy4EnDDgEcigDcspWiyqtn1z0q5FcPIeZMd8dKy0jLqTEepxyetTjTp5GVkYgLwxPBH0oA2bCUSahGnml+rY7Ct2sfQ7EW8jy5Vjjbnv6mtigD5UR++cY70NcdcHke9ZhnYtjnP8qehYkbiPYGgC8swJxg4A9asRSFnUg7h0A61mBwCQDu9eeBU6TM3C4A78UAbCyKRgsM5zjuamhnjzmMbvdqyUJIAHNWISSTzkdqANZrp3AG4bR0A7CkSQk8cjoO1VIxgD0/pU0Z+Zs4+g60AW0YZ5PbrVhJAoHPAqkhA6E4x2qZfu4PPbrQBqW1yYn3A/Ln5hWzcIl1CpUjKjNcxBklQeBx1ra0oO0rFN5jPQ+ntQB0NgFFmuBnHGKrRN+/mI55qxbxuPkGfmGRikjs5YnlcxfLnOTzQBlzs0l0SqkhT3qSO2aU5bPX6VLIgSVmf5iDn2pzXRAwgGfWgCRYEiUEHBHXNNkR/vNgr1Ax0qB5CQck5/rTo5Sowc496AHgkDgHbjj2pzOcdh3pgnB4ZeAMDbUMp7jkduaAGSv8+PT6VAZAucnk9xTJZVQ9CQeRzVC5uGJwDtUZ460ATy3ADc9BUSTZfOKznJH8Rz1J65qS3Yk5oA24Jgy9jjoSakLMRx07c96oW5O8HPX1q2jYz69qAAsTg8DnkVFK74GwnPtUsSM/A/yal8tVUqg5/Un60AT6TqBiwkxO7swP8AOuvS93RZypTvj6VwsSnzegyp5+ldFpW+a+S3BJDt8w9B60AdppcQis0IHL/Ofxq3SKAqgDgAYFLQB8ZRSk8DI+n8qsq+ByevWs+IkAY6mrUWccnFAFlWBAxz2qxByf6VUXGcdPxq1Ce+OegoAuR9+c1bhyp4Ydaz1YDJHJ/lVmJ84Hb3oA0EONwySM59MVMh5PcenrVWEOwyOh71ftoSOT9c0ALHuIwOR2zVmCE5+Zhg9QKcqKOMY+tTKASMZ6Z//XQBNHEjfKq4weveun0dFMamP+E4z6VzsRITcOp6YrX8P3IS4MR6Ngj60AdeDHCqHaMBeTU+n3VvPEZIyDk4OeMVmXpZoiUbgDBH8656G9+ywOIDgAnPvQA/WZFXUZREflzkDtVITc469zzVB5mJLZ5JJOfWjecEj8RQBomQAcYAqPzCWIz3/Cq247O31zQjBeevbFAF0Scfh0oMpOQP59aq+ZkEYwM9abLLtAAP4+lAD7h1ZOMc9vWsyQMTyCD61MzZI5H1prE7R+WKAK5BOd359cVZgTJ5xjpgVE4BYcY4xVy0iZnBAJ/xoAnjG05GAT/KrkUJY5f5QT+dJHBtJJBL+5xVhhgcnP0PFADQFAwM47UAg8LksegxUDTKHLSNhOxFQS6iTHi2G0dC/cigC2zx2+Dcy7BnlByx/wAK7HwP5V1HLdxxSKFOxXfqfXFeaW0El5dxW0ILTSttAP8AWvatHsV07Tbe1TH7tACR3Pc/nQBcooooA+JIX2sQSQxY988mriyDA57gcVl24yRyR0Ge1WpGcNAqTRW6PIBJcTIzJCn95lXkjpnHQHODjFAGgr8nParMJ7DP41VMU0V1La3cXk3UWN8YYMMEZVlYcMrDkMOCOavwRkf40ATxKWOOfpjFadpFk8L0PNVYVWM4HJ7gVcjkyV3c0AX4yFC8HNToxyfT0qor++Mc5qxCzMvQdxxQBYUgHkVNG25h0A9c1XXOfmYAnnikEqAdfb3PtQBdL7j7HpirFuRbzI7nBBGR6VmJOASyDp6etQySfPk9e9AHdm7aZBycEdqy76IqrAdHyfbNJot0J7dR1Ycc1oXduZom2n5xypNAHMFxzkc9D7UBwwyDkY7UMA0jAkI4OCuO9N2v3OfxoAkVzjgkVJG2B0P4VEEbH3T785pVznkcUATq3Uc8UsnPBxx1piKxHXFSHA6sp+n9aAI8Hdkj9KaVwCMEg1YRd5wCPxFWUhRF4OWP8RoApw229gZPlXFakYCKAqhQOgFMQqgyoGfQ9qa0oBy5wOoGelAE7NnPOOec9hVO5u0jQ+WWLdKrXV6z/Kp2r9KpSv8AKeMnvk9aAIZ7h5GILH6VahIEeD17YNZrSAMRxu9TW/4Z02TV9Rjt1+6x3O391e9AHX/DnRjl9TuU9Vhz+prvqitbeO1t44IF2xoNqj2qWgAopMHcDnj0paAPhqFxxztxWhbxFlBbIGOneoLO3A5OB3x/WtCMKOBwPegCaExi2itryTyrWHP2W72ljZEnJVgOWt2PLKOUPzL3BvRGSOeW3uovKu4sb4twYcjKurDhkYcqw4IqrEdo54p8bRxQxW9zJ5NtDn7NdFSxsiTkqwHLW5PLKOUPzr3BANKJgPbirCtuIwcdwPesq4ulsUuDqQNvLbANMm4MACMqwYcMhGCHHBBzVsXAQYGOeOKANRSR9/kD171N9pG4AsQB1C1j+bk5B47etLG4B+8QT3zQBqtNkAlsKPXil8zOctkAdSao+Z/DjPHepFyVXGcZ/OgC4sjSH/ZA4oDYwQ2FHr1os7d7ltkIwOpPpV+XSZIhuV92D0oAfoVyIb7bu5YYrtrQhlI45/SuJGlSRqJo3BcfNXTaLcmWFSw56HtzQBla/a+RdtIvRuv1rN3YPf04rrtXtvtETp/FjIPvXGklWZTkY4PagCdW7En86XeOPmOO3NQDJHGSfapo4jzux+NAEsBL/dHsasxqNxOctmoYVO87cYHX/wDVVjdgqeMZoAnUHBKjH05pdyqp+YHPT3qIuRgBufQetQvMcbTnP1/WgCaSbA74HfNU5ZTITzx71E8pYjJ+Xpwai3/gPSgCRmwOMHmoGO7IJ/WnOSVA74/Oop5AiE98evNAFaJGmulSMFpH4VBzk17j4M0NNE0xVcZu5gHlJHQ+lcv8M/DBtiurakhErD9yrD7o/vV6QQDg+lAC02Qtt+TqfWkkfy1y3Iz+VEbeYNwzjtz1oAcu4AZIJ7moftlt/wA/EX/fYrnfH2ujSNJaKOTZeXA2pjqo7mvHPtlx/wA/Vx+tAHnEZHUj8c9akWQ7yOorNSZlA6kipVmK5yflJ/CgDWjbnOPp7VL5+F4xkDgVlC4IPJ561IspPPBoA9A+E1x4UM8aeLryK2uYTJHZ2t9HsjiRwyuiz52OjbtwjONrZKgZNcveafJoeq3+jzMzvp8xhWRjkyR4DRP77o2Q/UmsvPmBg2Cp4II61b0DRoWvXW0jEXmAB9uQAB0wOg6npQBcD/Xip7ZQzgNwPzroX8LpEqhWd885PNWLXw5LC+4KXYDg+lAGL9naNeRgnv8A406KNpHCqBnrxzWrdwTRTxoYTJyAUU8keldEkp09VWGxHmP/AMs4V4B/2mPOaAMrT9Nu4LVrlonjgXG5iMCrvia2u9FlhLOJ7WdA0UwHB9j703WdQv5bd1kjm244RV4Fc3danfT2kdlc3DtBEdyo/Y0AbWl6j50giuGAxzx3rf0UxO7njk5HOMV54pyxKnpXb+CJopUaNgBKMZ96AN6ZMnGRwK4/VbZo75+CFbkf4V306Lg7MDB6dawdbtvPgJUHcvI9aAOdQBQMD+tKCAOlRqdqkD6YoLc5HHoTQBMpO7OelO3gHGeareZxkHntTHfGTnPY4oAtl89OlRPJ/c6VUMnHPT0pGk+UgZGPbpQBMzY5ycD1qIOS3GR61E0u0d8jjBNIZPlx60ATO/zg8Dvj1rsfA/hhtRuY9R1CM/YozlEP8Z/wrP8ABXhefWrgXM6bbGM5JP8Ay0I7CvX7cx+SsMKhFVcBR/CKAJHUSR7EO0DjgdqFby1O75UXv1pgzFhE5XqTRI8c6tGpR88MuaAFLR3K7VbI74qvqN9FpNlLcXBCwRjjHVj6U22thpyH96RAAXcv/CPrXlXi3xTFrmrBYDIbG2zsGMBjnBNAFDxZdXGs3puZueRt4+4PQVneW3qn/fJq+LgTS7SoVex9BVj7PD/z1P8A3zQB4C1woxt6+5piT5bLE5PP0qkgUj5iQK0IIk6ghieuDQA9G3EcYGewrQhycbuOcfSobSeNSyyRDGetdfpOnwyRI/lhyRnLHtQBnadp81ycqjKn9412ej2kVngbfm9TUttbKseANrdOf5VIqENkken0oA6CynyvzHuBV26uvJhJBAx2FYUEhABGMgdc1U1PUAsEgByxOPXFACajqMRDFXHmZ4x1qifENwuAsUJxxkg5rB8/EjMSWJ6ChZDKBsXAPegDoYfEt0p4igB7cGs64uJr26a4nYGVzkkDA/AVBBF3IyMVOowMnGev+fSgB8MQH3sdM1qaTI0Fys0ZKhe9Z2U6kgjsP8am8wggg4X0oA9FtZzKA27JPNTXADLg4zWNoNx51mhB56Y9MVquxxQBxmoKYLt0IOCSRVUtknkitbxGnKSAFcHG70+tc/I4XPegCwW+XPQY5NRmTcMDnioPMyCSev8AnFCsSe9AEpJzyc9zShgeh+nH86YpPcfQU4j1PPqKAEkYYwVFdP4M8KTa7cLcXCmOxRvmboX+lS+C/Cb6vOtxegpZIc47v7V6hHCLILHYx4hBwyZ+6MdqAJLJEsoI7KEYCDCkDAx71IymPiIZkbqTSNIoUKnzFu/fNJ5nkIFmbc56NQBJ56gCMkeb1xVSK3S1ufO2kPIeq0x0Econk5JOB71xXxE8YR2x/svTnDSt/rpQfuf7NAFT4oeLfODaVpk37sHE7qfvf7INcTpbIbXYBtK9jzuGazJmZ3x33dSec1dWzmidHUAZGdw7e1AGvHJFuVQp/wAK0fNi/uD/AL6rn42ZCu8jI67at7x/t0AeFFlynCkdcCtCCNWwUA98d/aufguMkYGBV+0u8ttzj0x2oA0vL2duc8V0OmapPbQKoyeex6VhRzwnJYgEc81chvLduN+D05FAHZ2Ovec4QxYZvSrdzqRiQEL83XmuQt5PLKurADrkVqpcrNFumfnoo7ZoAvvqkkkYLtsXqdprKnvZZpSVchemKZcuCdqngDtUUIxgdfpQBaQbsZq5EnTjn25xVNDjscnqO9WEb5QDnr19aALocEcH6U4PhR0/karK23knjoRmmmQY6demaALTMMdsn9aBICSegPtVMSEZJPTgc/ypjTdQM8+vSgDtPCl3iMxjse9dSJdwA7H3rz3wzcbZ3QnryK7e3lBXPJGKAK+sqJrd16kjPSuKV2U7cEjvmu6vBvjOcn0rgdSUw3r7eF68GgCTbncVPBHIzS/dB3A7vXNV1cMuBxnn/wDVU9tHLPIsUSM8jHAUdTQBIrbsYrvfBvhI3MiXWrRssPBSI/x/Wrvg7wfHZstzq0QeZgCI+oT613E/K7U6rwPagAnjCxqlv+7CAAbew9MU1LpTKIVb97jlfT3qKO452LlvVsUsypBh1AMh6HvQBIwS2y6kFmqtHLn5pztbOQp/nTLd5QCbwAjPymuJ+Ivjq2srd9O0oiS+Iw8oHEY9M+tAEnxL8bQadbnTtMZZL2QfO6niIdsH1rx9bhid0jlnY5JJ61TnmZ5GeRi8jHJLc5qLzQMAnrQBr/ah5ilmwOMt0rdkuisMJU71I6+9chI4KknpjqataTdtFdRpISYmOCD29CKAOhW6LOB5Skk5HUZq59pb+4tZQJWTA5/X6VazN/ek/wC+aAPAI+TkjgVbik2nPp6GqcTfLzUozgMMc0AXo3L9TjHQdauwHB9D0PpWXCCcdfX8a1bVMY3ck4oA1bWVyqrg7PStGJyq4z7gVnW7g4A4HNXImHTA9Dj6UAXFJOM+ueamTAxVUOVHrmpIpCQf0560AXY25HPHYCpfNIIHUD9KoiTJ4z9RT1bjk8UAXBLuJPH500uTnbz+lV1Y84Jz705RgY/GgBzueuTmhSR19euaZjjgg+nvS7c9elAGppEwivI2YHBOK9BtHyqkcnOK8whk2spB+YEGvQdGm863Rgeo5AoA1n5GfX371yXiO2+ZJlB4ODx1rr9oIGMEHjFWbTww2rZ+0kxW/c45agDgdF0i61i5EFihYnlmxwoHc1614P8AD1poyb1/e3OMNIy9PpWro+n2umW/kWkKxL0OOrfWrEp243HaM8Ad6AHztwwjJX/aNQI7M37k/L/ET1NHzSjcTtQHOOgNQm5DNstSrA8MT2oAlnlFuAsShi3oelMgWRVdpfm53DNMdY7OCSaWRERRuJc4xXlvjXxzNfBrLTG8q25Ejr1egDT8c+PlSOTT9FP7wgrLOOw9BXlFw5ky7ksx6k8k05myx9ueaqzvjIoAr3D7T+nNRwkkZbOeeKjmlG4ZJ5H50K+OPx60AWpWPl57getTQqdo5+bjOKqO26MY56Dp71oWkRNwqkHrk0AdCgMlwCR35wMcitHzR/cqjGNmHGTv5OetX90foP0oA+bYZCT3xjJqzGS4HJ/+vTYbcbvmGPQVbSMDbx+FAE1sQqAjA/Cr8b/JnPHt3qiow3GM1ZQ8At68UAX4ZDgZ4WrkVzjBzweAM5rIWY/lzxUizfMOgHY0Abq3ALcnJ9KPtBJzuGAPTmsdJuMDnjH0qWJ8tkk8ds0AbMc/J4wcVOjjqay4W2OM9TgYPar8bhR8x+lAFyKQHg43elT54549azC+TletW4JC6ZPXr1oAnJAPUjIzSdAcH86idguGJ5HvTVnDckjFAE0bAEYxx2rr/B1w08os4gZJh0VeuM1k+E/C+o+Irgi1iMVsh+e4fgD6Z617j4X8O6d4et0htIgbkrh52HzOfb0FACaJoqx4e+AaXGfL7D610G1c/dGDz0pjDB3HHpTXcsOMgjqKAG3EgQ/Lkt61DIyqivcMFPUL3NRz3UcOFUhmH6VTjtZbicm4J45U5oAniuWvSwUBFBxj1FVtVvbXQ4JLi5cR8Z93PoBWT4m8UWvh6FoItj3hHyovOD6mvIda1e71a5ae+naRz0Xsv4UAa3ivxff67L5e/wAu1XgRrwD7mubL8nGc9qYWGecH1zzmoXc8/wCNACyvgluMVRnkwpLdKklc55/AGqN3MVTA647mgCnPM287Bx6GmRyNuAJwfUVBvJc9fpU0ETySYxx3xQBtWUYMKnDHHIBPStrSEEnmyHkgcAVnWkYEIVck4rVsJo44GCMN/wB1sD7tAF0ygFlPJxgn0pv7z/np+lQm5jGdkYyD1bk0n26X/pj/AN8igDwmC/dQM8+laNvdCRQTjFczA3zAHoKvxzfL8hxQB0KspAPX2pzSDHXpWOs5Crk98fSp45C4+Yg8dqANBZCDknA9TUqyE4JJwe+azxIGxu/yalLgLnHHbFAGlGw+XBBqdCM7sD6+9ZkD54xgZ61cjfjryKALyTFcgYH19KliuMyBFOAcZNZ4kycA8+mKmj4we460Ab8RBHPXpnFSRnaPSsu3nxknPtXV+GvDV7ru6bi3s0+9NJ/ID1oAypI7m6bybKGSaduAsY3H/wDVXqPgP4ZpGkV74iJkn4ZbXqo/3q7Lwfo+maLZqmnwDzCPmmYAux9c+lb7sVJc5weOKAJ7cJGqxRKsaD7qqMACnuzABhjjv6VVkckKw6rztB60qzIVwSCT6UAXWIMYDEY61VM28MiHBFLBuZSGP0NQX17bafEZZmUMBkKepoArSwxWk7XFyyrEfvMxwAfWuG8XePUfdaaK3yDh5x1PsKxfiF4hutQKw+YY7c5PlqcZHvXCSS4XjtxjsKALEszyyGR3LyseS3WomlPc96gMhwOcd8UxnGTn9KAJGlOTj9aYZOcHH0qFn68jgVXmm2g5xu9KAHTyhT1DD0NZl0+S5/XviiWdsszc59qpMzTNtXPPrQAQBpCMHjuT3re0yNFjBbOMcZFZ1qiLtLfdB796lmvvLQlXwOwPegDYuL4QR7V+8egqvBcsJP3TEHPJrAkuWdizk5xk5NdBpbxJAufv9z3oAuLLM74K4OfpVnc392Ki2RHJZmBA6ZNWtyf3o/8AvmgD57EO2fA55q221R8+cc49KqmUEnAxULvuOwEAgc0AaO8bVUH5atxsCo5PHNYiTBEAJJxxzVuO8Urgkf59aANRZRwNoJqYSADk89cdqyY7nzJMEcD9akW53u2BxkYoA245SEA69xT5JiCMZHHJqlbzfIAT/n0qQSYPXPIxzQBoRHDZJPNamnW895cLDZxSTTMcBI1yTWPYvEbmPzxmLPI3bR+J7CvY/CkqaZY2s1lGk0k7Z+RSkcSj+IZ5Y+5oANB+H11Aqz6syCQfObNTliPc9q6/SJJQTbTIsaA/dQYVamt4zdXz3EMm13A3uTzUOrxrd2zRwuYVU4kdeCfpQB0mn6gqzC3iPmY+9J0AreW5RgQDlh+tcJYXdpaaesBkRHxhfb61d0G/a5OZG+YHB9xQB0jX4WZIgMbutW4LZI4hk+pBOaydSu7PTLGS6vJVSKIZyTg/QV5J4t+I9zqZa200tbWfTd0Zh70Aeo6t4xgt2e1051lnXhn6qn+Ncne6lJO7STyF5D3NcJ4fvG+yghuNx5Pc+ta0t0dhycUAYuv3Zk1Hk9Bxz3rIeY5Bz+VVdXvN9/Jk8A449azpLjGfr68CgDSkvQCQM5/lTGumZRnHr1rHaXD5PNBueM5xigDTmvGDEY56YFV3ny3Y5zWe8/JIyDSh92fToPegCZnLnODtHWpElQH5eABUG/CdBgdBVWa5WLJOP9lfU0AX5LhQpZiAO2e9Z7XW5xnIxwB6VnS3bOSzHnHFNjkzggEcflQBpNPyeRzxitbSbrcgDNnbxnPSuaBZsleh6Vq6IkpmKADkZGT1xQB6Bprxk4bG7oQK3/s8f98flXHWJ8llXIeQnJ9q3/M/6aL+VAHzTG8isWcnBoy3J7n9KrmUtxnFG87CO9AD5H2HK9c1JDcbclgfc1VDYHB796eZieo46YoA1reQAbh3HU1IsgBDD6YrLEm+PC8Y9ah8+TcCXPBoA6eKcKmAe1PMkuRjpXPJeMsnDZx0q9BdyMAM5J6AUAeo/C/wydennu73mztuPLHWRvT6CvY7Ozs47MW9srIhPJbsfSuN8Co2j6VAUjxAsILMP43PJP4Vu3viPydOBWNRPcN5cCkc5PfFAFu6nuo9RTT7VykagNJN7egNSeKL6O20o28MgS9AyjAZzmsm7t7m30F5LOXzLpBk7zy7d8+1YfhmDU9TuI/tMZLf8tHboB3oATT9L1S5ME9mzyDzA5LNwPXNdnqviHTvDMBYTx3F2w4jjORu9/avOviJ4pjsojoWg3JKCTM80bY/4ADXBw3DkZkdnf1JJoA67xJ4pv8AXbjzb+YlRgrEpwq/hWDJeHcCTye1Z7StnOc1GZmbgDP0NAHonhuXdp8TFuvNXdQuRHBJIDhVBJ4rK0R0GnwgZxtqzqis9nIoU5ZTgHvQBxbXRaR3zyxLU3zeD6mqu1hz/EDg/wCFKx28daAHO7bs5GO/rSBzjj/69RDJPfOe9TQx88j5vSgB0SF+T9cVZQEKWbt0FPSPC8gkCoLiXA4PA5zQBXupgCd3ArLmkLEsfTp7U+VmldiT9B6VGU4GT+OaAK0jHrxVm3+YL79aiMfHI6e/FTw7lZSBkigC4MjoMD6VueHITJeqw6RgkkdBVbS7A3jh5SIbfvIf6CulhNvBEIrRQka9SRy31NAFqEZuAMcFgc46VqecP75/Ksa0Lloyfugg59fatjMf9/8ASgD5kooooAKKKKAFBx0o4pKcMZ5oAenzAgfhXoHwi0GDWPFEQvQGghQyEH+IjoK4WBQH7Hjqa9S+FsMy24a2+Uz3SpI/dUA6fjQB7rLBHLHDaYRY0HIUY4rj71XufEsk9sFnt7aMJCE5w+eavXl/NFDq8wOwRr5SM3TJHb3rl/hvZ3WmXAd7syp5gdueSTQAeKPFM0O3T4bV5Z4yAQARyfaj4peIJvDXhG002yn2XmoANIVPzIo6j+lbUWNZ8W3M5jWM2mW8zbhWUDJyfUYr578Za5NrfiG6upXLxiRliU8hVzxigB1pfSA4bkk9fWt+BzIoP9K5SydW5JwQQcAZrqrV0MW5STxQA6Uk89RQjYwcD0603uCPypEG58849KAOw8I3QKPC2ODkCurdtybOCOwPQV5tY3Bs5Y5V6g9K7jTr5LmFXBBz1x2oAxvEGleWJLm2XIHLp6D1FcyMuRtHb1r02VTIuQMY7DjFcXrFgtnd/u1Aik+ZR6HuKAM2JCTgde5rQt02LnAH86rrsUEjA9vWh58ADp9DQBLM6jdnpzgDmsq9kJzk5HpU7vuPqPQVRnfe2OuDjNAEIOeD39alVdxx+AzUXR+lWYf73JzQAqW+5gMcd629K0yF3yV3EcHd0BrOtyN+eg+vSt2yuPsyqwCk46Z7+hoAtPZzmRQyBUHpwPwrQjt1UIoTvwKjsdRaZtsoXLcJjgZq017schkKke1AEYheOU7QSCeP8am2y/7f51EurpvIyAPUjP41Y/tZfVP++RQB830UUUAFFFFABT0O05xTo19vx9KVlwcfw0ASJP8AIQEyx6Y7V7z+z9bp/Z6zTFXa4lcIuPu7e9eDKiKMg89Oa9m+Dms/2Xotuu0uZbp1JA/1fGf1oA7D4m6Xcjw5crbzEeddgtgY49K5TwBo95/aF5Gs758xeCenvXV+Nbj+0dBvV3OXhmD4X0ri/C96tn4sPnTsiTYCr3z1FAHfatp974e+HniEkiW6aKV/NXrz0A/CvlWvszUJbW6gthK+EuDtkVudykYwa+RvEumvo+vX9hKu1oJmQD2zx+mKAK1pLscc4xXUWMxKKVI5HWuOBwQRWrp2pmJ1DIDQB0jHBIX+dTxj5TxgetULW6juCShAP93vVuM8j1PegCdGzn29DW14buRFcBJGAU9M9qyLePA59KnR8EY4+lAHptsQ0e5eprC8SwhrGR8cxMGz7Hg0/wAM35uLTyySzRnBPqPWpvEA36fe5/55/nzQBw00hxwR35qsHbsT7GhcfUdqazEcgcetADmfC4PNVN2evWnPJu+UE1Hnpn9aAHKNzY/rVtehB4FVocFskdu9T5+UngfSgC1ZZaZQuAexrbjTA3HDKDz6Vz0E2xww9eldToxjfejMpVx8uf4qAFSI/KUA24yPapHa4jhbJYr7irtm1tbBt7BiDg9yKklv7MgZGQc9ehoA5aZrguGHTOBxRuuvRq6nZayEFYoyCMZPPWj7FF/z7wfnQB880UUUAFKODmkooAeGII5OKlMijpVeigCfeMDAwfQV6P8ABy5ma+msY08xHIkbP8PvXmQNdP4A8QP4c8QQXwG6MKY5FPQgigD6i1O2srGKNZoPkvMRswHfFeZ+IvDUttrIlSN324YCMdMdCTXoOm6hJreipF5X751ynPftXV+GbJZdHVryMPdONkgYZwfSgDnPCZg1Kzija3R3PBDfwkd68r+PPg9mt5PEkERSaOUQ3S4+8OivXtFhoDaXrhmgkIUnOwDjmt/WNFt9Z0+6tdQiSSG4iMUi47H+tAHwLTlO1ga6H4geFrnwf4ou9KucsiNuhkIx5kZ6NXOUAalk+2RGVu+etdPCysp4wa4u2faetdBa3wFsCSC/0oA3lO0AucUNMBt5B+nasCW+aSMMpIIPrWvodjc34YxhsAZO4dKAOg8KXxgu3jfHzjt61v8AiG7EelTFjzJhBWNoulSK+94zu3YDDHFQeLbrdcR2yt8kY596AMN3x3yP1qKWUgcd6ZI2c56ZqKQjbjJzigARiWGT2p/T72fpUMfC4HX3qRDuYd/b0oAnQkfjUgOAOfb8KjA+bvmnYIHA4FADmY4ODxntVnTdRe3kWOU7oW/8dPrVbBIye/bFPEAbBKnFAG803mPv3bsdx1/GkEnmuVJ+U+nr6Vj2swhnjB3Fd2Dg9q6my0+BpvmLsOvpQBPokRaV5ZCfKU4C46ntiuh86H0jrG1CYQkRL8oC8KOMc/4Vm/aP9qT9aAPEqKKKACiiigAooooAKcjFT7U2igD6X+C+sR61o8Kq6rqNkojeMn7y9mr2iAN5pPATHb+9618S+B/EN14b1u11C0Zh5bDzFH8SZ5H5V9paDqVtq2lW97ZMsltcIHVuuM9j7igCVonublPm2wLxu7mtpAvlBRn2yKihiXywoBwv51ZXGzHOO1AHkfx78BnxXoC3VhHnVbAFo8DmVO6f4V8iTRSQSvFMjJIhKsrDBB9K/RC5HytXyv8AtI6VpUGr2t5YxiG/nLeei9GA6N9aAPFalWVtuM1EQQcHrTomCtlhnigCeKUg4B/SvQfCd1PPEkcbYVlwTXBQQGchYVJyfSvRtBtf7HgWcgOzD5Vz0PqaAOpnuY9GsAHZTOei/wBa4LVLozXUkr/eY59hXQXF1a3k4klb/SQOd3TFc54oijj2yQ4UN6d6AKxlUoSrZ57VVZjk9wOMHvWdFd+W3OCKvBhKu5e/egCVGyoH8Qqa3OTyRVRDh/m5X6VYts5BYH1oAt9P88VPHz8pPU+tZ88xBCr09RTVlJKsxIX1zQBs+Xk9sDHIqR2IQBRVOCbeohHc9fWrM7m3+Vs8jOTQBFFvZgSOc8nFdhZybYolAJfjJ71yGkubq/RMgoDlvYd661FZJgVwGPK4HXP/ANagB+sKS59KyvIf1SunktlnJcvlSOQex9arf2dF/wA9D/30KAPAaKKKACiiigAooooAKKKKALdmQHHSu38FfEvWvBs629vIJtOLAmB+QB3x6VwUZI6VZnj8yAP/ABDj60Afd/hbWbfWtKtr+zcPbzoGXnp6g/Q1vjp+FfJ37O3js6Rqh0HUJf8ARLpswFjwj+n419X27eagbsaAKmolxBIVUE7cge/pXyV8QrfU/E+s6lJcW0gNoxVSF4VQelfYmFAxjAx25rnNT8Pwz3cjCKMRzD58LyTQB8FTxPHIwKkDPpUtrYzXByFKp3ZuBX018YNB0zQPBFw9rZwowcFX2DIJNfN1u1zc3JRiSM8n0FAHU6Nb2VhaeZjzZP7x6Z9qj1LXrkp5aKqx9BxzTEdI4CoIwq/nWfKvmhnHCr0HrQBAt/MZcuxyetRalqTyQwpuJ25qtcnaDjAOM1nsSTk0AOLksW9TmtbTp1MRB6g8VjVJFIYzwaAN5yI0JPQUi37BwgC4PrUdwN8EJXjIGTVXyyrgDoDnPr70AaqOWcbh7VK+McAnHOarwEMQp4PrW5p8MTQt5vHGc+lAFbTo3+0IwxgGtW5t2nBIVjmnaesJfhl8vua21uoJE8uJRuXnnigDG061+yHaAN5PzH+lbsFzIHAyPu4yR0p0EVu5QgbWPUDmpXtlVgCwBHc/4UAMW4mKqVbIyR1zT/3v92H8jU1nbFXUs6ld3Rec10P2Yeg/KgD5lPA96Sg0u00ANopcGlxQA2ilxQAScDrQAlKOTRg5pVBJoAmiAwOMnmrltjo3PtVKPIIJzgVYiZgR0A70AK0L2t0ssLMGUhkK9Qa+w/gv4zTxT4aiFww/tC1AjnXPLejV8oxKJImByTj15rf8A+I7vwjriahaqTGRslizw6+n1oA+2xIOBkgkdDTZDkHORnPXvXNeEfEmneJtLi1CwlDcDcmeUPoRV7XZZYdIvJLdj5yxM0Y9wMigDwP9pTxVau//AAj8L7rhCssmDwPQfWvCdKkP2gLnHHNS61fS6lqF1d3ztJcu5dyeuc1Ts5SHkcDovHtQBoz7hkhjkk9DUU9y8cQwcAdvemW+6S5jQk4zzSamVLEAAIBQBTup/N6d+TValPtSUAFFFFAGxphaWDyyN2Bkf4U6WIjPZar6PdG3kIP3TV+7nSUv5YwCOBQBWt5tsqn+IduxrqYEDWPyEgsM4/pXHQPtbJ65xzXUaQ5YR5IweMUARozRrgcHPWtKB2+U8gHnPSr72MM8ZKKQV5I61LHYFY1SMF24wB3oAZFeyA42q2OM9DViTUCMDy8Huc1ctdIBJa4YIAOc9ajm0qPZu+0qevHegB2mXrSuqx5ySAdvpW/9tHpJ+RqnoejiO2lkEoYsNqkdx3NWv7IX++35mgD59K4OD0FIAM+uKl85Ccsp/OgSR88H8qAGqDnBFP8ALOMdvSlSRDjsamAUrweP1oAr+VgU5FwenSpWUZ57D1pVAUjAOPX1oAhcE9Bx605IySOKczAdASakjidirNwKAFWIfgKC8UeDnBqw6KwZT8o96ybhVSQqjbh60AadrqCI+D0PTIrbtplkXGV5HNcZWpplwwIGehwOeaAO98M61f8Ahq/F1pVyQDzJHn5XHoa63xf8ZdRv9Gks/saWzyJtMwbp9K81Ub13A4ao57D7XGi3UjlB0x2oA5a6l82Z2B+U/rREcIFXlmOWPpUt/CkM5jjBIBqOABWzzmgC1AfKfcTz6VVupCzkVJwobFVCckmgBKKKKACiiigB6OVNWLWQtcAse2KqVPbcHJ4GcUAWI1Pm7Tn0retJRDEoyeBWX5WJ9+T83Sp3dmwozwfSgDq/D98RcxnqQ2fXIrt5BAkgNrtEg52+gNebaUMLvXIK9xWi+ozxEZfLoc5IoA6jUBiVpCSDu69qpQXTSSqgAJbCkDtURna8gS4Eh8qQbsHkhu4rR0iKOHddzKSUxx6mgDq40KxRRx9AMdO9X9jf3x+lcxFqxa5Jzhs9O1bv2x/+eX60AfL1FFFABT0cqcgmmUUAXbeTzQUbr/OpZhtjPHrVCJirhlOCDWpdDMYzznmgDPjkCHLDPPQVIb2XflTgelVnGGIptAE8t1JIOTj6VBRRQAVd0/7rjGSTxVKrunnDj64oA37eQqgJIH1qxJcDyd3YVRx/IH8xTlcspVuQBQBj3hDTu2Ryaqlj09KtXKgSkDp/9ehUURk0AU3JPWo6fJ980ygAooooAKKKKACnxkhgAe9MooA245M7Ce3SrYfccH9KxLeRmIBPetaI5HP6UAaOkzrGzK+CCelW75VCFlOcjjFZtsoDsR2q5JzD9AWoA39Aj83QimSAsx/IjmtLUJPLMFtGoEaKGx6k81V0BQPDytj5mkYk/pVjUgBErgDdsB/EcUAJbXDGVSMbgQOR1NdR5sv/ADzP5muU0hRJqEQboCTXceaf7qf980Af/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    ERCP shows extravasation of contrast (arrow) with minimal filling of the intraheptic bile ducts.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael J Bourke, MBBS, FRACP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5011=[""].join("\n");
var outline_f4_57_5011=null;
var title_f4_57_5012="Submandibular space anatomy";
var content_f4_57_5012=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81946&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Submandibular space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 398px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGOAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiijIoAKKMijNABRRRmgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACsuW+EcjoTypwa1K5PXt0WqyAcB1D/ANP6Vz4mbpx5kbUIKcrM0zqaj+KnJqSk9a5GWRt3WpLeRtw5rh+tyOv6sjsBeqR1o+2r61gJI2OtOLH1o+tyI9gjdN6vrR9tX1rC3N60bj60vrch+wRui9HrS/bF9awt7etG9vWn9bkL2CN4XYJ61ILketc+sjDvU6SMR1q44tsl0EbYuB2NIbpR3rJDtiq88rAHHpVvFNIlUbnTRMHjVh0IzTqp6O+/S7Zj1KCrld8XdJnNJWbQUUUUxBRRRQAUUUUANkdYo3kkYKiAszE4AA6muL8M/ES08TRQ3mjaJrlxo09wbeHVFhj8mRg+wsF8zzQgOcsUAGDzWlaX93f+I/EUUQWaxsIYrVIGwFkuChkfLYOBskhHccmvIdJ+Gep6Z430G+8F6Pq/hO3ivPP1VJNVjmspoflLRRors7FsfxKoH4DAB7RH4r8OyW8U8evaS0Etz9jjkW8jKvP/AM8gc4L/AOz19q5bwL8U9K8SX2r2WoPY6ReWerTaXbwT3yGS8MZA3IpCnnP3Rn615JZ/DLxlZ6VpGjf2I0q2PjIaw92t1AI3teBvUF92RgkqQD0xnnC3Hw08YXuleINB/sF7Y6p4sbVo9Va6t/LgtwTh/lkMm/rgbP4u1AH0DN4v8NQXrWc3iHR47tZvs7QPexBxL/cK7s7vbrT08VeHnsr28TXdJa0sWCXU4vIyluxOAJGzhTnjBxXgXjT4YeLNS0P4oQWejiW41nWbe7sB9ohBmiRmJbJf5cA9Gwea2Ne8G+P7PxT8TdV8HW6Wc+qwWKadP50QMvloglCgn5G4YAsAPQ96APYrfxf4auNLudTt/EOjy6bbELPdpexNFESQAGcNhckgDJ71Y03xFompm6Gm6xpt4bUBrgW90knkjGcvgnbx6184az8MPF97Z/EYWWi6mE1mx0+KzXUtUhuLieSKSIyGSQysM/K55IGOBjgVr+Ifhd4q1LW/ETWVnHawXvhGDTIpjPGFe5RoS0RAJIysbLuxj3oA7nVPjDYr4uu9E8PwadrUUGiy6sL2HVYkhLozAws+CifdBLlsDPIp8HxctYfFWhaRrVrYabBqOirq8t8+qRvDASzL5YcDY4yvDhgDngV57eeA/F2qarJcp4Xl0+CPwNLoMccl3bHdc7WAVdsh+UluGOPfFTWvgfxbpGu+FNR/4RiXUo7HwcNInhjurYbbk+YCh3yLlfmGWXPB4zQB7yniDRnurS2TV9Oa4u4jPbxC5QvNGASXQZyy4BORxxXLa58SLCz13wdZaQLXWLPxFczWyXtreK0cXlgZI2hg/JIxkYxXlnhX4XeK/CmofD69ay/tT+zdNvLS9jguIwYHmMrIAXZQVHmgHbn7pwDxTPB/w28YaZovwrhm0pYbrQ76+nvQ9xEwgWRsxk7X+YH0XJoA930nxd4b1i+NlpHiDR7+8AJMFrexyyYHX5VYnipNJ8T6BrNwINH1zS7+coZRHa3ccrFAQpbCknAJAJ9TivBtB8EfEC58Z+BtX8TWWqXGo6bf3UmqX0+pwvb+W+BH5EQk+Rdo5ARSSec8Y7b9nXwDN4N8HKde0OzsfEbTTLJOFieZoWYFVMqE5XgHGewoA9aooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACud8Vx4mtJQOu6Mn9R/WuirG8Vpu0oSf88pVf8AXH9awxMealJGtB2qI5Gb71Otz81Lcrg0yA/NXiHq9DUi6U+o4TxUlBmFFFFABRRRQAoqePpVep4jVQ3JkT9qqz96t9qqz/erSexENzc0H/kD2v8AuVfqhoH/ACB7T/cq/Xs0/gXocNT4mFFFFWQFFFFABTJZEhieWVgkaKWZj0AHU0+uX+I8hbwxLp0blJdVlj01WBwQsrBXI+ke9v8AgNADvh1FIfC8N/cIUuNUkk1GQEYI85i6Kf8AdQov/Aa6aqgu7G2RY/tFtEiAKq+YoAA7Uw6vpoODqFmD/wBd1/xpXRXJJ9C9RVL+19Nzj+0LPP8A12X/ABqaO8tZf9Xcwv8A7rg0XQOMluievL5/jVoEZSWHTdZuNNk1ZdFj1CKOHyZLk9lDSByox97bj0zXqFfN9x8LPEhv9L8O6VbXMXhaz8Sf2z9ovkt1MaKTkI0c7tIDk7QYkIz83syTsPCPxC1OO7+IU+uGXULHR9be0t0ja1t/s8AB+88rxKQMDlmJ5+tXB8cvCzeGxrMcGpSxDVV0h4IVikdJmDMDlZCjIQpwys2e1Z2rfBEX8+qXA18LNdeIF1+JJbHzIVZc/upE8weYuCRnK/SoLr4GzXlnqMd14lQ3F94iTxBJImn7VDKHzEF808Ev1zxjoaAOkn+Mfhy007xFcahb6nZ3GhXUdndWcsKNM0smfLCbHZW3bWx83bnFUfh14x1zXvi7430nU1ubXTdPhtHtdPuY4RJbl4wW3NGWzk8/fbGe3Squu/BOLV7rxdcvrrxT63f2uo2zLag/Y5YN4GQX/eAiQ/3a6PwV4DvNB8c+JPFGp6zDqF5rccCSRQWRt0jMShcjMjkggDj9TQB3tFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABVHXI/N0i7Xv5ZI+o5/pV6mTJ5kLoejKRSkrpocXZpnn85yin1AqGL71TAE2kZPUDBqBThq+fPZRqQH5RU9VbZsgVaFIhiUUUUCCiiigAqaKoamiqo7ky2LP8NVZvvVZP3aqSnk1pU2Jhub2gf8gaz/AOuYq/Xl8/xIh0+yhs9Ps2muIkCNJKdqBh1wByf0rltS8Y67qJYPfPDGf4IP3YH4jn9a9SNaMYpBHLa1STb0Xme26hqlhpy5vryCD0DuAT9B1NczqXxE0a1B+zie6bt5abR+Zx/KvHXWR5N7sXc9WPOadHC3p1qHiJPY7IZXSjrN3/A7+6+J90zYtdOhjU9DLIX/AJYrGu/HniC4Y7LqK3jz/wAsoh/XJrnltjjB6U/7NxxWbqTfU6Y4XDw2ivz/ADLN1r+rXRxNqd2V74lYA/gKydQeS4udPt5JGdkD3rl2J9Yojz/28VeFv2A5qtDEJtR1GcD5RN9ljPbbCPLJHsXEjf8AAqE3ZtlTUbxjFef3f8GwxlyoP8XtSuu/HHPrVwQH0pRCag35ig8RPqfc0NESobIGPSr/AJJx0pPJ9qA5ytHcXNvg21xPFjujkfyrUt/FGu2uDBql0QP+ejb/AP0LNUzF7UnlAdqE2tiZKEviSZ1Nh8Rdbjx9oS2uE7lk2n9CP5Vu2fxNhLKt7p8iju0L7v0OP515uY6QpjBWtFVmupzTwVCf2T2zTfGWh35Cx3yRSf3Jx5Z/M8frW+jrIgaNlZTyGU5Br5xMZLFsdas2F/faY4axuriD1VHIB/DpWixD6o5KmVRf8OX3n0PRXkOl/EXVbUqL+KK7i6En5H/McfpXbaN440bU8KZjay/3Z/lH4N0raNWMjgq4GtS1auvI6iimo6yIHjZWU9GU5Bp1aHIFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcFImyORP7rsP1qiT81ad6MXN4vpM/86yn4avn5K0mj2YO6NC0PAq6Kz7M8VoDpUky3CiiigQUUUUAFSxVFUsfWnHcT2LH8NU5zgMfQVbP3ao3hxBKfRD/ACrSZMNzxraHvpy3IMjfzq4kIEgKowXvmqsORM8gG4Fif1q4LxsbMYJrqR7sr9C3FCrA7eamW3FVrebyyF3Ak9atvMAoweTVGLvccIBQY1BxUYmLTBQeAMmokm827Iz8opisya6uBp1pc3wUM9rE0yKejuoyi/i20fjVfTbFbDTLa3Zt5ijVWc8liByfqTk1X1NzcNaWucLc3ILD1jhxI3/kTyPzq7M/mTpEDx1NU9EZRTc2+2n6kyxqwyKXy1zjNI8giQn0qv5hRdzHJapNEmyz5Y9qQxAmolYqu5jSWrlw8rHjoKB2Y9ofamGCnJLmYLU6kGgV2ii8JFRmMitFSrkj0oaIUrD5jM2EUxkJPNaRhFMaCixSmZskeevNQvExXA6CtN4KjaIilYpTDRta1HRjmxuZIxnJTOVP1U8V3+hfEiGUJHrFuYn7ywjcv4r1H4Zrzt4vaonh44q41JR2Mq2HpVvjWvc+g9Pv7XUbcTWNxHPEf4kbOPr6VZr510++u9LuvPsJ5IZR3Q4z9R0I+teieGviPHKVg11FhboLiMfKf94dvqP0rohXT0eh5NfLZw96nqvxPRqKZFIksayRsrowyrKcgj1FPrc80KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOI1LjUNQHpLn8wKx5PvVs6oP8AibagP9sH/wAdFZEi/NXg1fjl6nsUvhRaszWmv3azLTitJOlZhIWiiigkKKKKACpohUVTxVUVqTLYlb7tZerPs0+5b0jb+Vab9KyNdGdMugOpQ1cwp7njiOyA7GwSakCyY8xkYr6gcVBpai4voIHOA7hSa9btozLbm3skhS2i+TDpu3HH+ea9CnS59T0sbjfq0lFK7Z5fHcBenWrH2rdtxk49K7LUPDKPuk+wDzev7pvlP4HBrW0mCC0t1SLRJVfGCTHnP41aw76s5JZrC2kdTzdLvE7k8cU2C42yyNnk11PiLwrPc3huLeNLYvyUdhyfwrkFtGj1Jba5bysPtkY9EHc/QDJrKdOUWduHxNKtG6dnbVEiTA6xMc/8eltHFx03yfvWP/fLQj6rU8dyPtSsT2xWDp1088T3jqUe8ke5ZD/DvYsF/AEL+FTiQg5FKT1NaNP3Lvd6/ebN3dfLtz3prXIa4jGflArJeUseaTzDkH0qbmqgrGxcXXyNz1pbW5AtgpPQ1k+ZuXmkWQp9KVw9mrGvFchbrLHg1bF2ASM1zbSHNL9oI7mncl00zoLO6yz7j0NXRcKe9cpHdFWJz1qRb7Hc07kypXOmMwDAetSBga5hb8785q5HqQPei5LpM2zg00oDWfHfqe9Xba7jbhjTuQ4tCNEPSonh9K1EEUg4Ipslt3WixKnYw5YapyxAcjrW7NCR1FUZovapaNYzNPwX4rutAu0iuHaXTHbDxnny8/xL/h3r2yCaO4gSaB1kicBlZTkEHvXznLGRmu++E/iBo7h9EunyjZe2z2PVl/r+db0alnys4MwwinF1obrc9SooorrPCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOK1j5devhjg7D/46KypD81bGu4bW7ggg/IvT6VkSD5q8Kt/El6nr0vhXoS2x5rSjORWTCcNWlA+QKyHImopRSUEhRRRQAoqaI1BUsZ5qovUmWxYYcVnajGZLaRAOSprRXkVFLHmtJq6Jg7M8U1OwfRtYguACbYuGVvTnkH6V6l4ddTDHjkMS361T1bToyJIp4xJbydiP0pmkEWMa26sxSPlWbriu7CVb+49x4+XtYxn20O28tSBxTwCBgGqFvc3EsYMUDOv94kAH86ke6ManzkMbe9dx5tnuZOtbjMAGrzLx+qpdaiEOJLiNLRecfNKNr/j5Xmt/wABr0O/vIkEtxM2IowWJrynUrl9R1e1Zyfm8y9ceuSYovyCz/8AfVZVXZHbgYOUn2en3/8AAuMW3GAB0qRbYGrKpUqpz7VxH0Vyj9mFH2UE1e2gnpT8ADA60C5igLUCnfY8itBFAGTTXbPAqkktWS5t6IzDa1E9pWqBTlj3fSpK5jDNqaYbc9q3JlUcAUiW4IJNCTY3NJGCYWzxSFHWtp4Av3RzUDQHNBSaMze6nvU0V2y9zU7w+1V5IPSlcqxoW+psvetiz1YHAY1yOwqakSRl6EinczlTTPQoZ4JxyRTbqzRlyprire/eIj5jWxa6wSAGaq5u5g6Mo6xJbq2Kg5FULK4aw1qxuozhoplf8j0rRmvVkU1m2kBv9bsbaMZMsyJx7kUuuhcfhfMfR1FFFeifJhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUU2R1jUs5AA70AOJABJ4FYOu65FZ27+WwLDrjtVLxH4jW3gdbf5tv3seleXXeqTprJ+0Nutp+hJ4BrCpVtoj08JgHU96ex0egalJeanfJcNl8hlz3X/P861rha4syNp2ow3S5Ij54/jjPBH1H+FduHSeBJYmDI4yCOhFeVWTUrndXgoNNbMpg4NXLeSqki4NPibaayMXqaqNT6qxPkVOrUjNofRRRQIKcvWm09RQhMsRGpduahjqwvSumJkyGWFHQqwBBrnL4Qi5VYBu2HJPbPp71o6tfFmNtbn5v42Hb2qnb22xSdpOBnAqJT5X7prCOnvCefdO24yyf99GtHT7proNZ3p3BxhW7g1RUQgLPMJI3B2hSM1BrweHRtQnhlMMkdvJIkq9UIUkMPoeaKdWUZJ3HJKStY474l3VxZzQ6OqN82JGcD/WA8DFcvZMr6jfyKQyCX7PGwPBSICPI9iVZv8AgddRpnjTTPiB8PjrZVIvEOj4Y2yn/luSFjAz1R32j2PHbnirW2m0Rhp13G8c1uBGwfrkDr7565716Na/U3wDhK0Y9PzZ0SsDUmeKzopsgVaWUECuc9JxsWF605Rkk1EjZqZThaaJYkp7Co6Vjk0lDdwSshyjLAU+Zti7RxTYvvUyc5Y0B1CJd3JqaU7QFFNhGMCmyH5zVN2ViFrK7GmonbsKWRsU6CPd8x6UkrstvlVwSAuu49Ka0K1NJL/AnShRxRK19Ai5WuyjJbD0qrLDt6Ctry91QT24APrUlqZhMpFIGK9DV2aKoBCXcKoJYnAA70GnmhBO2OtejfCDQ5LnUH1m4jPkQgpAT/E54JH0GfxPtTfCfw0kujHda6Whg4YW44d/94/wj9fpXpeqtFpOgSJZosKogihRBgKTwMfnmumlSd+Znj4/Hx5XSp6t7s0IbmCZ3WGaORkOGCsDtPvUtcRbwnSNQsJUOA+1GH+yxxg/Tg/hXb11HhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBDc3MdtGXlYAD1NcJ4g8SmaQwRn903AI7+1Z/xQvdQstSijORaTLmJx0JHVT71yVrcearK54bv/dPrXLVqu/Kj2sFgo8qqy1uaYlkWYrI2/upP8S1m6pZLNGYgOvzRH+a1eUmaMxPhJ0OVPYH/A0LiaNkcFGBwfVGFYHqJ21RQ0qc3lq1rN/x8RfdLd//ANfQ1q+GNR+yXX2CdiIJT+53fwN3WsHUUe2uEvIlw8bYkUf571euljvLUXEZyrgEsOx7N/SolHmVmOpBTVnszuJY+4qq3ymszw1rv2jbYX7bbxRhWPSQf41tzx1xNOLszzJQcJcshIZMVcRgRWYCVNWIZaRLRoKakFVkcEVMrUGbHVKgpijNTxrVxVyZMliXvVfVbr7Lb/Kf3jfKo96uD5VrAum+1ak5zlY/kH171rJ8qIguZ6jbWJY0MkpA7sxqZjGrrcC5Cqy4XJ4pszQSsLcyAPnpg4oWK1nVYkkUmPPAOa5zZu46FHE582cS8fdY5x+Fc38WtRGl/DjX7jeEZrVoVPvJ8gx/31XTW7QSu5jT5043Y6+9eBftO+KkkksvDNrJkxEXV3jscYRT+BLfitbUIOdRIyqS5Ytnl/hfVbnwvob6zZFVvJr+GKDeNyssJEzgjv8AObc/nX0J4a+Ingn4j2kUHiMQ6TrgXZ+8fYCfWOQ8Ef7Lc/XrXzb4p/0W30fTAMfZrNJZQO8k370k+4Vo0P8AuVgV7binucVOpKDvFn2Le/Di9hHm6Rew3kBGVVzsYj2PIP14rn77R9U04n7ZY3EQH8W3K/8AfQ4r558N+MvEfhplOh6xeWiA58pZN0Z+qHKn8q9U8O/tG+ILPamu6bZalGOC8ZMEh/LK/wDjorCVBPY9Glmc46SVzpkmNTJccYqzafGH4b68FOtWFzp07feZ4MjP+9GST+IrotP0fwh4jG7wz4kt5XIyIlmWRh9U4YfjWToyWx2wzCjPfQ5YS+9PEgrorzwBq8BP2dre4XttfafyP+Nc/f6XqGnk/bbSaED+Jl+X8+lZuLW6OqFSnP4WOicb6bIcvVJJCrA1IZfnB9akvlNCNvmFMfhjVcTgMKmeQNyKbZCjYhPL1ZJ8uDHc1AnL1PcjIWqvZCavLUjjGTk1YQVEgqzEOakbY5mESZPWsy4uCxPNTX0uWIFdd4F8FHUhHqOrAizPzRxdDL7n0H86qMXJ2RE6kKMOeZznh3wzqPiCbFsnlwA/NPJwo/xPsK9b8M+D9M0FFeOMT3g63Egy2f8AZH8NdBDFHDEscKLHGowqqMAD2FPrrhSUdep4eJx9SvotF2Cua1e4TUtQhtojuggfc7Doz9MD6DP4n2o1S+l1C5ks7RylshKSOOrkdQD2Hb3/AJzWlrHbRgIAMDFanCZniaQBwV/gXj8K7KuC1xvOvljX+IhPzOK72gAoqvfXlvY2zXF5NHDCvV3OBXF6l8TNKt2K2UFxdkfxY2L+Z5/Sk2lubUsPVrfw43O8orzWH4qQmQCfSpET1SYMfyIFdRofjHRtYlENvcGKc9IphsJ9h2P4GkpJmlTA16SvKOn3/kdFRRRVHKFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGX4k0W217SpbG7GA3zJIBzGw6MK8Kure50vUZ7O8QrcwNtYdmHZh7EcivomuR+IPhhdcsDc2iAanbrmMjjzF6lD/T3rGtT5ldbnpZfi/Yy9nP4X+B5pbTGdVaPHmoOB/eHp/hVkkOn2mPJwPnX1X1+orDtJzFISQVIOHUjBU98+lbSSbT56EbT98Dsf73+NcZ7slYW8RZoS55+XDY/iX/ABFZWlSmxvHtJiGgl+5npz2/Gtdf3Ei7f9U33P8AZP8Ad/wrN1qx3oDCMDOUx2Pdf6ihji18LJLyx3viNys0eGjccHHb8RXQeH9eF432LUMR3q8A9BJ7j39qwdNuGvbTY5Au4T39f8DRe2q3kAkjyky8qw4KkVE4KaIqQU1yyO2lixVfJU1heG/EjFhZawwWQfKkzcZ9m9/eumniBGV5FckouLszgnCVN8shsU2KuRTA1ksCppYpSDUkONzo4TkVaSse0n4HNaUcoI61tA55ofeziC2llP8ACuR9aw9PXYm52GTyST1NWdclJhjhU/fbJ+g/yKiFqs9uqMQOc81NR3ZUFaNxLiWCG6CeQzM3VgemaLY24udqxSq3IBIGKnjjjkB8vmSP5cuMAkdDReXSWNm9xdEYjXLbRkk+g9TUWuNeRhePPFNh4K8OT6ldYZ/uQQ5w00hHCj27k9hXx/atP4r8YpJqUxMl/deZcy/3EJy7fRVyfoK674nnxd4v16S/u9IvUsospa26rvESfh/EepP9AK5fQoJtMsdcv7mKSGWG2+yRB1IPmT5Ugj3iE/5V6+FoqnHzZx1+e+qaRla7ftqus31+6hTczPLtHRckkAew6VRoorqOcKKKKAPRPg/4LtvFN/cXGpbmsrUqDGDjex9fYV9Kab4b0uxtkh06ztoosYOyMD+VeDfs765DZ6xe6ZO4U3QWSLPdl6j8iPyr6PtZwJmRuR1BHauSpdysz3sGoxoKUFrrcIobq3H7i9nj9gcj8jkVcXV7qBQlz5MxI7qVLfln+VTgxlckgCmRRRy3W4YKqpH4mhJrZhKUZ6ziZd7Y+H9TBN3YPaSn/lrEu3n8P6isS/8AALtF52jXkd0n9x8A/gen8q7KS1BHSqItXgut9uzRsVOSpxn60mu6KhK38OVvXVHlmo2F3p8xivYJIX9GGM/Q96gSTjBr2Br8yxGDVbRLqA9TtBP5Hj+VY+oeC9J1RDNo1z9nlIyIydy/keRUezv8JusTy/xVbzWqPO0k5zVrzN6j2qfWPDWqaSxNzbM0X/PWP5l/MdPxrLjkKn2qHdaM2XLNc0XcvhhVmI5Un2rO8wHBqwkwCnmgTRNo9i2ra5bWSkjzpApI7L1J/LNe/wAMaQwpFGoVEUKoHYDpXknwngWbxNPK3JhgZh7EkD+RNevV14eNlc8TNKjdRQ6JBTJn8uGR/wC6pb8hT6yfEur2ejaXLPfPhWBRUHLOSOgFbnnRi5tRirtmP4eA+zhifmIyfrWjeTCGFmJ5ry601/XZwDptmTEOMiNm/XpTm8U38Uoj1i1dFPcKVI/A9azVWLdrnc8srpX0v2vqdhpkbX+u23dVfzW9gvP89v513MsiRRvJIwVEBZmPQAdTWJ4Rs4o9PW8R0le5UMGQ5AXsAf5+/wBKg+I139j8IXxU4eUCIf8AAiAf0zVt2Vzjp03Ooqfd2PPr25vPHviJo0dotPgJ2L/dX1x/eNWZ4NK8P3Yt0gM9wFyFVPMkPv7D8qd4NRtN8PNekhVkLO5xzgf/AKj+dY8dwzWrXc5/fXGZpG+vRfoBgV87VcsbWnTbajHt1PpkteSGkVpY6Wy1rTbuVbXUdOeLzTtTz41Kk+mQTg/Ws3W/CttPJI2kjyZVXcEz8re3tWVqZaPTZTn5lQPn/aGDn867/TVTzpw+BwCK5cTGeDnD2MrIyk3Q9+DIvhh4jm1K3m03UGZ7u1GVdj8zJnGD7g4/Ou7ryPwd8vxNuBB/qz5u7H0/xr1yvqKE/aU1LueTmNOMK146XSYUUUVqcAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAea/E3wu259c0yLLgZu41H3gP4wPUd/bmuE066EZUdY2+7np9K+hSARg8ivHfH/hgaHcteWcf/ABK7hvmVf+WDnt7Ke3oePSuWtTt7yPcy7Gcy9jU+X+RRUAJ5T5ML/cYdvb6inAZDQTnJwDuHf0YVn2FzvUwSt15B/kRWimZAY2wJo/unsf8A6xrA9Jqxi3iyWV0LpR8y8SAfxA961t6ELcxEGKQDfjsezf40y4iF3B8q/vFBG09x3X61m6TcfZrg2c2Ghkzsz057fjSK+JeaLep2CXEZkUDev3vcVFpviG68PbIr9HuNNbgMOWj+nqPatGPdE/lkkjGUY9x7+4qC7topomglX9zLnH+yfT+opSipbktKS5ZbHVW1xbalarc2MqSxMMgqf5+hqJ4ypryaC51HwrqrtZyEKD80bcpIPcf1r0Pw54t0/XAsMhFren/lk54Y/wCye/061yzpOOq2OKpRlT80bkDla0IZSRVNoCpqeJSBUJnPKzIb1zJfRj+6v8z/APWq4EiMkbuGUoM7ui1nMc6g2fYVom3aWJo5XAy2R9KTFLZEo3K8k00v7vHAz8oHrXIahcya7fL5JIsoj8n+0f7xq/4hvS8qaTadMDzWHp2Wp7DTvIjUx8Oe3Y110KdveZvQgl7zC1sFiQDHNc/ruh2OveIIdOvLWKa0tbf7RMrqCGklbbHn3VY5D/20rtktZ9oy0ZNZXhe0lkl1TUbmNkku7xyiupUiOPEUfB6ZWPf/AMDrrUepdSrdqPT/ACOB1f4OeGbuN1gtWtZOzwyEEfgcj9K8O8f/AA81PwjK0rA3OnE4W4Ufd9mHb69P5V9kNb5JrO1bS7e8tJobuNZIXUqysMgj0pqUomc6NGsrNWfdHwnRX0V4n+CGmTRtJpE0tlMRkITvjz9DyPzrwrxJoOoeHdSey1OExyjlWHKuPVT3FbxqKWiPMr4SpRV3qu6M+1uJbW4jntpGimjYMjqcFSO9fRfwr+J8OtyR6fqgEGp7cKwPyzYHb0PtXzfT4pHhlSWF2SRCGVlOCCOhBpTgpBhsTLDvTVPdH3fb3SyKCDSvcMl3GY/mJGCM18yeEfjLqGnJHBrcH22JePOjIWT8R0P6V7L4J8Z6T4p3zafOfMj4aKQbXXPfFc8lKO57NKdGt8D+XU9GjnkbAMRHvkVJwfvcdqy45wehqzBcA9eVPBqlIylSa2LE0KbSeKy205EXIBEuc7wcEfQ1qQsq5AxweDTp8HyyMZLbTQ0mKFSUHYpW+o3trxKRcx/7XDfnVLUNJ8P647b0NjeH+JcJk+/8J/nWvLbAAk8AVQNur5bAI6UndaMqPJJ80dH5HHap4F1az3NahLyEcgxnDY/3T/TNcvcJPbSGOeN4nHVXUgj8DXrcMtxaD9xMVQfwNyv5dvwqRr6K/h2appsU0fOCAG/HB6fnUOEX5G0a1WO6Ul9zOO+Et+lv4neGZgPtMJjXP94EED8ga9orzKfw/wCHJJ1mtpbmwuFO9TGWGCO/IP6Gma54x1y1ZrfT1imjRf8Aj5MXzN74zjP4VtTkoKzOLE4aWKqKVNW9dD0XVNRtNLs3ur6ZYYV7k8n2A7n2rx24vz428YgSlktIkLrFnlYwQOfckj/IryXx38Ubo30kU8V3c3yHB+1KY1T6L1/QV3n7OkVxeaBqmv37+Zd39z5YOMARxjgD0GWapxFRqm2hUlTwrag+affov+CesZit4lXKRRqNqjoB7VU1nT4tV02S3cKSwzG391uxp9zHb3K+Y0yBYyQSegqzD5flJ5J3RgfKfUV5KbTuhKTi7rcy/hBqLm3vtKmJDwN5qA9geGH54/Orfxicr4btkH8V0ufwVqwvBxNp8TbuFeBMJAR9QH/pW18ZP+QBZ/8AXyP/AEFq9uLvC5pOCWPhJfaszCu/Mg8CCPojWmQfqvP86x5bCAMVCkKOwOBWvq0zP4GiQoVCWqDJ75AA/nWBdSzxxmKZcZIUyL0xnmvBy/8A5ePzPQpX19WJfwz/AGSRBL5iMAmGHPJx1rv50bEkytsjjGCfYVxTyxyXFrGjKd08fAPYMCf0Fdh4nuDaeGLpxjMibcD/AGuP61hmUPa1YUv61aM6124x7mb8ILc3Or6pqLjkKEBPq7ZP/oNeqVxHwithF4Ykm/innY59gAP6Gu3r6emrRSR4uYz58RLy0+4KKKKs4gooooAKKKKACiiigAooooAKKKKACvOl+LmgnwJr/iwWmqf2dot61hcR+VH5ryBo1yg34K5kXqQeDxXotfMj/CHxFL8I/G9jJp98PEN9rD3FjaJqxWCaEywkM0YlEJOFc/ON3A9FoA+gLHxXoV5ZT3K6rYxrbQR3N2klxGGtEddymYZ+Tjnmi+8W+HLAWRvvEGkWwvUEtqZr2NPPQ4wyZb5gcjkZ6189fEzwjfS/ELwnoGn3At5PFOkwafrUCfMyRWzRu0mRxnapUHPO0jvXUeNPAOvxeKPHM2k6INWsPEeix6bZMk8UY09kRU2uJGU7MjflAxyBxnmgD1G18TyS+N9U0Oe1s4bOys0uhef2lE0jA4zugHzooyfnPBxWBB8R9H8Q/EZPBenx2Orafc6W17Jf214s0eQ5QxFVBGeAc7u/SvNZ/hN4t8vxHYRsj/aPCtppUF80y7Zp4ihePGdwBClQSAMGug8C+FPEcfxV8Pa3feHJdI0vT/DEekv5lzbviZGJwBHIxKnPB/PB4oBO2qIfFmgT+GtU8v5mspSWtpvT/YPuP1FJZzG5QBcCdOg9fb/Cvadb0u21nTJrG8XMUgxkdVPZh7g14fqmmXvh/VjZ3YzIvzRSD7syeo/w7GuOrT5HdbH0eCxaxEeWXxL8f66l/d8ouYyeDiQdx/tf0NUdasw6C4gXHc4/hb1+hq3HcAgXKcg8SD9M/wCNPG2NvLYboZMhfp/drI61dMq6ZdC+tSjkLOnU+h9foatriVCkgK9mHdTWHexS6ZqC3EQLRsOf9pf8a2RIssS3MJ3KV+b3X1+opIcl1WzMvWrH7daNlf8ASoPQfeH/ANfrXGfZl8+NgMYYH9a9KlBZVkTl0Hb+JfT+tcr4isRDKLqDHlSnJx2b/wCvQaU2n7rOwtr+/wBPYKw8+D+63UfQ10dhf294g8psN3RuCKzNLZLyygkOCHQH9KLrTwv7yIlWXkEcEVMqSlqtGcVWgm9C+qZ1CX2I/kKvt5VpA8rkqi5Y5OfyrItLia2LNcRGUnHzA4PpSzC51GZfOGyFTkRg/qfWsY0JN2ZzulK+uxBodobi5lvJRlpWLfSuoRAMHHQYqC3tkiiyuVIHarKLtjViSxI6mu9KwTkugjSLGOTiojcgj5SDSy5Nc9r8xs7KWaI7XJVB1xknGTiiTsXTpqW5rSXREqrG3JPI6gCpRcqCBKd2fauESWJv9ZfXTP14lKfoMU55XRd0WpXQx2Zg4/UGo5zo9jHY7WZhIxJrntb8M6VrgA1SzguUQ5QSIDtPc1nW11qmxGa6gcHnY8ZHH1B/pVyHVbuBCJ7ON0HQwzA/oQKV7lKHKrJnlXxM+EtpHp8t/wCG4TDcRLua3UkrIB1x6N/OvBTX2XPr8Mtqzm1uwCD/AMs9wJ9MgmvlDXND1SPULuZ9MuY43lZwAm4KCSQMjNb0Z9GzzMwwyVpwj62DxTo0WkNpxt5JJI7qyguSXxwzxIzAY7BmI/CszT766066W5sLiS3nXo8bYNdR4yUyeFfCNyylZDZvG4PX5ZpEHb0QVx1awd1r5nFiYqnNcmmkX87K/wCNz0zSPjL4is40ju1t71RxuYFHI+o4/SvXfCPxQ0TWLYB7uOznxzFO20g/jwfwr5WoqZUYvbQ1pZhVhpL3l5n3Vpt2GhDbi27kEDNXmlMjIDkKDk+9fPvwX+I0awQ6JrVxsmT5beWQ8OOyk+v8690ivYpEBDCufWLsz1YuNaPtIdfwNfCtCzbmYp82GbINTL5cgDY6jqKwpb3jy4eWbjPpV+CR1jVQyMoGMg4qlIznRaVx8lunmjzGZozxtJ4zT3iz2GKa+ZF2kjB60+E7cgykgHuOaZLbsV2iAm2nGWXjPtVeWBTkECm6zotlqjpJPLfxyoCFe3vZoMfUIwB/EGufbw3MCfI1rV0XOM/at/H/AANWqWkaU5SZ59+0L4etZvDK6rHGou7R1BcDlkY4IP4kGvRfhHpg0r4b6DbEbWe2E7eu6TL/APs1cb8S9Dv28KXkL65eXYlKRLFcRQ/MzMABlEU9cV3A0vxLZafHBZazpzxwosaiTTmztHA5WUD9DXPiH7ijfqc2Kj+9Urbr9TeltIfJMKOu8ndgnGasW8QghSMc46/nXNn/AISSF43lXQZ5tvBaSWDJ7HGH/wA/lUsN54phU/a9DsZcng2+o54/4FEtcnI+hjzFXTyIfivbnoHP84iK2PjNKBpWnw5+Zpi2PYL/APXrhvEOrarpfiWx1mfw7fJGjIflmhcEqeRkPkZHtVXWvFdx4j1KLUNY03UbTTIjt+W2aRVGeRlc5J9a9OFRQo3Z3Rgp1adZ7RX46nT+IJ5W0LSdPjiCyMsedx4KoAT+oA/GstXnmkMewRkH52Y8D/GsufxVZy3811fLeWzN+7ijntJY9iDoPmUcnrUEfijSBcs39pWaK+PleZVYn6E5rhwlCVOn7y1erOiEoJWujobK2SbxBYRxRqAC8hIHOAuP5tWp4zjm/sqOAyZDSDA6dP8AIqh4M1GwuNfmuEureRUhWNdsgOSxJOOfYVo+MZxd3trDFzyenqSBXm13zY1d1/lcxq1Gpprod/4Osjp/hnT7Ygblj3N9WO4/zrZpsSCOJEXooAFOr6tKyPnZyc5OT6hRVPWdTs9F0m81PU5lgsrSJpppWBO1FGScDk/QVzfh3x1DrdraX39iazYaVdxGeDULtIRA0QUv5jFZGMalRkFwucimSdhRWL/wlWhPDaPbazpk7XqSPZLHdxk3QQHd5eD8+Mc4ziua+FfxO0rx3oGnXckljpuq3nmlNKN8ks+1HZdwGFYg7Sfu0Ad/RXlnhv4rXGux6VLDodrDHeaxPpUnnatFG0Yj2/vEV1Uyk5PyKMjHXmu2tPGPhm8vIbSz8R6NPdzO0cUMV9EzyMOqqobJI7gUAbtFYWo+MPDOmXz2WpeItGs7xMF4Li+ijkXOMZUsCM5H51JceKfD9vHfyXGu6VFHp7rFeM95GotnY4VZCT8hJ4AOKANmisK48YeGrbVP7MufEWjQ6llR9kkvYllywBUbC2eQQRxyCKzPDvjT+2fiF4r8L/YPJ/sJbZvtPnbvP86Pf9zaNuOnU59qAOwooooAK8j+GHxgtNe06FfFUtvYandapNp1osNrMsEpUjavmHcgc56FgenFeuV8/aL8G/Ev9k6RoOr3GjR6RZ+IDrstxbXEsk8nXbEqNEoXqctuPXpxyAepy/EfwpFrDaZJqyi4W6Fi0nkSmBbg/wDLEzbfLD/7JbNVbj4reDLa6vILjWDG1nff2dcu1pOI4bjJGx5Nm1eQeScHB5rgJvg5rjaXeeGUvdN/4Ry58Qf20bwySC7VOCYvL2bSeB8+8f7tVfEHwX8RajoHjyxgvdJWXXtfGq2xeWQKkQdmw+I+Gww4GR70Aeqaz8R/CmjarNp+passVxA8cc7CCV4rdn+4ssqqUjJ7BmFdbXhmtfBy9m17xZKsNhrOla9ci7+z3urXtksEucnfFACswDYIyVIwOe9eseItJur3wy9lpV41jfxKj2syMwVZIyGQMM5ZCVAYHOQTQBt1ieLPD1v4i03yJW8ueM74JgOUb+oPcU/wnraeINCt74RNbzndFc2znLW8yHbJG3urAj34PQ1sUmk1ZlQnKnJSi7NHgZS50q/mtryPZcwnbLH1DDsw9QRVtSoAjzmCTlCOqn0+or0nxv4XTXrQT222LVIR+6k7OP7jex/SvKbWUxO8FyrR4bY6MMNE4/8Ar1xTg4M+kw2IjiIc3Vbl2SL7VC1tLgSDlT2z/gaYLKXQ/I3tut5Tgn/nm/ofY/z+tbOmaVNcsrSFd8fzKR0kX0/H9DW5q9jDe2JLJujI2up/z/k4q4UuZNs5sRjlSmox1XU5AfuZFC58tuUPof7v+FV7q3SRHhkH7ibOP9luuB/MU6HckkthdM29eUfuy9m+o7//AF6nhKyK8NypDDg47HswrFq2jO+Mk1zRIPCV1JbyS6ZOMvDyh9VNdWBLJglVCg52561zVlCF1SOZ8CZAY3I6MDyD/Wuot3BGM4px7F1JX95E+0MvzLjPanRkbsDqKZJJ5Y+fgevY1EZFMkbLzzzgdqu5z8rZspynFQQ79r7SCgbAB7VLG52DPA9hTLZgRKowSHz+FWcuyYrZIxiszU9PS8tpYZwSjjHynGOcgj3rXQAkj1qJ3QDbL8jejUmrlQm4vQ4K7tL3TPvxm8th/Gq5Zfqv9R+lVEudPugy7EVj1KjBU13smwn5SGPoOaoXmk2l4d9zaxu/94r8351m49jsjUT3OXt/NkhVvPjyR0KH/GkuoLhoz5cqv/eVFwce2a05vDMTGQ2s89vsxgBtw/I5qlJourQ/6i6hmHo4KH+tTZmiaezGQXMXlIkbbAg27TwR9aiu7kTxsixif1JTcFqBra8tmL3unyytjllIcfoabF4isfM+z/aEidf+WedpH4cUgcbaoq6npWlX82kRXVtHPbmGeHa4/iVkbOP+BmsXUvhj4YuQzpBJbnHVGwB+WBXR65PDc2thOrq4iuXjJHYyRMR+sYq99ntXTB3kEDIEhpxk03YqtTjOMHNX0f5v9Dymf4MwTRrJZ6k8e8ZCS4OB27Vgaj8H9etwWtpILhR+H8s17pKz26bxmaIcdPmX/EUhe6dT5VuynHViBWiqyXU4pYKjL7J8yX3gvX7JmEunyNjuhB/Tr+ldf8OfG+oeGbmPT/EUd1/ZjHCvMjZg/Pqvt2r223ka2iKzq6u53OzLkE/Wo510+RT50Fu+f9gZ/Sm6vMrSRNPBKjPnpSa/H/I6XRNVs7y1jmsZYpInGQ8bAg/iKvTS7AXTGRzgdDXBaVplmjTT20ZtlY4HkNs3H1Nag+0IhWK9mI9JVD/qMVnzHW4RbuzrPtiCMMGySMgDrTI5ZIkZ5FPzHdx2rlRqV5ahVWOCV+gCkqzfhzVifV75Yz5mnStj/nnIrf1o5g9lHodOsxli3R9+maqG5CR7TgMPvZPeuZn8Wx2NsVksL8sg6CHO76V4Z8SPHHiLXL0pa22oaZYJkBQrK0nuxH8hVxTnsY1ZRoJuSuemeL/Edrqfjnwx4cs5llkbUYp7rachVRtwU+5xn8K9hvZJIoC0ON5OMkZr45+DhI+KXh/eCW+0HOeudjV9luyKpMpXZ/tHFc2LjyySPM9u68nNool4LmZIroEXG3kgceuKsxK6TmNRiBUG2omti90JRjkhgR0qaOaRrmSIpiNRw1cYzP8AE0ckmmExzSRbXUsYyASOmOfr+lci8axMs8vnXDr0klcyFPcDoPwFdvrX/IJujgnCE4HtzXD/AGsqfljmDf7hrooRWrtqehhbuBHdXcL24xKpIdTjP1/xq0rLLHzhlPUEZB/CoNPZTHJlRvLncGXmm3apbW0kkAZWAwqg5BboAB9a6DqstjT8NeHdIvLAyXulWE5u55GHm26Nhc7e477f1qrqXhDQU8V2Frb6VaQRs8YZbdPKHLc/dxXXQww22lWUMDfvIo1UY9cYrLw3/Cb6eJG3t5kZz+NeBhK0qmKbvu+55la0ryt3OuHgnSkObe41q3P/AEy1i7Uf98+ZtP5Uf8IrNH/x6+JfEEHp/pEcuPT/AFkbfr175rpqK+xPDMDU9KmPhO/0+7EniRpo3jaK9aKEzq3BQsiKo4J52j+teNaB8LtZsfEsqeGLXWPDnhqbTbq3vLHUtRjuIppZEdYxEkcjnCs4bc5BwOmSc/QlFAHzX4S+HvjC1u/hjFe6DJbxeHYtQhvZmurdlzKHKFQshJByB0znOQByWeAvhv4uisPhvpeo6E+lHw7qU+o3t9JcwMrqz7hGnluzEsMA5AHHWvpK6uIbS1mubqVIbeFDJJI5wqKBkknsABXFWvxS8L6nJFa6RqEst9d281xZLLY3ESXCxqSzK7Iqso2nkHBwQDQB5b4c+G/iuz/4RL7TpWz7D4rudTuP9IiOy3fbtfhuc4PAyfas7Svhb4ut/Cvh62l0YLe2njT+1pR9phylrhcyZD4P3fuj5uOleofD74nJqnw10TxH4nt7mK5vo55Jf7M0u6uIY1jldMkxrJs4UH5j61tz/E3wjC2kqNWMzatA9zYrbWs05njQEsQEQ8jaflPORjGaAPnDxxZT6fb+KvCSfZtU1vV/FaX0MtrewzTPGTkJJCrmVWXknKBRk89M9T46+G3jC4t/ihYaZorXy+Ir+1vbK4S6gRCqSFnVg7hgwz6YODz0z7SPiT4Sbw/p2tRauk1hqM32e08iGWWWeXONixKpkLZ6jbkVmfBnxvf+OdM8QXWpQW0JsNYnsIRDE8ZMSKhUuHJO75jnp9BQB5X8VfAvxC8SxeJ7J7LUtSgkNr/YqQalDDZwouDJ5kZkUtJxgFlYdSCOK9J8AeGNa0v4s+Otb1K0Men6pDYLazmVGMrRw7ZOASww3qBntmvTaKACiiigAooooAKKKKACiiigDir/AP4pXxpHqK/Lo2vSJb3Y/hhvMBYpfYSACM/7Qj9TXa1yHjGNPEEN3oD5FnLHsuGU4Y56BT2I4OeucelY/gbWtYitbrT9TmN3qmlyC3ulkPMq4zHMp9HXB9A24dq53iYptdjZUW0n3PR64/xt4YF/nUrCJTfxjEkeP9eg7f7w7flXS6fqEF+hMLEOv3o24ZfqKt1smpK6M7yg+zPMtCvElhRFfbg4Qngq3dSK3g7Zabb04mQ9vf8Ax/Oo/F3h50ll1XSYt0x5uLdf+Wo/vL/tfz+tZWjawtyEZXHmAcZ/jHofeqJepQ8U6O7Kk9qRvQ7omP8A6CfwrEgl+2QrJCpE8eVKHr7r9fT/AOvXeuFERRjus5jgEdY29D/SuL8Qae+kXhvIgTGcecF7r2cfTvWFaF/eR6mX4nlfspbdCEHzI1mh5ZRkgdSv+IrRsb0s+w5zjcCOhFZ+5VdJ4jiKQgsR0Vj3+h/nWhpluVNwoQ4A3ofT1X+ormSuezzqO+xqxlplCk4XuKuqxAVB0PGKoW0oKg1YhfzLgH+FOTVJkVImhDKQAAePSnyjpKnyuDg+9URKob7w+hNTwXKOSoOR3ParTOaUGtUWx0PHPtUbb2nQTgKg5UdcmpFcGnyAPEVIz3FUY7MaykjjAFQvGFBLcAVaRUAxub8eaYEUztvYsFGQD0osJSsUrdTtkLqQXOQD6UyWMelX5SDkmqUoBOSzAegqWjaEm3cqPGOa87+KfgW28T6S8lukceqQjMMvTJ/uk+h/TrXo4iZB8rqynu3BqlMB5nJzio1WqOpKM04y1TPlfwlc38Oh+K7GSeZLmzjS5VWbJjeNzGcA9OZcVn2PxB8RWmB9sEoHaRR/TFddPFGvxP8AGNjD927spAQM9R5cx6f9cya8lPBIPWt4pSbuuiPKrVKlGjFRk9JSX3cv+Z6XafFvU1Qpd2kcqkYOx9v9DW/ZfGC0YAXNrcRn2AI/nmvFaKp0YMyjmFeO7v8AI+hLX4o6FcoUkuWi3DGHjYfr0rd03xV4fuVTyLizd8AcEE5xXy9RUPDrozaOaT+1Ffl/mfW/2yxuSTG6pJ1DR8fmB1p1tF5iEy3T7gcEKP8A69fJ9tqF5a/8e13cRf7khH8q2bLxr4gs8CLUZCPRwD+uM1DoPozeOZ0+qa/E+nBarHJ5kE0gfGMuAf8A9VNkmmiKh41bccAqa8DtPirrkIAmitpgPYg/1rctfjAWjKXumsPeKTd+hxUulNdDeOOoS3kevyrdSAAxERnrsYFsfTNPae0cCOSGHAGAskfP615/Y/FrRZsef5sB/wBpD/TNa8/i3QNftltZL22kRyDhpMEe/BzUcrW6N41YT+Fp/M6fTrDTP7asLmO1gEyTLtZR0PtXokiq6ESLuXrivILPRtE3wvaXd0jK6ndFqEwPXrjfj9K7y58Pz28DPZ6/rcTrjbmZJe/H+sRv/r965qyV1qceL5rq6Ne3uZjOsSxKsHQDnIos5bp7lllOYzk4x0rFtNL1yS3Jj8TXCtnGZrOBsjr/AAotIn/CUrdGOPUNIkQkjdJp0isR9RNj9Kx5fM5Lvsbusf8AIKuv+ubfyrinuPJkCOWUEZB7GtTWZfE8WmT+Zb6LOCAvyzyxE5OO6NXJT3evPC8Mvh9HyOPKuw2D6gsq10UIux3YWSUXc0VgNy7XG9ogeFK9Wx3NWdLtWuNdtYZJvMhh/wBIkyuOn3R19f5VhQ69cRReXcaHqCGIYYq0LAf+RM/pXQ+E9atIYJrnUNM1hJLht2V06WXCdFHyK31/GssbJwpNR3ehvVrKMWztbGFJllkcLkn0rA3A+ONPCDpJGP1qJPFukxu6i6lt4/8Ap5tZocZ/3lGMfp3rM0fxJoM/je3Y61pojjfcWa5Reik5OTxzXk5dSn7dXi1/w5585R5W7nttFVbXULK8x9kvLefP/PKVW/katV9keMFFcv8AEfxtpvw/8NPrmswXk9osqQlLRFZ8t04ZlGOPWsO++L/hm11jwjpqfbLm48TRxS2ZgRGWNJGCqZcsCvORwD91vSgDqPHWjp4g8Ga5pEkskK3tnLB5kaF2TcpGQo5b6Dk9K8H8E+HPEepeNvCEcultDYeHtBn0571rW5to5WaNo0OJ4o23HIJChgOTk5wPfB4n0BrBb4a5pZsmn+yrcC7j8szf88w2cb/9nrXN+CfiRp+v6Hreq6uLXQ7TTNVm0tpLq8XY5j24cswULnd93np1NAHmdn8FfEtv4e8J6ddz6Jqlvpdld21xp1zcTLbebLLI6Tr+7O9lDrwyj7nB7jS8CfCDX/D+sfDa7vLvS3j8NQXsV2IpZCZDM0xXy8oMgeYuc46HrXa+P/idYeGNK8P6lpyWus2Or6lHp6zwXiiOMNnMgYBg2MdOPrXTxeLPDstjHexa/pL2ck4tUnW8jMbTHpGGzgv/ALPWgDxjw18GvEmgaN4Lkiu9HuNX8O6lc3ZgeeVbeeKbbkb/ACyysNox8h613/wY8Gap4M0zxBDrctlJPqWsT6in2R3dVSRUAUllU5yp7eldfceINGtpb+O41fTopNPRZLxJLlFNsrDKtICfkBHIJxmue8VePLTT/B8mveGn0jXoUnSEkaxBbQ5JwczsSgIyPl6nNAHaUVwfxV+JeleAPD1/eNLY32rWyxuulG9SGeRXkVdwGGbADE52npXa2Fx9rsbe427POjWTbnOMgHGaAJ6KKKACiiigAooooAKKKKAOW1zT7q3vpr60XzIXG6QA8qQOT7jisqzu7f7W18sEZuJI1iacKNzICSFz3AJJx7mu3vgWsrgDqY2A/KvIvCuqokdpHcfdC4I/CuGrh48107XO+g51IPS9juVFveMskT+VcL910OGH41cttXuLQhNRjMkY48+Mcj/eX+o/KubVo5Lxvsr7QFDD8SavRX7xOIrnBOAc9qx/eUdf+GG4xno/+Cdhb3ENzHvt5UkU91Oa43xh4VeSR9S0ZcXH3prdePM/2l9G/nVoRwyP5kDPbzdpI2wT9fX8auw6lfWvFzGt1EP40wr/AJdD+ldMMXF/Ec8sO18JxmkawJU8uQZP3ZI243+2OzVr3EcVzbCORt8J/wBXKeqn0b/PNSa7pGna/K1zpky2urY5SQbRL7MPX/aH61zyXl5pN4bbUYmt7jHSTlJR7HofqPxrqjJSV0zBxcXZlHTraKz1s6fdjbaTZVB2Df3Poeo/Ku1gt44ofKVQCvyFu/sa5nU44NQhYxhlfbzH3Hup74rb8NX/APaNmokwbmP9zMD3PY/j/U1MYKOxtVxE6qSkyC+04x7ngPuVXoR6j/CoLWQKm0cVb1bVU0m4t0uone2uNwZ15KMOhx9PT0oNjFeILixuFeJ+QyfMD+FZTpa3iehhceuXkrv5h5qPw6qT6kU2FAIwoO0gkgjtVOe2ktpfnbcOxHenLPtFYt2ep6cYqUeaDumaKGdeiB/dTRBdSO7b8Lg421RguixJ7dKlkKOM5ww6EU7kOn0aNAT+9Q3NwUxIp+YcY9faqsTkopZyaUyICW7+tHMSqSTJvtyMcMSjdwaRmLdAdvcmqMU376Rh6ClkuCfvNx9aXMaeys9ELJcZkKHj0rK8R6va6Ho91qF9IEihQt7n2HvWD488Y2HhfT2uLlw9wwIggU/M7f0Hqa+bfFvjHWPFUwbVLj9ypykEYwi++O59zThBz9DPE4mGGVt5dv8AM0vB2qSal8SVvZ+Jb83MePQywyIB+G4VyeoJ5V/cx/3ZWX8ia0vBNytn4y0G5c4SG/gkbnsJFJ/SovFds1p4i1CBx8ySkH6102tNeh5F3PDSb6SX4p/5GVW9dabbDwVYanCrfaHu5baViTg7VVunTo61g11dp/pHw1vUAGbO/Vz6/vUA/wDaRp1HZX80ThIqc3Fr7Mvwi3+hylFFFWcoUUUUAFFFFABRRRQBPbXlzbHNtcTQn/pm5X+VfcnhDUhrHhXSNQzvNzaRyN3+YqNw/PNfClfVP7NuuR6j4D/s1pM3OmzMhU9fLcllP0yWH4Vw46F4KXY6KEnflZ6ddW8kjKEfy488BWxzVvgcgDd3b1qOaCOYoZM5U5BFSMckmvMOswvFk5js4Y1VnLvkheTgD/HFcytzEVJDDjqD1q/4m1OH+0im/cUGxVXklu+B/npUWn+H7rVb1JdQjEUIAPk5+dx/t46D261rKtDDwTmz06SVOmnIi0fTX1++Ejx5sYD94j/Wn091FdfH5sAMaxljngjpT4M2avAiqgxhcDAqWG+RYisow/fNfOYvErEz992MKlSU3dLQjguvstvJu++cls1mfD+zj1LXLy6uoklREJw6hhlj7+2ag8RX3lQPEOJZl2gdwvc/j0rtPBGktpWioJlxcTnzJB3HoPwH9a9fJKEm+d7HHipqMH3ZJdeEfDd3n7X4e0ef/rrZRt/Naq/8IJ4ZX/UaTDben2Vmgx6Y2EV01FfUHlHl/wAd/CGpeIvhvBovhmza7niu7d1iedQfLQ8kvIwzx6nJrhrj4HXfh7xh4a1DQGfU7eLX0u5WfZF9gs1YssQ3PlwCzn5Rz/dr6JooA+bNC8KS3X7Req6HBcJJ4Y0i/wD+ElkgXpHdyxqFQ9gQxLAegp2l/DTxbYmx1GXSvPOn+MbrVzpwuYt1zbyLGEkQl9m4bGwrFTz2r0fxD8YtE0PUfEtpcaXrU48OmD7fNBFEURZsbWGZASMsAeM+xAJovfjH4fsRrourPVo5NJsotRdDDHm4t5CoWSP58fxrw+0jPTg0AeY6n8LfFt3apdR6WE+2eMl1ttN+0Rf6HbfNksd2wscjIQnoOva94j8AXsHhf4yXOuRJp1reXn9rabcmZDlotzhvlJKknC8gH5ulelf8LX8PJqa2dxHf2+dCHiFppIl8tLYjODhi2/2AI96gX4t6SPBV34suNK1W30GCJZEuHa2YzlmUKiIsxYOdwOHC8dcUAeW6X4B8Q+KvhHb+IDElz4j1jWYfEF3aOwiF1Am4RwAt8oBUhxnjnrU3jf4beLvEOn/ELUrLSHtZdfvbF7XSZLmASBYcB5XYOYwTycBieTXY/E/4ha1ZeFtHvdIsNV8P3Nxq1lC4v7eFjLBNvyBhpFB+XkZDLxnGa3NZ+L/h7SdQ1CKa31OWw069TT77U4YkNtbTtn5Gy4c4xglVIFAHmXjz4eeL57X4n6fYaE+pyeJby1urO/juoEURxyBjE4d1YFQMDAIPr0r6I0mJ7fSrOGVdskcKIwznBCgGrdFABRRRQAUUUUAFFFFABRRRQAjAMpB5BGDXzvYErJCD1Vyp/UV9E189Tr5Go3UfTy7px+TmubEdD2cofxr0/U6C1umt7pcZIMZ/Q/8A163bW+huC6TkbmVSPy/+tXPBCJbcnod6/oDTZMi49MRr/M1kpNKzOurh4VfJnVRPJbqHBLQliPpzitS3uiyAqQymuT0/VfK+0RT8x8kZ9xn+dWtPuROyJZy/MV3Fa56lHXmpfccU4ShpU+86OWO3uQBKgFRXdo1xam2uUTULTqI5j8ye6v1BqmJ50JDoDg4zT4NRTjOVrJTnTd9jNwUlbc5+90uWyObCR5Yx/wAu10Qki/7rfdb8wfrVTw9fi28RRKu9RP8AuJkcYZT1Un3B4/Gu6S6WVMOqSIeoIzVeTR9MuZ4p/IVJo2DKR2xXZTxd9JHNOguhT8XWrXWjSuinzoCLhMeq9R+RasKwtg97ZPZXM1q1wC8oT5cqBkkr0PYZ967p4s5GAVKkEfn/AI1gaHpElnPLHNzEmI4fZGO4/wDso/CuxVIvZnO4tdC49jBcNGjNOGKl2bzCdo7dcjPI/wAiqz6PG8QaORsMflDZyfxH+FazRhnmxwZGCcenU/zqf5RMQuAkacD0/wAgU3FS3RcK1SnpCTRx1zZalZl/9CeeNRndBIrcfiRzXB638UtF0jUm07UIdQt7lGCyrLbspQHnJB56elevancG00yW4GDIq5UHpvY4X8uKxf7H0eRd1zDDcSH70kke5mPck1n7CJ2LM6y3szl9N8ceHtRjX7Jq9m2R91pArfkcGpNR8W6LZRFp9St2IH3Im8xz9FXJNdIuhaEPuWlmP+2P/wBeqes6dpcNoqxQ2Y3yxoxWEBgpcA85OOM1PsF3Nf7Wlb4Vc8k1T4zW9hdSRf2Lfr3QzYjLDscHnFcxq3xr1S4jZNP063tiejyOZCPw4Fdb+1Hp9lFY6PdQxxx3BkMfyjGVwf8AD9K+eatUYIwlmOIl1t8kXNX1S91e9e71K4e4uG6sx6D0A7D2qnRRWiVjjbcndjo3aN1dCQ6nII7Gus+K6KvjvVJI1CxzStKg/wBliSP0xXI12HxJxLd6NdDB8/S7Ukju3kpu/wDHi1RL4kzqo60ase1n9zt/7ccfXV+Fv33hLxRa9wkN1j2Tev8AOQVyldZ8PP3lxrdqPvXOmyIP+AyRyH9ENFX4WGA1xEI93b79P1OTooorQ5Aop0cbyuEiVnY/wqMmt7S/BXifVGAsPD+qTA9GFs4X/vojFAHP0V6vo3wE8b6gVNzbWenIe9zcAnH0Tca7jSP2crCDD+IfExb1itIgn/jzE/8AoNS5qO7KUJPZHzhUltbzXUyw20Mk0zcKkalmP0Ar7H0X4ReANNjBj0d9Rcf8tbqRnz+GQv6V1Wniy0n/AEXQ9KsbFOmIIlQfkoFcNbNMLR+Kf3am0cNOR8j6B8IvG+t7TBoU9tEf+Wl4RAAPo2GP4CvZvhZ8G9a8GaxHqt94jtLdiuya1giMiSof4SzFfzA4NeuXUt2qkvOxP91fl/lVeWdJYCEhbzO7EV51fPaesIxv6m8MJs7ll5I/M2xP5vuoND+YvO0IPVuar28y2y5I6d6jm1JLh9gcE+g5rxZZhOpFuCs+yX6nWqTv5DNK0ewiMlzHDEsrkktt5OamgkFvcyEYAbpUttaBoAzSlV9AahilELNGUEijoc1x1Jzm4yk9e+5V731uSrJHM7LKOM96paxd2tjASvQ9B3Y1n6trUER2xAPKOyngfiKk0Dw3e69cLeanuhs85AxguPRR2HvXfhMBUxDSa0/r8CJyjTXM2TeCtHl1jU21a/GYI3ygI4dh0/AV6TUdvDHbwJDAgSJBtVV6AVJX2VCjGjBRR5NWq6krhRRRWxkFFFFAHk3iP4Pf2zcfECX+3PJ/4SxLVcfZN32XySD/AHxvzj/Zx70mqfBmDU7/AFqe61l/K1LQodGMaW2DGYyhEu7fzzGPlwOvWvWqKAPKND+FN/pviKDWZ9fsby4g0BdBSGXSj5LIpGHdfOywIGCuRnJ5A4rDuP2e9Pu7bxGJtRtLSXVreOBI9L09ra2tykiyCTymlcs2Vx94AAkAV7nRQB5r4o+HmteK9B0/T9e8UW8slle2t4ksGmeWreTvzlfNJ3PuGTuwNvCjJrLvPgrZ/wDCQa7qFhLobRaxcm7lXVdCjv5beRiS/kyM4Cgkk4ZWA9K9eooAAMDA6UUUUAFFFFABRRRQAUUUUAFFFFABXgPiCPy/EesxjtdSkfixP9a9+rw3xhH5fjfVUxgGRW/76RT/AFrnxGyPWyl/vJLy/Uthv3Vu3pIP1BqS7j2zIcctGf0I/wAaqxNnS437rsP6irt7km3Puw/MZ/pXP0PUejMy7O0SnpujH9RTvCF2lst1cuTuxtX8OtU9Yl8tQP8AZOaSxjMelQofvSkE/ic0KTi7oupSjUhyyOuk1eM6eVJO9gAT7n/9dTzXtvJbMUwNo4+vQVzMx/1KDqz5P0A/xIp0jEIFH8TAf1/pV+0b3ON4GH2TpiojtjPFLgKMkVaS6ePAlHUZzXK/aXSHy8nazKCPxz/Sule6SRIQcEHC5/WsnQhU1WjOarTnSeuqNOG4LDKNmrC3GfvgVjTHyH3w5K9x/n6VZhu4pFzuANck1OlLlZmkpK6NNZI8g8g08bWztI5GDWaJoz0cU8P6NVRxEokOkmTanZm+tGhcEAuHyvqDkfyrCudAuesdwQe25a3FmcdGNSC7fvzWn1ht35miVSS0sjg9S0fxFFGxsJLWZuyyM0f6gH+VcH4hv/HtjDIsnhtbmIjBaC7D/ptB/Sve1uUP3kFKUt5RyMZrSOJn3TJdKHVWPhv4geJ9d8RahEPEEbwSW67UhZChX6g965WvuzxP4R0nWbNodQtILmI54deR7g9j7ivmTx78K7vTvFGn2PhiOa9j1JmWGI/ejYckE/3QDnJ9DmumliVN8slZmc6PKuaOqPLqK+lPDX7PWl2MEU3jDV5ZrjG5rWy+VB7biCx+oAr0rQvCXhHRAp0TwxZh06Tzp5jj33Nub9aK2MoUP4kkhQoTlsj420jw7rWskDSdJv733gt3cD8QMV6dqXwy8Va9p/hrTotPEOp22ns08VzKqFE8+RVPJ5+VV4GcZr6dj1C8nkEMKwxADsucCsHVTPH4z0p2uG33FpcQFlO3Oxo37f7xrglm9CS5oXdtTvwuFfvwb3i/w979DwrTv2cvE8uG1DUtJs074d5GH4bQP1rqdG+B1t4ZF1qj+JFvLyGzuBHbx24RWZoXXBO4n+L0r2a4s4xFlm3tjqxzVazSHzmikQBZPkzjI54Nck89TlyOFr+fcmhh1CSqJ7O/3HmegfBzwAdPtLu7Op3kk8SSlXmKrlgDgbFHr612WmfDvwLYKHs/ClrLt73CmX/0MtT/AAlKJvB2mb+JIoRGe+Cny/0reSebyQojyPqK5KueV1JwVlbsb18HCnUlFLZsLV7bTNsem6VZWaHoIUVR+SgVflmujHuMoTPZVH9c1kTM6uHcoCO2elRT6zDtwXy3tzXKsxxle9m36f8AAEsOtOVFiOR57grcTSMmcYLHFSX8dvFFiIDPsKyW1RHj8u2t5ZG659/1pIDqN1IFjjRCO7dqylQxMo2rNJvq3qbezs77I1I/tEcQVWXaR64qpLNFavvadS/cDqPwqG70+6BAvLtyT/CvAFT2un2EIVpl3nqSx/yKzlSw0XapO/ov1f6Iasle9/QjuNZNwQIo3lbvtWiNtSuIx5QigjPcnJqa/wBV02BBHE6KO4Tn9BWO/iNIkK20TNnnLcAVsovnbpU7+b1/Oy/ASkraKxoQ6dE8/wDpUzy465OBmr9y1lZ22FMcS+uQKwraPX9VP+h2jxxt/Ht2j/vpv6Vr2PgG4mbzNVvsMf4Y/mP5n/Cu2ngMZiF+9en9fIxq4iC+JmTda/HEuy3zKfUfKtOs9F13XMMUNvbN3k+RcfTqa77SfDel6Zhre2V5R/y0l+Zv/rfhWxXq4XJaNHV7/wBf1ocdTGt6QRzWg+ELDSysso+1XI/jkHyqfZa6WiivYhCMFaKOKU5Td5MKKKKokKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvGPiHH5Xjm5b/AJ6xxP8A+O4/pXs9eR/FZPL8WWsnZ7VfzDt/iKxr/CellbtXt3TMy2BfS5UHUK4/In/Cr8jb7aI+jKfzBH9ap6ZgxyKehYj8x/8AXpwnCadubsqn8iK5UezJXZg63mS8SJf4zsrVIBniQdEXP9KzbcfaNY39RGC34ngf1rUhG6WVx67R+FSbS2SHgbrv2RAPxPP+FPcAzRj0Bb+n+NFupYyv/eY4+g4pACbqUkfdCp/X+tMzCUfPGPct+XH9afHO8U8IVjtyWI+gx/Wm9Z3z0VQv9T/So+tyf9lQPz5ovYTSkrM2pNWjS0nlJxtYD8hVi1SJrOxkdsmbaWP/AAHNcbq0xTTpcdHY/wA61pLiQw2kROFTPT2GP61fNGXxK5xzwTXwO1zp7mCGNIzG2AzBSc/Wnm3RHVVmPOT19Mf41ykk8gVAHb5pB39Aam+2zK0Q3E8Ng/lStTe8TN4OolpI6WUXEDKFbcGOB+VLHfYwJl2npWJDqbboDM2SJOD+BrQkmhmlgR8ZIY5/Ks5YaE9YaGMozp6TVzXSRHHysDTwaxZLd0kP2dgeC2M9qYbuWMYfI7VyTpShugjaWzNi7utkLKTzioNFhWGK41KRVMiKYomI6ZIz+ZA/KqNlbT6lMFjzsz8znoo/xrZuDDMY7C2P7qH7x9TSlUdGm6r+Xm2NpfD94wxKbUuTumbqxPNRWt0qwbOBjg0y4t5IwyrJlR2qI3FpFBuuEKt0BI618o5VJ1LLf77nQopx7joJxFcu2cKw61k+JTjVNAuQ2FS7eEsP+mkTf1Spp9TEymO0t2f3I6VleIIbqXSYZpyqRxX1s4wfu5fYT+TnvXZhsHUg3Gq0k09Hvqn0OvDx/epvS+n3q36nTzTxov72dRj1OKpRatDBlUBlbPG0VXisLWGTNyxKjkljgGnXWqaXAu22I3AdY17/AFqIQoJ/u1KbXy/zf5GDUVozL0C4uo4b+zt7fclvfXMYLA9DIzD9GrVtrS/upNr3IjUdcdqxNO12Sx1XWba0g8wzTx3IyeR5kMZ6D3BrTitvEmoNmC0kiVu5QIPzavSlh6s6jdOmvmrv9fyNMVVUZtvS9n96T/Usy6VGsyiSV5c9WJ6VZmTRbaDDGISDuWyc1BH4K1q7P+m3USL/ALUhc/l0rUtPh7aJg3d5NIfSNQg/XNdFPLcXO/PPR/h/XocM8XDT3jG/4SCzt4iilpD/ALC4/nVJPEE/mMLG3YsTxySfyFegWnhPRbbBWyWRh3lJfP4HitmC3ht02wRRxL6IoA/St6eQ01rN3/r5HPLHL7KPK47fxLqZzHbTKp7sgQfm1X7fwNqlzg397HGvpkyEfhwP1r0mivQpZZQp7IxljKj20ORsfAelwYNy81y3oW2r+Q5/Wt6y0bTbIg2tlBGw6Nsy35nmtCiuyNKENkc8qs5bsKKKK0ICiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAry74yRbb7R5x/EkqE/Qqf6mvUa84+NCf8S/SpcfdnZM/Vc/+y1lW+BnblztiI/P8jkNOkwXA9Q36f8A1qbeyYsZU/2mT9TUOnN+8H+0gqvqsh3vEh5LcfU1xH0nL7xLoo2Ws1w/VyfyH+TWlaL5cKluoBdv51X8oRW8FuvTgH6DrVwjMe3u5C/h3pomTJ7ZdsKA+nNNsx5ibj1kYt+Zp9xlbdyvXbgfU8f1pP8AVQMR0RePypmREnziRx0ZyR9Og/lUEbYMsh6bifwHH9KtqBFAoPRFyfwFUWXFkR3K4/E//rpFIzdVyYLSLuzqD+JrXbmVB6KT+Z/+tWbdjzNRtE7B8/kDWkB/pEnsFX9M/wBaRpLZCScyxD/eP8h/Wlf/AF0Y9FY/qKVl/fn/AGUA/Ekn/CjGbj6Rj9SaZFxsxx5Q/wBon9KjmuJPPjO7G1D+p/8ArU+f/WRj0Un8yP8ACqkzfvm/2VA/r/WgaSe5dt9XlhmfkkhMfmf/AK1b/gW5/tCbULm8RJIraMIAyhupJJ574UfnXCM53Stn2rtvAK+T4O1G4/innYZ9sKv+NUptJvsjmxVGEYNpaux0DXkt0y28SrbQMOi9cf0qrcRC2kXySeODinNIjxoRmOVFweOtY8889/OYbc5Ufecen+FfHTnVx82py0WrfRL0MqdO22iLFxqMhk8m13TStx04FMg09fPLai7MVGSM4Aqs2pW+kxGK3US3P8R7D6n+lS2Gg614gcS3TNb2zHO6QYyPZe/+ea7cPh6k/dwqsu73f+S+4dStGmuxa1HX9OtoBb2cYfH/ADzGBn61zmtXd9qHhnVjHbMtrHD5u9VJAKOrjLdOq16TpXg/SrBQXh+1S/35uR+C9KueKbRbjwrq9oiALJZzRqAMYyhAxXr0sojF+1qayOWhjYwrQ5VpdfmcfY+B729CTajfKqsMgLl2x+PAroLDwRpFtgypJcv6yNx+QxWl4TuftnhbR7nOTLZwufqUGa1a9OlhqUUrI4q9WopuDezschokEVh8QtatoY0jSewtZ0VRgAK0iHH5D8q6+uelsLlfH1vqKRFrRtNktpHyMK4kVl9+Rurg/jJ/wmEHifRbzStO1bVvCkULi8sdHv2tLhpjnaxZCHKgYwFOMg56jO1NWTQYuSm4zT3ivwVv0PXaK8J8NfFZrnWPh/p/h43FxpWvz3kd0dY3SXdu0WD5auGAIBPVtxIxznNcfqXjHV/HWofDXUbtLC2v4vFFzaRGKJzEAnl7WZS+SeeQGGfarOU+pqK+fZPjP4ljs4rY2WjnVYvFg8OXEwik+zyIcjzEHmZDcdCT+tGpfGPxTpdh4gubi10ScaDr6aTOEglT7VEzEBkzIfLYbe+8HPbHIB9BUV4Zq/xa8RWPibVvCK2emHxQNbt7LTlMMnlSWcwL+c678kqo+YhgMsOODXNweNLrwT4m+JNxp1rDcahqPia0022+0Z8qN5Ec73xglQFPAIz60AfS9FfK3x78Y6lqvgvxt4W12Oze/wBCv7Ei7somiinjlG4fIzOVYd/mOfwrtda+J3jDS7r4gaXb2WjXl/4Zt7e+hdYJVSWB1VnVl8zO5VYncCB8p+XngA90orwTU/jlfHSPE3iDRdPs7rQLI2dpYO4cNNdzKrPvYNgIgbBAGScciqfxS8bakNC8feFPFmnaPq0um2Fpfo8Ec8EEytNECjqJd4KsQQRIM46dqAPoeivnPx/4z1PW/DvjHwxpkFhZaXo3huGe7aWKSSSZpYVZUiO8bFCt95t54969Q+Ha6o/wf8GDRJbKK6/sqzy13G0iBfJXPCspznHf1oA7yiuY8P6/fvrk2heIrKC01RIftMEttIXgu4QwVmTIBVlLKGU9NykEg109ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcR8X4BJ4TWTHMNzG+frlf6129c78Qrf7T4M1VMZKxeb/wB8kN/SoqK8WdGFly1oPzR43Yvs8tj6EVFApudZRj0XLt/SoUfbbJ9a0NHjEVtLdOOX5H0HSuA+rel2X0+e5c9kG0fXv/SrKjNyB2Rf1P8A9aoLRdkYL9T8zH9TVizy4MjdXO7/AApoxkSXBz5UY6s24/Qf/XIps+dip/fYD8Bz/SpE+e6lfsgEY/mf1P6Ukh3XKr2Rcn6n/wCsKZmhl5/x7sO7kIPxPP6ZqrcEARr6tn8BVi5bMsaf3QXP8h/Wqlwf3pPZI/1P/wCqky4lGzPn6uT2RT+pA/xrUh+Z5G/vOx/WszQ0Pn3Ux6DgfgM1pw/uodx/gXJpIue5JCN7yt2LnH0HH9Kcq/vJm/2to/AYp1tiKAM/RF3H+dLCNsKbzjjcx9O5qjK5UmUmZ/bC/wBf61nTtl5G9WP5dP6VoO5WBpT94gv+J6f0rJueI9oPOMUmawKkrbbck98mvTfD8AsvBukQSDDTfvmH+9l/6ivNTbteXdtZxffnkWIe2TivXdUWCMlXwIbWHAX/AD7AVzYuTjh523ei+Zz4yXww+Zk63dGSRbS2A8yXg47Cse4nkjb+zNL3STyNtdk6sfQUyedra2a63YuJyVjHcL3P9K7LwDoAsbUahdL/AKVOvyAj7in+prjwmDdRql0Wr83/AJLZHJiKqowsiXwr4Rg01EuL9Unveozysf09T7/lXV0UV9HCnGmrRPFnOU3eQU11DoyOMqwwR7U6irJOW+GLMfAulI5y0KvAT7xyMn/stdTXK/D793aaza9rbVrpAPQF94/RxXVVFL4EdeP/AN5qPu2/v1CsLXPCmk61eC7vEvI7vyhCZ7O+ntXaMEkIWidSVyxODxmt2irOQ5Kb4c+FJLPRrVNJW3i0aRpbA2s0kDwO33iHRgx3dTknPfNU0+FHg2OxsrSHSpYIbK6kvbYw31xG8Uz4DOrrIGB+Ud+McYruaKAOPX4a+El03T7BdIUW1hfDU4AJ5d32kf8ALV23bnb/AHyc0l78M/CN9b6rBdaTvi1S9XULxftMw82cEkPw/HU8DA9q7GvNfjPqnjPSYtKufClvcyaRG0j6rJYiFrtEAGzyxMrJjOcnax47UAabeAIJvi4vjm5u0eWGw+xW9qtuFMZycyNJu+Y4Zl6DAPtVy7+HnhW8j1tLrSY5V1mZbm93SyEySr911O7KMM8FNteQR/ETV9f8U6LbaD4o1Sz0K78Mz6mZ7uztBcGaOWZdz/uig/1YBCgAgccnNVrH4p+Jtd8KeFYoLm+tfE99pt1fStC1rBbNFC7qJX82CVskRk7UC/gCMAHr918L/CF3ol9pV3pLXFpfTrc3TS3c7zTyL91nmL+Y2O2WxV658GaT9u1/VLC3S31rWbT7JcXcheVWATYmYy20gADgYzjk1414Q+IvirxlqHw40+bWG0VNX0+7uLy6tbeEtdSRSvGETzUdVOIwxwP4zx0q14i8aeNrvxvqfhjwvfzXc9hpS3VpcWUVkFvZSR88pnYARD7hEXOQTx0oA9F8F/DHRfD/AMNY/Bl9FFqtgwY3TSx7BcOzbtxXJ2kYXGDkbRzVv/hWnhNtK1XT5dMee31RY0vXnu55Zp1jIKKZWcyYXAwA2K2fB1/e6n4U0i91WOCLUJ7WN7hYJVljEhUbtrKSpGc4wT9TWxQBx2s/DPwnrFw899pbmWS0FjKYbueHzoAMBJAjjeBgfeyeB6Cum0jTrXR9Ks9N06LybKzhS3gj3FtiKAqjJJJwAOSc1booA5Pxdi38WeC7zpm+ms2b0WS1lbH0LxJ+OK6yuZ+IsNi/haefUL59PFpJHcwXaJ5jxTq4Me1P4yWwuwctu2jrVLwnqnifUNInfxholvpMP2dmE1vdFpm9zCFPlnbzgSOQeOaANqLxT4fl1Z9Li13Sn1NG2tZreRmZTkDBTO4HJA6d62a+YPBFxqHgzXPDHhfw7rOg+NPD11qW5rMWgF9YKWDm4kA5Qpljufn0HTbjWHjDXodC0LT7zxFqi60njsW11DJeyecLY4Ajcbs+WTnCn5Tg46GgD6f8NeJ9H8S/2j/Yl39p/s+6eyuf3Tp5cyfeX5gM4z1GR71s18cWOrXOmweJ18M6vdw+Ln8byrZ6fbXbg3EZb598CnDpxyzKcYxkc51fHXiPX7Sw+KWp2viDWYbrR9ft47EJfSiOFGZgyeXu2lTx8pBHHSgD6yor5o1vxhqnhbXPi1al9Z1jTdNisJre1bUZ1eBpVQuwmVvMRAWJIUgYGOBXLaj4w8Q2Xh/4n2ll4slvYLOz025tLuwvZ3WF3lhEghlklkk2/MynL84PC5xQB9gVzmseNvD2ja1caTqWoeTqEGnvqskXkyNttk3bpMhSDja3AO7jpXgV/wCJPFWja54rs9B1PVbt/wDhD7fU4oZ53uTHOWhV5UD7tp2u7YHGe3AxladqFq3j0X2h65d6lOvw/mllvnvpJ5VucOzfOzEowODtBG09gaAPozRvH/hnWdU0zTtN1PzrzUrL+0LWPyJV8yDcV35KgDlTwSDx0rqa+PrHV7eTxT4N1LxTrt3amTwQ7yX7X7wztJ5s+3Eu4MWJAwM5J456V0fhTxP4qs9b+Dt54x1XULOyvba8S7a4neOK4OJPI80EgM5BjIzknIPWgD6G1nxLpOjarpGm6ld+Te6tI0VlH5bt5rKASMgELwR1IrYr5C8F6zqOqQ/CK/1e8vdTu11vUf3k8rTSsFVMKCxJ9gK0fBnjnVr34geB7m01SS1g1W/u7W80NtSu7yS3RMKon8+VgHJ3FdqJgDvnAAPqyivDv2XoNS1fwsnifWfEviDUrl2ns/sl3emW3VRICHCkZ38YyWOASBXuNABRRRQAUUUUAFFFFABRRRQAVV1S3F5pl3bEZE0Tx/mCKtUUDTs7o+Zo1aWKOHnexC/SukdQqw26jjv9BTbvTfsvivVEIHlwzuEx/tHP8iKltxvkeX1+VfoK821nY+vc1JJoll5j2DrIQv4dTVyLCKWI+VRk1XUZnI7Rjb+J6/0qWX5hHEP42y3+6P8AIqkZSJrSLEKBvvH5mPueTUVupYvIesjZH06D9KnmbbA2Dhm+QfU//WzUcsghhZh/CuFHv0FMhXZWch5pWXoW2D6Dj+eazr6TFvPJn7xwPoOKuN+4tj6qv5n/APXWTrG4Qw26H5mwv4nioZvBalnS18vSkJ+/M38zn+Qq84yixj+NgPwHJpu0K0MS9I1z9M8D9BUsCl7knsg2/ieT/SmS31Jp+I1j/wCejAY9hyf5frTLk5QIP+Wh2/h3/wA+9Pb57hm7INg+vU/0qJjvuWx92MbB9T1/pTIRUv25SMf7x/Dp+v8AKsuc5lUenzGrlzKHkdx0J2j6D/JrNlfCSyevA/z+dSzeCOi+Hdmt54oNw4zHZxmTn+8flH6bvyroPEEv2idI4pCTcNvYdgvb+X6VH4Gs/wCz/Cst1L8s2oSYU99nQf8Asx/GszU51AuZojhXPkx/Tufy/nXHi5e9GPbX5vRfqzhlLmqyn0Wn9fMteGLE674iQyLutLcbmB6bR91fxP8AWvWa5zwHpn9naFG7ria5/et9D90fl/Oujr1MJRVKmkeJiantJ+gUUUV1HOFFFFAHK+Ff3Pirxdaj7ouobgD/AK6Qrn9VNdVWda6VFba3fanHJJ5t5FFHIhxt/d7sEd/4jXgFn4g8QeFtf8v4oWviqCa71URW+t2Gos1kFZgY4xAD5YXAOcqWxnuMVME0rM6MTUjUmpR7R+9RSf4n0hRXz9efGjxFD4c8RagtlpJm07xONFiUxSbWhJI3N+8+/wAdRge1YSeJNY8HeK/jV4h0X+zpFsL6xe4gvInbzkYuu1GV12H5jyQ3YYqjnPp6ivlDxRqlvc3nxs1S402G7gmsdFuDZ3bSKp3JGQGMbI3BI6MOR6cV1uo/FXxLptx4rsdJtdEis/Dej2V9Cs0EztIHiiZkJEox984PPQZz1oA+gqyNc8M6Dr8kT67oml6m8IKxte2kcxQHqAWBx07V5He/FzX9Qk1I6DZ6ZaQ6X4Yj8QXH22KScyyPCJViTa6YXDYLHPTpTtD+LevX+ueHLKa00xYtS8LvrcpWOQMs48z5V+fhPkHByevNAHdav8MPDOseLbLXtSskuDaWH9nR6fLFE9p5YZmBMZQ8gscYOBgcV0Gp+GNA1WK0i1PQ9LvIrQbbdLi0jkEI4GEDA7eg6egrxiw+Meual4M8NXlr9gPiTU7S6u30630p51KRSugfc1zGI0whzksc5x2BoaH4rl8b/E74NeIbi2S2mvLHU/MiQkqGRJEOM84JXP40Ae33Hgzwvc6faWFz4b0WaxtN32e3ksYmjh3HLbFK4XJ5OOpqTU/Cnh3VYbeHVNB0m9htxthS4s45FiHooYHA+lcZ8X/HeteDb3R1sdP26Rc+YbzVXspL1LXaPlUxRuhyT3LAYz1xXMyfFPX9Q8SjTPDV94evLL/hG31tdQksJ1WZ1dgVEfnAopxjBJKnJOcYoA9vtoIbW3igtoo4YIlCRxxqFVFAwAAOABUleCy/GfU9R8LaHeaHHbjXb3SptRm0s6a1xtWJnVpDKbiJY4y0bY++2Ox4zc8PfFTxB4v17wfpWhQaXpsuq6O+q3kt5byXCptkaMLGFkjz8yMeT0I9OQD26ivDfFPxV8V2fifWdA0fSba41PRbKCaeGHTru9+2TyKrFIzFjyk2scPIDk8Y716rF4lsrbwtp+t+IZI9DiuYYpJU1BxD5DuoPluWxhgSRg45FAFDxYguvFng+zlwbcXU12yEcM8cLbM/Qvu+qiusrh9HvR4r8bwavYJI2h6VaSwQ3LxlFup5WTc0e4ZZEWPG4cEyEAnBruKACiiigAooooAxf+Er8O/2y2k/29pP9qqSpsvtkfnggZI8vO7IAJ6dKbpfjDw1q15FaaV4i0a9u5lLxw217FK7qM5IVWJIGD09DXkPhnwh4r8NeLH/AOEai1nTfCNzLc3WpWmsSWciZZOPKMUjuSW7nHAGSea4f4P+Gdd8T+DfhpJpGnm1tNE1G6v5tTmljCOfNOIlVWMhztw2VAwOpoA+l9J8XeG9YvjZaR4g0e/vACTBa3scsmB1+VWJ4p2m+KvD2qag9hpmu6TeXyEh7e3vI5JFI65VSSMYNeB6X4E+IV/4q8F6n4ittVfVLC9u21LUZtSikgVHAWM28SyfIoUcgIpJPOeMdH8NvCHiPTfhlN4L1Lw6bHUMXyJrhuIGRWlSQJOu1mk3/OEPyj5f4u1AHrmleJdC1e9ns9K1rTL67gyZYLa6jlePBwdyqSRzxzWtXgvwr+Hmr6PrnhC413TdcjvdDtp7Xzzd2AsVjZXGEWJfOkDFs/Pggkkk9D71QAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVS1nUI9K0q6vpuUgjL49T2H4nAq7XB/E298x7LS0bgn7TOo/urwgP1bn/gNTOXLG5vhqXtqqgcOXlELyznddTuXkPq7HJ/n+lTxARRZxxGufrUWPMuf9mP+ZqSQ5kWIdB8zf0FcB9O+w+DKqAeWPJ+tTW5DSvJ1A+RfoOv61WlYrGSv3jwPqalhZYY+fuoM0Iloe7l7nb/AAxD/wAeP/1qbcHe8af8DP4dP8+1LbLhPm+8x3Mfc1Cjb98vTceM9lHSgSRHcHfNHH2H7xv6VlxH7Zri8/u4cuf5Crk0uyCafu3yr9BxVfRoiljJK3+suWwD/s/5z+dI2WiNGJtwkmfgN830A6VYt38mBpZBz94j39KgccxxDoeT9B/9eppPnkSIdB87f0pozY9T5VuWbkqNx9z/APrqu5aC2Jz+8Pf/AGjU8xy6Rjp99/p2H51z/iLUXW5gtbGeD7WsgLxPzuBUnB7jjnPvQKKuOuG2Lhe3AqC3tG1HULTTojhppBHn0Hc/gMmoILwXO7ejRSxf6yJjyp7fUehrsvhnpwa5u9ZmQlYAYovdiPmI/DA/E0Ja6l1ansqbkdJ4lMdrYx28Hyx26rFGo9ccfkBXMwWLX+uWWmD7oID47fxN+nH4Vo6lOXviLnBWANNIPVj0H8q0PhnZtPeXmpzDJH7tSf7x5b+n5159FvE1rvrr8un4fmeXVl7GiegooRQqjCgYAHYUtFFfQniBRRRQAUUUUAFclD8OvDEVzZy/YJpEspBNbW017PLbQOOjJAzmNWHJBC5ySetdbRQBxGofCvwdqFzfT3ekuzX12t/cIt5OkclwucS7FcKG5PIHOTnrS6j8LPB+palqF9e6VJLNqEyT3iG9uBDcOn3TJEH2NjsCuBk+tdtRQByepfDvwtqT6+95pQkbXUhj1HE8qiZYseWMBhtxgfdxnHOaZP8ADfwpPNq8sulbn1a1jsr0/aJR5sMaqqL975cBVGRg8cmuvooA8q8a/CC210RQ6PdWWjW6aYukmRLe4kuDABjYXW4RHXaFAEiPgjOTxjoIfhj4XWy0OCaylll0iy+wW9wLiSKQxFdrK5jZdwbnIPHJ45rtaKAOHX4U+DY7LTLWHSHgi02KWC2aG9uI5EjkZmdC6uGZSWb5WJHzEd6t6N8OvC2iz6FNpul+TJoaTR6eftEreQsxYyDljuzub72cZ4xXW0UAYfiTwvpviNdmqNqJiMbRNFbalc20bqeoZIpFDZ6cg8cVxV58GtFu/GSao0rwaKmjjRxpNoZLYbN5bJljkUlSCQVIwepJr1GigDj9Q+GnhK/ayMukCE2dobCE2txLbYtznMR8tl3IcnIbI5PqajHwx8JpDo8cGnT2x0iJ4bGS2v7iGWFHOWUSJIGIJJ6k9T612lFAHJXfw68L3M8U40+a1njthZiWxvZ7V2hHSN2idS6+zZrprG1gsLK3tLSMRW1vGsUSA5CoowB+AFT0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUANkcRozucKoyT7V47qss93qF9qMyHdPIdi+iDhF/Ln6k17DNGJYmjb7rDBrIufD9rLjAxjkCsqsHNaHbg68aDbfU8rijMEJMvb5mPqaIVOCW++5ya9BvfCqSAbW+UHOMdTWLf8Ah6aJWMand0Fc7pSR60MZTn1OYJ3y8fcj4Hue9JJzIkfb77f0FaD6XJbR8qdqj86qpbSrlnU72OT/AIVDTOhTi9mMnf8Ad7BndJ8o+nc1FckiNY1+83yj2pyAu7ORgD5V+nrUYYNM7n7sYwPr3pFoz9WLO0VpFwWworTRV3qif6uFdi/XvWbY5kuZ75hkJ+7iHqx/z/OtBl8uBYgfmf5c/wAz/n1pIqXYfBh5HlJwp6eyj/Oakt2zukbjcc/Qdv0qOThFiX+L9AKSc/KsQ/i5PsKZFrivcRwW811OdqAF2PoB0Fc1eXNlcW9zJPbsLjGZFMe2UnqMd/pj09q0NZeC+ik02O6Edz8krBD8yAMCDj6gVzWpoTczDULZbi7lQRQOiZVgM/8AfJyST7dOlBcUP01Lu5u/MljbzyogRSMNKSRgkduoGPUmvbo1h0DR7SwQjMEW+TH8TdT+Zya4z4aaT518dQuzug09AAx/ilx1/Ac/Uiui1yRLqaKIH97MfMlb+6g6D8h+lcuMny0+ROzl+S3OTESVSoqfRbmDqMzCzbf/AK+7fzG/3R0/WvUPCmnHS9CtrdxiXG+T/ePOPw6fhXAeFrMa54mWRh/otthyPYfdH4n+terV0ZbSdnVlu/6/DRHlY6rzS5UFFFFemeeFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU1kVhyoNOooArS2MEow0an8KoXWg28yMAApPpWxRScUy41Zx2Zxt54XwhESj2xXP6l4ZmjtTHAp3Hj8a9SpCoPUA1m6MWdUMfUiePjw/PbCOJVJSIZJ/vMepquLSbzXkdCAPlXPYetexyW0UgIZBzVGfRreVSMAA+1Zuh2OqGZ/wAyPJIkYlpZAQD0z2UVFu+9I/G7nnsK9QufDMMqbeMelZN94Q81cJjB61DoyOmGPpPc8cEULXN1Begx3DzNPDNnDEN02t6gfKR6AdqTTJr2Wa4tp1SWVGWNHThpCQCvy9B19eteiar4HlmiMbxLJEeSGGRVjwX4OGn6kbuWBI7e3BMagdXPf8BUezlfU6XjKSi5JmvY2MWjaFb6a8mCEM1y47k8n9ePoK5W/uDHbSSE/vbklVHcIP8AOK6PxHFNJJ8u4NN80noqjpWd4U0yTWPEAuJ48WlthiCOOPur+mfzrzHGWIq3tvovRf5vX5HF7RQpuberOy8EaR/ZWjIZVxc3GJJPUei/gP1JroaKK+ghBQioo8WUnJuTCiiiqJCiiuN8Z+N08Oa3p+l/Z7YSXcbSi5v7r7LbKBxt8zY/ze2B25rahh6mIn7Okrv/ACJnOMFeR2VFc7J4ssbKOz/tpZ9PludmGaGSSBS5woM6r5fPHVu9Ml8ceHo9XTTDfs1210LIeXbyunnn/lmZApQN6gnjvVLB13tBv0Te3p08xe0h1Z0tFef2nxIt7nVNDtYLNrmLVDOyz2izyrHFGdocgwgklwQR0XqTggm94X8e2mt6FLqklhqUEAuGij8qyuJ/MQFgrjbHyDtOcZCnAJyRW1TLcVTjzSg7f8Fr80yVXpydkzsqK46Hxgup+LdB0/QXtrvTbyymvrifDFljUhE28jB35BBHbHBrWm8UaTFq82medPLeQFBOsFrLKsG4ZXzHVSqZHPzEcc1lPB1otJxd7Xt1SvbXtqNVYvqbdFcxbePPDVwzhNTVEWFrgSSxSRRvGpwzI7KFcA8fKTWfrnxEsLBdL+x2WpXjX12luoNjcxfIQS0i5i/eYAztXJPaqjgMTKXIqbv6W/MHWppXujt6K5NPHOlLeXsVxPGEhuRaQpAk0s8soUM6+SIgcrkfd38Hnb0qR/Hvhtba0uBqDSRXUD3MRhtpZCY0OHYhVJUKeucYwfQ0ngcTp+7f3Ptf8g9rDujqKKhsrqC+s4Lq0lWW3nRZY5F6MpGQR+FTVzNNOzNAooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAhUHqBSFF24wMU6igCrcWUUykMo5GKdY2kVnD5cKBQTuOO5qxRUqKTukNybVgoooqhBRRRQAVzniTwrHr6XUF1qupxWV2oSe0iaIxuo7DejFfqpB/THR0VpSqzoy54OzJlFSVmcJd/C7QLnULW5Ju1W2aBo4dyOoEIAVQzqXVSAAVVgDjpnmsXS/hrejXo5ru4Wz0mGe5u47aC6+0N58y7C4ZoU2gA5AO/kfWvVaK7YZtioxcea+ltdbdPvt13Mnh6bd7HIaZ4B0zTJ9Llsbm+ibT7I2C4dD5kRJYhsrwSTncu08enFVZfhppEuh2OlSXV89pYu5t1fynCI45Qq0ZRh3DMpcHkNXc0Vl/aGJvzc7v/wAP/m/vK9jC1rHLeFfBGmeGbyO5sJbp3jsksEEzKQI1YtnhRyWYk/yFQan4A0zVvEA1bU7i6uJgWxHshjG0qV2l0jWRlAPAZz+NdhRS+vYjndXnfM1a/UfsoW5baHn1p8JvD1vpd1p582W2nh8nJht0lQbgwIlSJXJyo+8zZ75rauPCKXU+lXN5rGqXF5pkzzW9w/kBhuUKVKiMKRgHkruG44PTHT0U55hiZu8p3evbqrP71v36iVGC0SOIX4b6bFPHdWmo6rbX6XNzdfa45IzIWnAEgO5CuMAAHGRjrT1+HGiRQSQ2r3lvE+ltpKrHIvyQs5d2GVPzsWOSc/Su0opvMcS/tv8Ar/h3977h7Gn2K2m2cWnada2VsCILaJIYwTk7VAA/QVZoorjbcndmqVtAooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5012=[""].join("\n");
var outline_f4_57_5012=null;
var title_f4_57_5013="Liposomal amphotericin B: Patient drug information";
var content_f4_57_5013=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Liposomal amphotericin B: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=see_link\">",
"     see \"Liposomal amphotericin B: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=see_link\">",
"     see \"Liposomal amphotericin B: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F134881\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F134882\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      AmBisome&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10026645\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026647\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691491",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat yeast infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026646\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to amphotericin or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026651\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698465",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697798",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may need extra potassium or magnesium. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026652\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flu-like signs. These include headache, weakness, fever, shakes, aches, pains, and sweating. You may be given drugs before this shot to avoid these signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698217",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of low potassium levels like muscle pain or weakness, muscle cramps, or a heartbeat that does not feel normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697875",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Anemia, low white blood cell count, and low platelet count may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697935",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698395",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Kidney function that gets worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699057",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Big change in balance.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699104",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698630",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy or pink-red urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699038",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad muscle pain or weakness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026649\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696445",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor for an office visit.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026655\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026656\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11506 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-B86BBD9DD2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5013=[""].join("\n");
var outline_f4_57_5013=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134881\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F134882\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026645\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026647\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026646\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026651\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026652\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026654\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026649\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026650\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026655\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026656\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/4/1096?source=related_link\">",
"      Liposomal amphotericin B: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/3/31799?source=related_link\">",
"      Liposomal amphotericin B: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_57_5014="Body stuffer wrapping method small bag";
var content_f4_57_5014=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F85934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F85934&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 596px\">",
"   <div class=\"ttl\">",
"    Body stuffer wrapping method with small Ziploc&reg;-style bag",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 576px; height: 410px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGaAkADASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDj9N8UI4jstQZ4p/uAseDWxDIwRsZbnjBrnfHVusmpQyxxqJd21mUda7fwjYT6rCkcCru2jnpivnK1GM0qlJfF0Pdo1pQcoVOnUpws5CnJXHPWo2kZoJX3HJYd66DWvD93pLKlxJbyBgWBjkDCuaX5o5EB5z+Vcbpzg2pKzOmNWM1eJovLINhPPyjvVC53NMpDEk8de1b8elvNHGHljTKjnNZuqW8dpeCNZUceq1PJKL5mOFSLdkV5ZWFxPtJICDjPTmpkDCAtknGSeeaZC9oI7mV5f3hx8uKhjuon80FyEzyAKOWTQ7oe4IIVHK4UZGeuTmq7b1ZyrNyeeavWZtJrj947Kvrio9Z+xwS+XaStJu+8T2q1Tna/QSmr2JHmLjO8hhGOM1GGdQVL5OKqPdIMkoxG0Dg9s1saZLYTT7pkccdfQVmqbBzUehVg8xNuJDljnr0qt5sn2hsszAdDmtfVrnTY5QtjExIGASaxIrtdzeZHnORgUKDuxxnzK9izFK5gA3H75GajcyhmJJxjIrW0m5sJBsNqASc8k1c1yS0SBfstohJGM1p7Jpc1yPbpS5bHNiRxu5ZjjPWorIl3MshbardAf51JEz7sMgWtWzkjMQiMMav/ALvJpqm2maSqpdDmtItnttS1GXJPmzFlOc4rSkkLRyYY7h0qRwFvJyoXcDnAGBn396rfbGj3ExhuehFXiFJ1LvsjLDNcmi7/AJkchZGYc8rxz3qKMyPJGTnGSSM9Perp1hfLkh+zod4wWIyfwqpbXhd8FeBnqMZqbNI3532EHzSneWwT1JNSSeYq4QNtHOfWpl1Mxr5a2qEZ67a2bbWU8oF7OPCnGNnWnZvcmVVroc0C0fDE880gdnO/cwBGMVZ1rU3urnekSxjPQLin2V9GIVM0YPPXFNprUftHa7RE5fKLuPue9OUMZMlm+9371rJqlqMgQKx9QlSNqltHnbAGBP8AcqWmtLk+2f8AKVpWfewBPHT3phDHBLMBjp6VotqttI+wW/pzs6VPPfwGIItum7HXZWKpNbiVbyOclMmRk4UHr60MXdh83OOxq8kiEyJKigZ4OKuwRwhcMq/XFWkynWt0MFW2tjcSR71M0dwpd5FZEIO056113gu30y4vr9NREQRbcsrEcgj096wbyKWTT5J95McTH5T79xWk6bjFSvuTHEKUuVIxQzR/MM8jinOCwXcdoxwfWoHJKx/Lwy/rmnxhmll3nK4GBUvudHQsROwDAs2QvUU1pMRhQxP09ahjWTEix4C44zzinRIUVQzEsGxnGM0rW6gSBP3ifPJgH7rHirMXCoCxL4454qFNwlZjtIwefWiIkSK+c4zgVEm2KxaRirFSzdcgVNvfGASPxqNWG8N2HU05myWbHfjNYPUCqYxJd7mZiQMjB4p2pljbICx+9Ssv70sMc4BHpTNV4gQ5xg4rRNuURpK5TjdizfOQoXOSaZGSI0Yn73ofemTbkXCZbcMHI6U62IaNTglxgZPaujpcbsRkSO0IJYsz9KtsXaRgCfmJ70tpJ5d4jMcCLLA4744o3Ez7hx7DtSlJsXUfGQkO5WYY+UDNMjaQOMyc/d96kVAI1DeuSar2vnmecyKWiTlO24+lStb6idkXn3hwvmEBh1zVa3kcwMq7sB+9SxSs6qzJyONp6GnRoEt/lHWTcahOysw7CMSFcsSMDk/4U+M/Ko3cnuTmkkbcjhepPpTYn2DJIwoyc0rtoaRUvVZrqJtxAHOM1WVtrEcuGJzg1Zn2uVeLD4UkEHOaqRuPJY4yMZx+NdEG+UqxoXMjbEZed+0fTFKjO7qWJG1sYzTGc5GR8oUH6VJAAcDueTWT0RITSurgAtjPWkikkmuJCDhQMfU0+QbmAam2oOZkz8oIwfwpX0Az76WTc252GMY9+afFy7b2J54we1MvlOZCcYGBx9aIH3BcqR6E10fZ0KsWnEjDAYqAOx5pyOTtKscZ9etMUuOCO360kbMAN20MAcmstbCJI5WbcQW6kcmhZXC5bJz0waWP5l4OSeDSxsMkfhSbCxHdkm2UEkEsO9Z8hdpnCSNkEcZ61oX5P2XLcDcOcVmhk2u3OWYda2pN2AfAtxyBORzyRV61Vk80ZyWxliecfWq1sOCc57mpFkCeYXYDOB9aU23oDSGMS00u3IwSM59BVSBiCp3HccAnNW0A2vwRkkjPeqNurMQSflyM1pBjWxT8ezyWt7bDJMbyFD68969W+HcckFs/l5MflKWzyQPWvPfHNr9pMT4V9jls4zit3wJrJFlKJT8iAbW9RXXCSdCDXS9zxKkZe0kn1SsdrraW8s0qyFllB4IH6YrhbyJI5ZNsrFd3PGK1r/VYLm8fyRJz6tXM37+ZMqoGyW5ANc1WfPLQ3oU3FWZq3F+YrdQjSZ45qhO+9izbs+pNV3ceUiuuPrTgy78NyPpWLR1QjbYhhGZbltpxx3q6ixrCG2jJPIzVNZCkrEKB8w21ZLYVvl4z1xTlcCzC0YLZQe3zYqMNG9wfljxxjkmoors5LbeB7CmQznzDtAzkdxSa0CxekWMS8KnGMVLvwGbZGORjioWuH6g4z6mlFw2Blgfx6Vk2xctyeAl5SfLUDk/dqFVBkcFAPotTW90UQjzFHp81RWTF55d0qkZ4+Y00rivYv6Wshw+AE7fJXTfZnuLYnYSAvUR1BpFopgGXXH1retkWGJjJLsUD14rtpw01OKtU10OLa12zndkEf7NSW0apKW3EtnA4q1rOpQxSNteMnBx1rJtLwSlXDAkdQBWTsax5pK7IZlZ7i52luGx0xms2ZJM5Bb0rXRxI1y8pUANgcdazjhspG45PTFTiPjNMM7RM9g4mI53AdajhEhlUc8g9xWnLCs24MBx3xUSQos+GHYjpUqWh0cxCiS7s7mGB2NXWadYDh5Bn/bFSQ2rMpwCRng7afc2JMAHzDj0FNambkupi3IkABy2fduaYUcRgDdyf71WLm1YKu4MFHTipVtGYZw5XrnFPmVi7ohjM2Bhmx67qWGWXzOWbduHO7ip/szs+Iw+M9Mc02K1lWRdySYDegqWx3Rdkd0cFAee26oDezrKPvMM/3qnuoyMn5gM+lUSjiRc5PPOKyg9AsrF37dIkgd1LIO2eprShvgUHmRDOOMEVzVwjBCdzAlhmpZN0e3BY8e1adFYl00zpbO5to7sNIsgBGGKgZqtcXOLC/jJARjuAI68/pWBE0sjjYzFiwGK1JU3Wd0XPITpjvQ72sJU1FmVE/wC7yPurwB70+AHLDoeBUFqv+jOzZX581YXBQlf74wfalLqdRPZKFEw4Hce9MSTcVGfmUk06J8I4IOWIApEJllkyBtXqfSs+rYkSxgMwOPlWpJ2jVgik92ziogqxzEDJHB69aivnJlVgTgJ2FEUnoTJ6lq1YPLjLYxzVl7gFwFHArFhkdlI3MPTipklAzgkAjNKVPURaWZPMlJOcEDGKbqEiOsSuQF3dazo5Vkkc5blyM4pl+QRGWZsA1ape8hruWfMiLkbjxwDjrT4EgjEmZiQzdAtY3mjeTubb0pFkK7GycMR/+ut/Y6bibNjdEsoTcdx59ulPEkKkYJLcc1j78yuQzY7fWpI3IGMtx04qXSGmzXTy5Nh3EYNWYBbmRt0+M9RjgVhJIQfvN05p0Dje2WP0qHSB3fU3xDBuAWYFTxuAxTZY4YoViWcFQScgdax0mIHDtgH0pHdjHHubvxxUqm1oyde5r2cUcscp+0JHzkbqz9Si32jpG6k7lOD0IB6VBFIVVmDDlvSk3nB+ZTk1ShaV0NX7ludkIDRERrtxjpmqdqu1WJ24PUZqG5dg5VSDxniq4uGTHAIxyc1rGm+XQptrQ3JgTll28jgZxmpLY4UFgN+OQKxppXKKFI5HrViF5FGTydoOc1nKloTdmntKkMqlqghjlBcvkF3J4PAFRG8kC4xkCoReM20hcVChILskuI22/dyS3WnRRlUUBTxVSe4cRjjgN0p0V84YfKeP5VpyS5TTmZclDiNmCtnPpTV3hgCOCMkn1pyaiRglc08ak5LEqOvaotJdCeZjI0IUleC3OAMUqKEXJB4/nTl1U7QCoz3J5pj37OvUdMjAocZdQUmug67GYRztAINZs2NzFj8ueQOtWJrrERJOORUD3isApVMnkcVpTjJBzE1nIrFgikJgYyOtSJCskvzLwPWmWFxG0p8wjn2xWjE1pu/eHHHO01M7p6A52KUgyzbfmC5rIt2xgbhkMM/nXRXrwBHFqW8jOcMPm/GubXBEZboWH861o9bjUrxubuuyeWkjAZyWzmsTwdOJY7tYSMoM4PPU1Fr2sPcxeQi7GJOWbqfoK2/COkSQadPcSxeWsiALgcn610QpunRfNuzyp1lUqRUdluXYraQRfaCCqgVio2b3eSx5OOeMV176Xc3FvbR2yyMHXLBjnmrMfge9iiikuAkcYJOScVnGEuxt7aEd2cjdN/qsIcAZPNDoWJOzAI4rrbrQbZEVWctg44NSPp1qpXClwOOtZOLS1KVePQ4ZA2/7oODVlw7AgAetdV9ltll3CBasyQwDpbqOPSk9dQ9suxwEkUrOoQKR3q3Z2pC4GCN3UiusURBj/o8ePpmp1nRHwIUAHtVN3Vmxe0tqkc3PbEMAWGAB/DTEt8ZAIPocV1ksmWIKJ09KjZwvzbEJ+lYNpaXGqr7HN21szE785x121esNNcu+A2PpithLg7vuoBj0psF3I0jYwOOwqoqLe5Mqkn0J7KKSOH7zjb6Cp9Qutlm+2WTcq9CBzTdL1NoJQ0qq655VhxTfEbfbkZrOIcjBAat1L3NGc9m5q6OInuPMuG3BiDyafpbmKRflkOT61o2GiXLzF5UCD3NbFrYC2ZOQcGpjB2OmdSK0RiRyx7LkFmJDZKt2NUY0M8o2Fgc8fNWxfRpI1yFCBs9qzbdWhZGCriliFafyQsM/cY9gezHI4wDUcKjzQHDMWHrUchzcvtPXnOa0NOtDJIGJ4X3qIroaSdtzSfT3WyWUMy+2azbtisfLk8+tbt9g2AUHke9csFMzc+uK1qR1VjKk3LViKWLY+Yqcng1pw2jMnyuQo5IB6VFb2fBP4da0oIFRfvYBHrUKLe45zS2M9IlR/vnOfWpkjQOuXPXpuqutqfMwc9akEB85cDgHk0nF2uO6fUnuUhY8uCenWq729uZFyoxnsakmttxBIb14FV3smMgKu/AP8JrGMXa9i7ruOngtNqq0ZyT1DVKtjbkB1TnHd6pTafcyMNoJOfQimTWF/t+SGQk+imtEnoF1/MWkt7eKYkDBzkbW5pJMNpl6zHI44J561mR6XfrIjG0n3E5J2GtRdNujpl3LJaTKkcW9iVI2+9VOEr6IpOK3ZirIDFgdAScUtuFKzZPyBwQvvS2AWSA7iB3yKS2XzbYKBn58nPaoel0dJadiIhgcHjiiHCD5ujHkeppUdQpZAcjpmjHG7tnJrLyGLu4I25IHrVC4cEIFUgY5zV9nAjIAwQMnNUbmM74t/VgO9XT31IluOVAduARxUUiHLD6VYyVTABJ+tR5IAwPfrVpsRUtEIVgVx8xP1p97/qF4B7Zp6qRsO3B68HrSXkZaEfUd605ryuNLQzcEjLDHH8ql2A2qYwM9KjZX3qvPIOeafbEtD82flOMZ6Vu9rk+o5E3YIHOan5A3EYANRRRsxJBPB9fapY9xwrA475PWs5DG8lR/CxwMU+IAOeOnOM1JMuCmAckE9aSAbT3yOtRfQY3ORuzxnpmllYhkAzj2NSLExAx65pHjbfg5454FK6BWQYxarwfvk0mAF9aaSywgHpkkcU7ICEnGOucUDRTu22ZIB5GOlQLmRfbNTXO9m2MmFYdTUMaFRg4I710R0iTIlwoZcnGMYGKsDAC88Cq0isWTGDg5qPU7xLOHzZgvyngZ60uVzaSJlJRTbLcjDhFOSetMjUkFScY6VkaJqv8AaM0jNGFAOOG7VrBtkhPX8aqpSlSfJLcmjVjVjzQd0RXWQi7W/iFM3FhkMR+NPn6gg8FqYqgksOM9PahbGrROSdpw360kbtnlmyfQ00giI9cjrTFD4yvJHTNJITZZ8w7FzkYpsbuR8zE54GKjdWeDaOMnFEEYjBAzkc0rKwtbj7pmMJ5545xVKZ2LKRjA45FOvrortUDOWAbikYYJLH05rSEeVahzJtpE1vIQT0OOlTwuQTuwCahhA3MRjHSpFGXHTNRKzGi6WYwup6Bc4rGgJKw/Nj584/GtlMbXyOMEGsy2CgR7h8ucGppO1y1sb+n2FtOlozxI7yNkt1r2yy8J2C6TCN7hnUMwHI+leK6KX/syzkgKnHOR25r3PRb37VpVtPM3BQZC/Su3CKMpyU9TwcU3GEXHQadDk+X7Pc+QijAWNMcfWoJfCrT4869lfB/i5rVfVYUBVB+JNQnV/Q/rXc4UDhVSZRPhCJgAbh8D0FP/AOERgx/rpPyqz/bDdm/WmHV3/vfrUezw/wDKP2tTuVj4LtC2TJITT/8AhDrQ5zJKe9POrt/f/WmnV2/vfrSUMPtyh7Wp3Ih4IsMn5pfzpR4I03cDmXI/2qe2rN3f9TTf7Wb++fzNJxw9/gH7Wp/MS/8ACHacevmH/gVL/wAIdph4Kufq1QHVSBy/6mmnVRj7/wCppJYdP4A9pU7lkeDdKBz5bf8AfVOTwhpCHiI8/wC1VI6qO74/Gk/tZO7j86pSodIC56n8zNA+E9J7w/8Aj1PTwvpSZxFjP+1WUdYjH8Y/Om/2zF/fH5//AF6fNRX2EHNUfVm6ugaYv/LJfxag6BpR626H8awf7ahx/rF/P/69MOtQf89F/P8A+vVKpT6RQvf7m6PDeiqzMLSLc3U560N4d0Xp9igrn/7dtzn96mRx1H+NB162/wCeq4+opOrT25UC5+jZuL4a0MNu+w2+fpVlNH0iP7lrAPoK5c+ILXvMmfqKQ+IrUdZk/MUe2h/Kh2m+rOrbTNKx/wAesH5VGmkaOpyLO2H/AAEVyx8SWv8Az2X6ZFNPia0H/LZc/UU/bw/lQcs/M7FLHS1HFvbD/gIp32XTQMeRb/8AfIrij4otBz5o/MUw+KrQf8tBSWJj2QvZzO58jTx0gg/75FHkafn/AFMA/wCAiuEPiuzxkP8Aj/kUn/CWWxxhj/n8KX1mPZD9nM73yrD+5F/3yKUJYjosQ/4CK4FvFUCjnd/n8KafFsOThXOOtL61Dsh+xn2PQR9kHA8v8hRm27FPyrzs+L4wfuSfmaY3jFFP+qf/AL6NP63G/QPYT7HpAeHPylaratcxLo98rwiVfJfKgZyNpzXEWni2OWVUMUvzemTTvEHiix/sm+iiunS5jgctHt5YEEcU54pWYKhO6VjyPRrjzNOLop5YjHoKtWnEAEZzg4zWToKGLT4wchgOa2LdlFkuG4JzwPevArxSk7dz6mL0RPE2EyCNxUfhQrkEbjkD09aib5FKgZ3dhUtsHeSKFB+9kcIoPvxXPy32Kbsrlq3i8+3m3JtxxgjrUFzat9oiVcOyqBgc9q9rbwXpsWjQWReRJBhpnU58xsd/aqX/AAg1puLRXEkeeyqK9JZXXjseS8yptnlUGlTeUN/B5zkU8aUDuLOeT2r0+TwDC5P+nT8+wpg8ARgELeyc+q1Ly7EdI/iP+0Kff8DzT7BGCu4scelRXVlbeSAVYgn1r0z/AIV6o+7fv/3xTJ/h4ZEA+3HA9UpRy/Epr3Q+v0/5jyxbO238xMePWk+wW0YLJD1PPWvTD8OJccagM+6Uh+HlyBgX6fipqngsT2D67Sf2jzE2cTMfKUpz35FQDT2SfaMsT0wK9OPw4uxgC8ixn0NCfD7UUAC3kXHTrU/VMQt4lLG0ltI4SHRjIoaQEEDGBUAsIVdlO4c/WvRk8FazG+5LqHP1qCbwJqrSGTfAWP8AtVMsHXtpFgsZBvWRwMdgSvytwM9sUp08gHcxyTXd/wDCE6uqFQIT776hk8Ga5nIji/77FSsLXtrBlfXKf8yOFl0z5VCsehJpg02XaBuyOld0/g7Wgy/uI2AHXeKZ/wAIlra8m1GR2DCh4esl8LKWLh/Mjg7nTpHmAGOnUmq40yTcBv689a71/C2ueZuNhkDvkVXPhfW1YMdPcke4qlSqxWqf3DeKg/tI5B7CQEFfzzWJ4j0C6v48jkKc7c8fWvSv+Ef1hTzp8mO/FNGiamhIbT58H/Zp03WoyU4oirUp1YOEmrPzPKPD2j3Ftc8geWSQ68ZHpXSNYy7ydmQK6G68Oag06vHZzR5ILYjPIqydMvQ7ZspwDyPkNaYmrKq1NLUywtqKcL6HFXUM3ybYz15BFLFayFSSh446V1EmnXQA3WdxnP8AcNM+xTr1tpsjn7prDnlbY7fbJmA1o7Jt2H8qYLaWOVU8onPU+ldGLeUON0EgAHXaaDG+4s0cg7ZwalTkt0DqX2MBrVioQpjJ496jNvIAx8tsj0roGiUbCyMT24oXbudVD/iKOdoFUOaWAyR5mj285pj2paYjc230rpZCgU8H8RUZ8osW5474qo1HcOYxY7ErHgMck9xVyDT2kbIZeOfmOM4rXjMTHkg465FSS2qOCygHI4C1Lk31F7QxbgCK3BHBYn+VYdkiiSM5LZPc8V0Wop5dpGXI7+9czpsZBLAsMthQee/WtqK91myd0ifwvqDpDPYTOqeUx8vHevSY/Gl7BpkFlDBHvjIXzPUemK4HSNMePW5bp02RgH73cmt3TxG14yEAqGz1q6tXlq3p9dzgjRU6dp62OxtLfVtXmNxBI8cZxkL0zV650vU7fHmXMgzWdB4is7G2SMQXDOpPKvgD8O9Rz+NEkZkMTsFHds1o6yS31OP2E29FoSzR3abQbuQ+vNUpWuM/8fcv/fVRjXY5ZFDxNyKvxNBOSwiIJFYSlPozVQS3RkBrnzzuupyvpupZWnViPtExH+9WsttCG3FCOahnS2eR9wYYHrSTmtWyrQfQyQ0uCWuZsk/3jSF3MwT7RKQBnO81Yla0XA3H5eRTBJaGcsWbjHFTKc77lqEew9shfmlk9M7jTGIEgUySYxn7xq1LcWillOT6EVVNzZ+aOufWsHKTduYtRVthP73zvz6mo4TzLuZuGHenPfWiJn5ifaoTfW4jdjGeCO9CnJbsfs0+hJ8gQ5LHJz1puAyZAOfr1pkN9Ad2Yz04+bNWY7qHywfLPHX2p80rbjcEuhFtGTjrzkUlvtZl3DI5p0t/EmB5bEk/pVVNXiR1DW55JGc1XM2rXBQ8ipZsW1G7AXCb+nvWiq5JG2otN1OB7y4AsmAB6561buNehik2paHcB0zV1m29+xnRTtourK/lnLZj6+1HlE5/dsMggcVGviM7z/oif99Vpadq6Xh2vb7MDJ2mkaOMo6tGciMpA8s560SJIMFYGxnkY6VtJe6ez7d5XPGSO9XHtw8IeBwy+1NJtXTIc7bo5gRscbUbIPYUpil6iNsE45FbkSoHIc4Pck1alsmaDzIyWUc8UrOS0E5pPVHNiGQJtEZxjNS2scsm4MhGBWlGCrlTkYHQ1atIHYHGSazkpNFOSRkvFMpHyMVJ9O1QpFcGWQ7CUxjBrbnhl4681WRHw/PPAFZxbSKumZxjmJAWPGO5pywSsBuVatbJN4BB60eU3m9Dg0XfRFXJ9JZ7dsSyDy5PlZQOo9M1T12a3Ok3SeUonKld44yuemPWn3R8tx1BAzxWXcEvDcNL2Qtz3rSUpXSYqcE5cxhwK8NgSgyDyc1a2lbOFlIy44qATFLBS54PpVthiOBMAfLuJom3fXud46As/LgBuRT4ZZIZVlXG6OTcrE9weKB/qnIPJqGHa69SRnC1l5hufQFlqS31hbXUxDNLErlUPAOKR9TQHCsR+IrzKx8cXUOgw6f9nQS2o2LOo5dfQj196oSt4k1O/mmsTMICoYbcYOfavejjFNJJ3fU+bqYOcJO+iPWv7UI/j/UUh1Vs/wCs/wDHhXlF5H4hsola6vJYwRkBgKojU9Y2krfPn3UUSxii7Nijg5S2PZRqr5+/+opf7Vfs/H4V4wNV1kA/6af++BUc2ta2m3F5nPcxjipWNTdrjeCme1jVX/v/AMqd/asnd/0FeGjxFrvzZuV6d4xzUya/rpAIuIzxknyxxVPF/wB4X1SZ7b/ar568/SlGqv8AX8K8UbxBrqZ3TQMMdfLpy+JdZAGTCc9ilP65/eF9Uqdj2n+1n9B/3zS/2u2eg/I14wPE2tZPy2/HqpqZPE2r7A3l25/MUfXP7wfVJ9j2MaufRfyNKNWHcL+tePr4o1bqbeHj3NOHirUxkm2jz1xvNUsZ/eF9Vn2PX/7WXuqY+tKNVjP8K/8AfVeQjxdqH/PoMf75qQeL73vaZ+j0/rvmL6rPset/2pH3Vf8Avql/tKI/wj/vqvIW8Z3C/es5Mez0n/CdOG2taSggc/MKpYt9yXh5roewf2hCT0/Wl+3w91OPrXka+Nixx9lm5+lPPjVVGWt5QPXAp/W7dQ+rz7HrJvoPRqPtsB7H8q8nXxvAf+WMw/4BTl8bW3OUlGOvyU/rXoL6vPserfarcjkH8qDPbHjH/jteV/8ACb2YOSZBn/YNOXx1YEcSuP8AgJpLE37C9jLseomSzPUL+K00rZN1WI/VRXmi+N7A/wDLwQffNSL41sD0ux+JNP267IPZSPRTb2DdY4T/AMAFNNlppP8Aqbfn/YFcCvjKxOMXa89tx/wqRfF9iR/x9xk/73/1qbrR7IPZyO3bS9LbrbWx/wCAiom0PSHHNnbEem2uQHiy0I/4+YumfvCpF8U2hHFxF+Yqfawf2Q5ZrqdM3h3Rj/y5W/4CkXw7o6ni0iX6Vzy+JbYn/Xx/mP8AGtXTtUjvAfIdWx1welClTf2QbmurMbx/oOj2/hq4kjEcEkQLIw7n0968O0lwQoBJOCc/jXrHxe1P/iQT2US5LDcz9QB6V4zoTBXiQnJbj6VzV4Rabievl0pctpM7q8RWnMnIYA454NW/CEST62m5cqM54rGv7h/tCoo+UJzg1r+FCI74uoJLZ74xx2ryYNqSlI7q1Pkpux1ut6ZHaRQ3ECI0chJZTWW1rp7TKWtwCepFGuPfXdtCLZX8ock1U8P6Vf6hfAfNhOxroabnaKPPirQvJnXaZ4ciu/Le2h5xjNdF/wAIq9taGSSMBVGTXQ+HbZdMsUL4XC5dm4Ark/HHjONIXgtmxGPfljXpujRoU+apuzg56lSXLAw9Y8qBGAPIrk7m6/dsWHJNZ19rUt4+8vwTVC5uWMWzJOT1FeTUkpOx6dGi4rUSe6MkzhMlgPu075vmJJxwDzWdbsXuiScdgOmatmQhyrcCpkraI6VpoX5HzKFxxioFk8y5CgjIyaWRwMEE80mnxhr85A5Ga50inoiaaBotpYfKBkmqEjh45ACcFuDWtrErea6ZyAABWJEjOzAn+KrjbcUdTW0GzW4uNhcAe5rpNRs7WytgXlUf7Oea5fRbN7y8EcZI+b6VpeJrT7LHEHOT71qlZXaMpq80rmZeXkAuCQ4OeAKr281qZIt7fNg9BVZxGHJKZOOKgRCHj796LJo1UR2na3bjUL2CINvV8HIp5lMs5PPtXMadG6+Jb0EkqST0xiugXKk59OcV04mEYyVuy/IxwnwO/d/mSXPEilevQ4q/ZTNFbSAnnpms92wyljxnvWnpFm90xRAa5mtEjonZbmcrv5pbduzXd6OkqaS2ScsM/jVKLw3HDJ+++91xXUW9vGtugVeAK2px1OOvVi4pI4sM9wrhmPmKSOa67weQdO2MS2CQa57WIFs9S88DEcmcg1c8OahHFeCMfckqKf7ueoVffhoX9YhWG4OOpGRVG3upkUeUTnPIrY8Sw7rRZgcNHz9RWNprpIhcEdsg1Na8ZaGdK0oXZ0NmGljLTMMkcGqF3dWkLupYZzg4qpqmpNboI0worAs4p9WuX8lSeeT2FS53SUUXCje8pOyN6G5S4udlvhj9KvXkkNtCrOAZCOAPWo5ILbQNODSYMhGM92NcrJqUlzdguCVPQDtTfuJdwjD2jutiSZ3lkYuc56Vn3jl0uI8nO3FaUmdqZ65GD61Rn2i3vXZVLjJBz3rntrqddPcynjY6eGByADkelaHlqTEoYkhQffpVIuv9lknv2B71cXLSM2cPsAFVO9vvOjqNuEBiUKMk84B9KbGuwJu6Z59qe2SAX+9jFKEAto968lc/jU30sMmQKZuTweo/rV1vFtzaT401DAioEUByTgetZshaOANzgjHSshEZJ3Qt8ynkHvWlHS7TMKkIyfvam9q/iXVNWkV7y48wqAFUKAAKprezbW6cd6qYIIHHAppYvwauXvascYRSskWotRlMjKeAB1296gv764SBTv79QKY2TJ6ZHSobsHyQxyPWnGK5kNRREuoyqVbeTkYxVk6hKIyQTyPxrM2kKdv3QMdOhqWUZ2bTwAAfyrdwiTyl2O8uJCCZGwAOKcL+bcSshIwO1VdwxheGP+FMhBjR8EF/eo5UPlRe+33AQljk9sinrqdwY8bufQDms9JCJFEgxuHT0qw5K7iQPTik4rsHKi81/ceQxz29KadRuGTIPJHpVbcxjILZJ/SopTtOc/KTtFTGIOKNJtSnCDcqenSiLU5sMxVME1j6vA1xY7Edo2H3SD1+tctLY6ii7ArsM53rIcGumhh41Y6ySObEVfZbQbO1utfRE2s0W8NypPIpIdULqWMSknoQa4FNNvpxuSBEfOSxbk11tqgS1QMp3BVBPvWlbDU6SSi7syw1aVZvmhyo3/7QXDfumzjkZp5vYWG0xMT9etZCzKxZQGHTk09t2VKjggmuJxOzkRotqEPlAiIjnmnRXlueob15FZTEMeP/ANdAOZHAyAvc0+XQORF+4vLcbd4O0nrioY7m23AfMBjuM4rPujkICQfmyM1DHlt5OQTwKuMFyh7NXNmGa1kcZIwenFSqLZwWLJjOOaxISI1UPknGBnrmnqxZdpG04zik4eZPs0bKRwEHaUOPeo4rWNgxAU5Y9KyFDBWI/WpIgY0GDwScc+9OzWzF7K7NSWzj8k7VBIqEWCH+EjjtVWV2ETNvIA96pvcSqzEOePQ0QU3tIHSR0EejoyhugxzzWhoiPYySNHJLHuGPl6E9q5qC6njEe1255wTkZq7DqdxKoQ4wOuBgihyqLqS6CeliHxUJFR7dZJHDfvJNzZ5rB0WDy5BITyeBntW3qalkyzFsrVOCJFWInr1XitYVHyW7m0KSjZo171fKdtxKhVAH51reGZl+0xo+MKDyfWqGqhjLI2PkyMk9KS0nCT/KB0JrjT2ZcvfptHqkF7awaPHudCcflWTpviiHTdWMkbKVIIJrg7+9kngSPcygdO1Z8TMXGM5HFdDrSvzR0PPjhI7M9H8U+O7u8TyoJmKfpXn+rXck9s+5mLuc9adKzHCjkAVnTBmjJB6Go5pVJc03c6KdKFNWiiazkVSTLnKrxn1qWSRgy7Rx3FVoyHL785CjOKldgCScfKeKTWpYlrKdxZwOGPanyyM+446sM49Kqwkx25zg5Y7eanhmBlUYOSeaclZ3Q/U0ACcA88enStPSI0QyTN0RaqworHCjjGDTZ5TEJEDceg9a5U9QlqrFe+kMkrydy2RVe3YmMsBgluadu5PIPNMhYCB8dQ5xmtEtCrWOv8HiKESTSMMjuax/E2oNfXx8sjYhIGe9VEuWityoY5NZxlJmlB4AGM1UW3oZKn73OxqlsysW3YHSnQktOhBwMChOIJHUZycdKiti/nRqSMAZzV23NStYrjXbxQM854+nStDyybkoODt/rWVARDq93LEMsz4YmtEzj7XMoB3KgOTW1eL5k12Ry4Zvka83+ZYlh5Clc45zXZ+CYI40Mj8t71yIYmAEc+mTir9revbWON/J6GsIytuaVYuUbI67WL5Gu9kZHGBmtO2mjhth5rAjHevPbW5eaUbiOTnOeK09SvPs9uqiXcQOeelaqr9o5pUNolzxFdw3QKRfwnqawdLlKXkbk4AfgVQW9Z5mwTgn86Ybhs7iCee3aspNt3OmFLljY9A8U6gv9lKquNz46VyWm3DIrurY+YCsme/klO1jkqMVLp8pUhTyBSrNyV2FKjyRsdPDbPqkqhmVYwRubv8AhXX2v2DSLZljKJH1J7k15w95JE5KfLj0NQTahLOjAuWA6g96mjNwWiJq0HUdr6Gl4i1R9Uvxg/uk4Vf61WggMbF8gkVnCfZJyvWrENwBECxOTSd3qzbk5VZbGik5cRiQd9oNZ8xVBPGzEhkOfrViznSSQRDqDuzVVyHnlHXarZqGrMUNGU4AP7PUFSULZb3q+JFclR1bkVQtkY2kaE87s1ZcGWRQqlDgk44qpq7OmwryZZck4YcfWnNuZC2Rt2gZplwAGjAB3Y4P1pxU5iycjGD7mo6IaLCfNBCrHkc9OlU5LNozI4Hy9vWtGHBcE5xnbjsDVh13b9wB9/WpUnEwk7M59oSD16inrE20kc4OKvTRr5xjKkGrUdsjcL71o5sfMkYwG2XGSceoqO/Ui1BJ/M1sy2DRztjqRjNE+lNLAfYgU4yvJBzqxywTcNqcg1NNC0VsHkwHPAUDmujj0dLc7to5B4Paqs9qZZfMbBA4HvXRKdiFO5kJFgAnlu9GOv1rZawcqcIeBk4qGGxdiFCnr0xWfP1ZXMjLeMvL1A6AGrQhMijAJYnoK6Sy0DMZkYdTzxWhZ6ZFEjFVUt2zTbZm60UcfJbMY9gJDdyOtRC2CFUAJIOa6y7tUSQucfUDtVWLTxPcKVGBjc1QpPZDjV6swLiA7QgGcj8KjtbCRhjpk4FdlcaUiPGO3XmrsdlAsJOxQaak0rEOuuhxDWC7ijnIz6Y7VTmt/JJAx179hXTX0CwuxLbsknp0qhNYC4B5OT0NTGo77lqSMfb8nfHGPen7dpBJOOnHepprOeInKkBSBT47dnfphR7etaORpdWKvkytKkcagljkn0pZraWORiQQpPWtuO28mFmyN5p8irJIqkZAHX1qXNrUz59Tlb7AjXjJDAUxSVU552jOBWzqVjwCozlqoRx7XIPLH+VbRmnE03K9u7uGLx8DoSOtSqMkFuDiryRFhhec9hRJZtDHujQsRxzUuomxbbsoKRgg9BTXTzIwoJX0IqaaEuuBnIPX0pDCV+7gtjHPpVKS3Ha4wxhbR1J6dzVFgYyemD0FaskINvgg89aptbPMuEUk9MmqpyXUGrDYwdiE5I9q19Lsw9t5/mBX8zZ5ZHJHrmt7wf4OudVCtOGSFepxXe65o9pYaJawpDGnlNgMqjc3uapwc4uXQ5amKjGSitzx7W9ySuqD5VHTFVLR2aOJHPzKAT7Vq+LBHDeyDdhOuSax7Y/Mkm4FSB071nTXuK52Rd0mb/iF/Lgl2Hv06Z5qrbx/PlgAVUkmp/EChxn3xTY8+Yyk4+XA+lYJ+6RHRFQkSQpkneGz+FRQZDq2cruPFSJAfkKEt8x/Gr9npjzyAIrAdckVr6ETaWpBMpaTCngjrVIg4I6YbtXXrpJBI4zjinJow8ncY+RUJtMn2sUcjbxvukBX6ZHNBt90rsxOM/rXXQaaoYsy4+tNnsogCGQYJ54p3ZPtVc5KOJmIU9uelFnG28hh/Hn611P2KNivy9eOKWO0gjHC9+fem29h+1RShUoucYJ7VSliZ53+Uj0966ZYY1iGFHBqEpE8knyjPauezT0GqiOaeJguSMZqO3hkEa5GQSSfSujuII9hUqMnoKjaFFgULwzZz9KpTdiue5ishPG3pzVd4XYPwcn9K6FLbKADpUiWIcEg8CmpW2FzpHNFZBbEAHr2pkcJWWIqCTjmukj04EFTj6+tTmG1tPvBchepq02k2Dqq+hwFqsx1S4GwhfM4JHWryW0i3U75yGQDB+tH20za5PEFIVWBXA4xV2CF/MlwWJ4IzzXTWk016Iww/wALv3Y4hhHtIzx3quhyu3Jwvr3rUFlLMcAEsaS40p7eHfKAAfSubpdnTzLYm022/dby6A4xg1Q1bcoxuDcHkGleTamASw6VVuCS2cHHemugKOtyC33BiSeD0qTI83AYbjnin20LyFY0Ulj0UDrXRW2iPaWQu76MLIR8qf41T1YpTUTnltSisW5LDoa0tJsJJgdgAAPXoKRY2urkRopxjrjgV0cJXT9OZf8AloTnFZSb5bsUp20W5z+r2xhUqCC59KrxW58rOen61du2y5cnk9ageUiI7RwvX3rNN2NE2QOi7yT1x+lNYBkBGBtpRGzSttyRjAHpWlYaZLJCvynOcVSvfQJSUdylYrtuI89cHn8KinJEsqDO5wRxXR6npX2CWz6ZZWrBc/v2B54NOacZWZFOanqirZHbDbpnk+vrzViN33NvwrMOOapgSNbIIIw77/XHFWjgmLPGFz9PWlNanRuxs+5rkMB8oA5z3qddpRAOo6moZ8s4UHqR19qex3IwUHcB2qXqkUXrNQIk3c7pePf1qzIgy5J74xVSFsrAFI49an3s0jKAeWqNzmqLUL1BKqup+Ze9VhOwZtvr1q6pyxCjt+dZ0iunGOM0XCPY1rC6WRWMh5J69qtzzKls21ucjFczaO4LFScZOAalu70+WoXIGRnmtErSE6dy9eXYY/e7UyN1OzOOOg7Vh3chfqcAYz71Wea5aZRE21c9Mdq2UebYlx5TrhcxBiGcDPv1oguIWulAbI3AVzJZjKPm3dq0dFiK3Idz8inmoS5RumkrnoMrLDYKcADNc/PqMUZwrDPpSeINYV1SCMgqBk1yk0jMC2R14q6kuZ2RjQo3V2dO8yThcMM8UR3YtpFOOOma5mK4kjkjKt1PNakf7yEEnJxxWS9w1lTtodBqOoJLsOMYBql9qbZgMe9VW+aIg53heOelVrWRmO0jA9c1VWd1ciFNIs3SeeBnPPOaQJtZVI//AFUizbYgPTrxUkMiyMccVEdimTqFkCqygr0+tSrYR7iyDGewqJhwpTj3q9ZuFOD1FUtUZybWqMy5tnZlC5xnFMaFUduOlbNzt8sEHknisKeR/McdmOMdKJRsrjhJyIp8Sbc8rurOvLXYxkVep7VoSyeWEIHAPPrTXkEseFBxjqRg0cytdGkbopafIqvtYYyO1auF4OBj0rGRWRiPQ9a0lfcq5OTjNJ2ZU1rdEc9urxtsGACc1nTxgNx0xWqHGwg9zxWbdPtb/Zzimt9CoMWGLzYsYzxjFei+BvCkE0EclyoyTwDXEaQiPNtOABgkV6/oc8aWUeCOldeEgpSvLY4sdUlFWidUunw6VY/Lsx7VwXjHUrWS1OZgsysAijqfWtDXtSZLVx5h6dM15xcXkMqTKSzXG4BSOcjPNduMxEVHkirI4sLRcnzSOZ8ZKhvnEgGGUEjr2rKs4mEcPy4AAOK0vFQc3zFgCQoPXOOKo2shAjUnBAHBrz4X5Eke9TS5UbGsKFlQBfkLfdzSRBUmZm5FGpt++Tv82eaazFQ7DGTiuZbIVtDc0TS/taqcDarnNbyRw27eXwCKpafqUdlo24gBicj3NYD6rJLOMn5upNdDkopWODllOT7HYxzxCcqSMYpi6hbRMyM4yelcfcXsm8neB61Qa6k81WJLc1Kn2K+r3O1TUIHlYE9DjFR3EsEoAR1Xk9a5S0mJEjswOW4AqVZvlJyevGaHLW4KjY6DC4G1wMelQq6pwW6+tY/2llgIOeSeartOzFBnOKlu60L9mbr3Q2MI8nk81kGZneRtxyxHFW7fctuzbsBjT4reORmJxkYPBrDq7jS5Sum/byxJ9fStXT7XzbfPHPBzVN0WPdk/L1qW31Hy7VWUZ5OKunyrVhNt6IuhUXIZhxwcVBcXkEXAfPsKyWldwzEk56VDNbMULkEtnjmqUrh7PuXptWVAQgPr9KzCH1C4VmZjgHIqSOzmmkQrG208citbTbARq0hYcDFUnJob5YmBp+ioNcklDcbcHnNbo+z2qyDIL4AqhPcCG8mCHkelZ9tNK090zgbCRtya2q3bV3skc1FXT9WdpbT2ltZvcyEBgucVy9/qNxeAFxweAoFV7+4YqISeMVs6UkdpZQSybS+0scjt2qH72huoqn7z3KNtayAEyR4JOee9SwWT3l1HBZxmSV+MDtT7Nr7X74Q2qEA8EgcKPWvS/DGmW2kWzxRANcHHmSHqa0p0eeVnsZ1sR7NX6lHQvDEGmBZJwJLojr2X6Umr6e904XBx/KujupI4UUk5ZjjFZU93GjMxYBVGST2rqlGMfdPPjUnKXN1KEOn2ek2TyyBcD1HeuSmuftEzzMpHPAFHiDW3v5ysRItk6e59ao2bNJhc8k15+Imnoj0aFOS96W7C5t3n+ZRwDnimvZvyBuBx+ldloemE2+ZlBJoi09JtTZDwgPH4UlSfIrD+sJSa7GRoGgyTyhpFwvX613dlpEcKAhRirWn26RKdoA7VdmdUiOK9CjhoxjdnnVsRKbPOfHMqnU7eGLO6ONmNcWyZNzIxACxscfhW94huzPrFy4PCjbWKE3aVfSOAT5Z69ua8+r71Q9PDLlginpvFsp5BIJPtxUxDNDkfQE0zTNq2eRyxjI5qWJvuqVOBWU/ibO5EU2PlUHBI/LmnrGq9ySG4zk018C4bOdojB4+tPSQ7UPqaNbaAi1br8wyBnf1NTlQDnn72ODioLV/NR8ryrdatRsHiUntnFQYz3CFyZWPQ4xUF7OqgNt7kZp4JE5YcD0/CoLp98Kuq56g/SjdkpFa1fIBHTnoKrX7hYVyMEEEYqe3ANugXjg55qK+QmAleq4+laxtzmq2K8kxeHYRkE4z6VYVhsTGDjgVURNoG4+pAqdUwq7Qck5rSSQrE0HkmeSQ/dB5Getb0eqW8ER8uJAeMcVzjfu0kLDoelN3swB6ZNLXoQ4KW5Yvbnz7h3OF54xxUMfzDaR0qA/MyjAwW5PtU8YCgg4OM80NFpW2NC2WJY0M6guQcelWormGJcSL6Yx3FYk74xk844zTZHbcm0kjPNLlbRPLfc6CW/tVjmIXLFeCeMVQjlVm9iOmazZTgMDk59e9TKuMHksOtKUdLjjBIvy3UQDA5GR1NSWrLv3Rvwe45rB1IFmhwWxn5gPSnRXA84LGxGBzVRp+7oKUTsIOSD26jnrVkSqsvPCj1rl4dQYKFbqB27VNFfOQxzkGoasZOk2bs9zDKymNssPyrPK7pCcnaP51AZCtuCrDLd6W2kDDDtjJxUSbaGoWFlXc0fPBPanRQHewDdulSzEBo1UAqDzSLg7s/ShOyE9SB7QbDluc9akKgABTkY4phyo+ZuAeAaJGAUbeW9BRvsMXytygbgAKo3cPP3lI6Cp3baAQ2CaqtG8jx5bhW3VUdClc1NCsmuLjarhDjkmvRLSwnhtkBnTgV5nZXJt5Gw2Tj1rRm1uUQAB26Yxu6V0UJqKbZy4inOb0NfxBdPsdGmB+hrltPIEkjktvJAGOg571tw3VvcaBKkEe+92kybuTjP3hWCLe5jhSZl2xMcDnqadb3tSqK5U4szfEshOoXPzBlCAceuKo274CZxkAKfarOsuN9ztwzEdqgtkPkoWxkkcU42UEd0djU1VWN6ingqcgg1NuP2dgQCxxjil1ddtwpZee3rUTgAHGcnB9q5d0hR2LGpMBZw/MeT07Vn2yl5y3ORWtd2U9xaWgjQkfzpqaXcI77l47ZrX7NzmUknYpXJUuRx0HeoEjyuR9Kvz6e8bsWHGMVVHEbKBjnGazTtojVS0JNOVTI8WcEtkD3q1cIMFTwxbIxVDT/ANzd5bgA8ZrXvbdnVGU5ySTVyM3uZczD7ueBzx2qOPAdQp4ApJopFJLA4I/OljQmZUQUNWVilqa8TDYASAvYVX83JlZHwe4pIEwduckUxYGDOSBgk55rH5hYnedWiGDkle9Ng2m0AGBxTTGNoOB6UBSIYfU5xiheQrIuxbPIG1RkDgVXkuACw4+X8aUfu4cE8t09qoOeoPX1q7sOXW5cg1GaNQryHBPA9KkivmDOCcY7GslsqB5f31b60RMGaUk+341b1QoxVyuZlfVrli+Oi4qTzAPMVQT0zis+BlOo3SsPmLenWpoipa62sVwwziuipHVeiMMM9H6sljlV7k7ySAK6fRrC51zEVurKpPzOeij0rnLCya5ukB4QuBkdTXuukWFvpOkBY1CJtz9TTpUlUfoPE1vZrTcy5WsfCWh+VboGnboe7H1NVfC91LLb3F3Ofmlbr2wK5fxJetqGolix2Jwi5/Wty2l3ada20A2ptAYg8k1SqXlpsjmdK0Lvd7kms6i92rLAxXYcqw9a5W9vrieGSMPmPOGx1NaOuXfkD7Hbf6xup9KpWGlu7EtuAbmsqjcn5mtKKgrsyghAPyAD6961NEjUzjgdeR6VYu7KOCLCAhjWr4c0eQ7pHGAaz5G2ayqpRudLppHksByQK5+wuSdXYEn75rq7C3CZHtiuLsQw1yUkn5WI+nNbTi0onJSs3I7KO8SNzGCNx5xmo7u7JiY9MCsDcV1QfMNpbGTW/qNq0WnPJ91ip61tGcpJ26GMoKLXmeT3crSzXj46selV0YSaLeBTglMf1qZWURTnII3UwDd4Z1eSMEKked3ociuCPvSPXWi0KFi2y2XgkNHgfXNStGqAYZivUknpUWn4fS4nbIYr0J5zmns+T5XtyaUviZ1pEjKzSSOvQ7Uz6U4qrbMn5ckGmliN21BtBBB9TimZLuoYjkEkYqdQRqW0X+jzPj93khj+FSWaA2q8+9RwShNFuw+STxnsD61Jp0gktUCEY6VDXunNP4mJsznA5GTmoSpWMDqBzgjtWjEh+9wDg54qSRA0fAyemKTsiVMwmQjAHHGAPSo5ot0BUA9Oa1r2HbGJAPmA5yKpNkxupGCOhPemm9zVSujNSEsobHLHFXltjEy7vmxzmnwQjytoB3DmpblxtwMEcDOa3exm5NuxXnhEo24Iz0IFUTFtwpyD7ity2AMQ3DIHNI9qJXGR0FTewRlbc59EcyDGSPTPSpOgwVI960hZkOcDA7ZHWoXsJQyBQCO9Pmu7GimihKW8047AUgUjofl6irstswk5GDwOKS4hKDpwegx0p83QakU5Fwu7PBNSohKs3O6pDFsQ8EgdqnC8DAzweKlyHcyr/wDh5IAPNQWrIzHk/N19atarG58vsM9etVlXc4JOAD1reDTgJ7lnKbsg4z2qVTjgn61CwAAO3POOalTucdTUSA0ThbWFf4dwAqvM3zHbwQasomYouRnJqjKytKQvbqaxjqSty7azlpF3EHbxx9KuRvyWDcnmsW3Vw5dTk5JI9asW0zFQGBz29qco9iXHUuy9xkZ7dqFyshZumKry53Fs8enrVlGDqO+elTsrklObI+U4I70sZIACkjIpLoFWwAcGkQsX3Y6etN6o0WwL8vmHjiq3mNJsGGOR1q1tJMjDjjmp9KhE08agc1pB6kSdtSO2E8LxyQbt45BXtV+SO/aOCW8geO3Gdm5cDPfFeveEfDmnNAGm2iTGRkdaxPic8qLHbSRxiCCN2QIvP1NdksK40nUbOFYtTqKKR4vdsWimY7ckEZxURBVItoHUc0oy8M3QLg/Wmx8NGpLEDGSKxjpoev0NrWWL3eTnZn8qiJYI2SQRjHvT9RZtzkdAx4qogfdv3Eg9BXMloQloekaaynwtDNIUTa3DE4J9qzxdRHpIpqzoGl2+p+HPOvrtY4bbLcnFcRPeI97ILXPk5+UnuK6JX5UzzoQUpyR0eoyxHeQQTjtXOXDAYK85NOaZg7NuycVGk6sgGPm681za7nWocpYtLd7hxgd66u1sVaBd/wDD29a5rQr1I5JPM5JrRk1UpcoVOI+c1smorUwqRk3ZFLWwsTBYxwetZcDt9pOBx61Z1S43Mz5OOMVVgILhscnGM96l2Noppal9M+ZnkHNXZ4mNsCo+8TzVNiFfPQVoPdr9iVQASRxntWCCV9LGZKTjaMZHeoUlO1A/cYAqNpSWcsR7GkZhGisOGHT2rSMR2LM0qkqA3CjFVlAaQZJwegph3BCOTk96YkjcheoHYVSQ0TRsu9yB1JqFTt3H1P5VF5jZQMPl6UearKcHjpV8o1uZMSE6y04YZRtpB6VfsIji7dMndJzmq1kjNqUxAHNaMKPboMpgvJz6V1VbvTyRx0Gld+bOg0G2MmrWMAYHawdsV6lrkjGOKJT8pGDXnfgqN5NTluJFUYIVTnnrXoOqRmSAEfwmqpK0Gu5zYiV5o8+ktw13ImCcHrWjZSNZQlWBMh4RTV2ezWx866ujtQfMPfNZOltLqWpea4O3PygdhWCTizbm51foXNL0j9+1xdEmRjnmugjt0EWFAH0q7Hab1HHbFWba0G0jvXRGn0Ryzqtu7MGDSvtF0m5cr712K6WllbDeNvHAptpBHE6uQOOTRqt807gc4xiuiMIU4NvcwlUlNpGW135d3GMcE4rDntRBqtwQPvtnNXLpszIccqfyqHUmw8cvqNprim7rU6YKz0I4LVZL5WJyFYNVzxVfy/YJAhyCMYqlDcRRRltxAFYevazE8TKrZz1Halz8qavuWoOc07bHINzBPsIyX6etSW5DaLfwFtsbod57ccj9arW0mVmbHVuKs2UG/SNUAOW8o7QO5rljo9T03sZto5FpGR90jBPv2q0mGbPO7AYEdap28gWwXcAXB+6e3FWlCptwSSBkg9aJrVnStgLkROzbVwSR60xeWjZ/lft9Kbc4aBdwwGGMH3NWLpMToB/CPmwOKnYE9S5LJs0C6QocF1AbNUrNzFGu3hsdRWtbRk6Cc7WDzkgEc0z+zwYgY+OM4PrSfw2ObmXM7jLbUfm/enKn9K0lukdflIYdcDrXPT2rwIc5zT4pdjx7cgd6Gk1oNwT1R0JAbjG0EdDWRPlBIvU444rQSXzl3BskLzVXUVPk7u+MH3rONr6Ex0dmUYLkq6+p4Y0txhSA3IznHrVCJyJd2R2GAe9WJtzHB4IwK6ZdhqOty3HeCMjb0OKsRanDI7Ln5lHI+tZnlklcHBx070YdFZVxjdn0qUooUo3NcXsTPhgRVmGeEjBbPH5VzhLeajZGMfrUiFvLG7qScVLuL2aN9pLc8gjG7FVJzBuUknk5PNZEchEYHI+Y96fOxGBjGTQ1cpU7FohfLYq3BOcmoxhZMkn069arxOVjIP3jwBUozuJPCkfrUtFpWIL4cxgNwT3qlEmZCw+Xnip9QLjysckkmooHIOHHzda3hpEHuSuoCoevNSYwqlugNRowbyxnLEdKkkAHDYzUsa1LsP8Ax7cEE4P4VRBUI7Ec+wqwCREADye3tTVK+Wc9SccVmtAQ63UhYyP4utSGME7gOQTSWwxtyRk+9TQ/ORhvrRdkN6jSmCvc4PNTqUVQwGAaaVJ4HOBTZHLAqPugAUrtksZM6thcjJ5+gptuvmYUdj1pkm0OVAG7HX0rW0e0WSReuScCr5bg5cqJbPTWmibKEA9zV/T9IaOZCg6V1Vvpu2zKjOQM06GzkIGzjArrjRasefPEXuZ+rX2q6ZZbrVXKj+MdRXNy6xe3mmXsmq75nWFkjL5BGf516Hd5XTyrsoAH8Vcp4gltLnwxdeXMkssMbfLEPu5YdTWtWPZkUai6x67nltuW+zT5Kj5TTIlG/cGOeBjNJbSAwSHac4PAoRTjcQFJOODWNrNnuRd1c3r5SXcsAFJ4Aqm+WOV5wOlXpGJaQ4OM9+9UVCiQKeAP51xxJjsacscs+jLtdtg/hzxWfaWTxqHkUgVtaeYU01Hk4+ZhgmqqXqyAoyjbnFbWaicik+ZpFe4iyCozzz+FUCvlEEAk1uXs8f2E+WF3rxmsRnZgpYfNURNU20O0+Q75HK/Kc8ehrWlgcwCRlOMYFUtDtZLu6xtIXPJFdL4j2QwLDHwRgVbV7sylKzSRy1yD5RYEEqOQelGlwGS5BbGO1MWUq0iHGT61Y0st5zbQMe1Ju0dDTUszpgfMRkHG0UsiMII93AqYRAuSx4pLkGQDGdo4571zoL6mZLCGyp4Xv9amkhAPznO0DFTXCIkbBuOnFRTygyHgHHFXdtAndkDqN2AOBUWCEJH4miWZtwYAYxjiq6yF8gE8ZOMVpFaFDS/78IM4Az0qWKD5BnG4EHFNRZTdIV5B7Y6VsLDgMWKrg1pLZWIUilpUGNRmYIOw+lblzpuy7gTBw56/jU+j2ce1p5DkZxkjFdLEbe4u7JRtwuWLfStp62T8jhhU5W7d2a/hXw8iKGSMknmurmsYoomEgwO+a5LV/HNvotoYdOVJrrgKQOhNWNCvtX1oCW9n3K/8IAAArupTpQShHVnHUhUl+8lojA8YLLqNxHHEClnFwf8Aab1rT8M6bFEFwvPrU2rQ7sxqMEnH4iuo8IaT50HmOdqr+tZ0aTnUKnU5aaQohjVOBzSCNVPAren0+OP5mcfSs25CAjBHFejKjyo41K5EEAQnbnjise8OJTkdqu6nqSwQ4TANcjfariTl8nFcWKqxirI3o03Jkl7OglAz0BNYus6ooVEU896x77VWknkw+OMVjTXLF3LnPvXkyq3Wh6lPDtPU07zU38vBcfhXP3N0RB8x3c5IpJpS52npniq8gycHHB7elZpX3OyNNLYsRYFmCp5fkVsaTGzWd6beQeZHbMzBiBzngDPWshztto8LgirenPhLhsncYiAB/OjrcU17pj2xzb7nIBJO6rDYkXcAcbMDtVCyO2yG0sTvIJJq3ETHx8wHbPStJqzZ0x1Qh3/aLeN8sAVyD161ZuCzSkrwvU/Sq145SaOQncBIAMCrQYNyo4xjmolsmC3NRL2SLw4PLhWQtJw5P3R3xUS6p+5CsvUVauYXg8O2EhVljldiCehrNv7YiAGPrtz0qHZ2TOVcrbLBuVnt8LySM81TlGXjHuDkVBbxSJGpbuuOe5q9GucM3Yd6Je69C4pIksGZZWBzjrmr00Zkt3C46dCKz4soHJGfQitaJfMhyR26is9bkz7mZpljHJIGfoTgfhVie1TzyEBxz1qe0UxSbR0z3qe4U789j1xXQ9jJy94zYo03LxkjjOOagu7Zw7Nn5R1FaRQAg8jHXtSEB9wPQjoam7GpdTDiQkng5PSrTwZQAfyq5HZBZE254q80CrngFu9Jle07GFNENyjBBHU1LJaFo1wQSxyM1ovEqtwvtSSbVxg9B+VFtB87MJoJElC8HHTmpkU5bJBOMdeKfdIRuI5xzTI2O7px61Ld0aplTUQcRFRg5xz2qOFAMdScHmp9RIcL904znPFVYWVUwDxjOTW0dYaC1uTBCZYyewOKnkHmKuSOD1PY1VV/nG05HTNSl1UKWPBNJp6AWIiQWyR6A1DACwOMZ96R5Pl3AZY9frToCoRjuGeBmptZXAksyd4BxjB/nU+7awfoB14qrHJi8QE/KV6DtVhj8jEcgik0S9ywsgbkfXNRy4G7nJyKhVipXIOCMEU5pAfvnBzn60kS0QcAtnv69q09MuvJlQjJ56VmPlo3P3cmm+bJG8W0nkkn8quOrCSurHoEficrE6suQBioh4uSLAX5uOK4ie4IV8sfu8gVVMmQMDOOnvW8KskYfVYM6XXfEM2oRiPftizyAa09ItYE8Ca9cbkJaLCnPOMjNcArM5kAB9B9a7XTtBvbXwJqtzdKUieENGN3XkZ4px5nK71CpCMIpLTVHntoubJ2jIJwcZpySGMRs65JIUkdM03SuNLcMOB6nvmpv9YVAIHzAEfjVv4mn3O6KfKbF7IVnePoM5qEkI+4EZJBqW5LGWcMvzZ4zVcv+8iG35jXGl2DZF7V0lj0uAqV2s5J9R7VTs1xHgjk4xWjeknQQzDJDkA1k2ZLbQAeOOKpawsc63ZKxYEg/dzURlUKOMn61JOhGT+dUZQNnHBzzThFM0N/TdSaJDsAUEZzjvUNxcyTbnlJJJ9agsIibbLZOO9MuScnHQH8qOXoZpK5EQEO4dCepq9pAJuGCrjJqi4MkBKjgD860/Cr7pmUruYdzTtdBJ2WhtRQBIt85VR+tZ1zPn5UHTkCrWoSyOxUghe1ZjKwJ3HI71z3exMddWVbh3YlnPPHFNLFgzMcMTS3AxcKgKnnvUc2cyKCOuBWq1NUVXBLLGmWLHNaNjp5AMs/HB4NTaNYhWa4mbCoOM96jurveGCnC5wOeKuTfQhybdkRXMyrcgRDCjqasRRvP1bALDk/1rMkciUpgMQuc561Kiyvb73chBwwzjFCVkhtG7quuWUELWVixmkQDcw6A/Wq+nC6uTAZpCFK8beK5i1USXs4UABjxjviuvs5FSC3QYDIMY+tb1Uk16HHQ+F+rI5YN95FCozmRe3Wvd/CmktBpEbEfMw9K8h8LW4uPEUKyDd8wCiveJLyO0tAqjBVcAV3ZbTVnUkcmOntBHL3scaXzpjcQc1pWV29vEVjbaCc4FUpFU3Jkc8uM0DHYnBreD5ZOSOR6qxYlu5JXPzHFUL++WGMlmxUd/qEVqh57V5x4o8SeeGigP1NY169lvqbUaLqPQ0vE2vBY9kTc9yDXHnUGlkPz5OMkVi3OoM7qrbixPIqS0k3SkgMQF5ryaycrtnsUaUYqyJnl3TYY5z2qGZ8sxBJwcYqHAN6TzkL0ochhIOmT+VSopHUh24qQcjNRSnABBx/hUQAYnc5PpSXONqY42gn61qo6gzUKF4YsHnaO9aOl2264YNLsXYRkgkE4J7VkQ5aFTGQDgfjWt4bkzrUMdwz7HOBtGTWKVmY1Phdjnrdh9gyQwOSSD1JNW0jBA2nOCCCe1U4FYROrvgLK4IJz3q/EoVCzMCTxxWlTRs6Y6q42dRMyKSAC44qcjYNrIMZ7HnFRQoj3keDnALdeOBUiseNwBDdAO1ZPoh21NO7llm0GxhJk8iJyE3L90nkjNTKQYPm6Y6GmXmRo9oMEAucCrUUO6FVbnpUp3OKWjZVnjDMcDioZRjGF5HXFaBgzkE8Zz9aVrNhIrbMg8/SnyjUkZ8MbfxdCeAO9a1qP3QXPGKmS0BgyABz0xUyW+1Mj0zSUUTKaehQjg8yc7ug5FXp7YrAJM88cVU3GKVWz8pOK2gVlsGC4BxmuiOqaMJyaszBlUbTjqaqorfL1yScVbmAAZu3SkC7tpXsKwtqbJkCEoAckNnkVdY7x1zkdqpyL0yeakgcsCOo6U5NILDupz6HrUE3DrznIJqZsqegPPNMcZfOMEnHSluhmdcRFQ5Ax+NU4j1jJDYPNbDqrE8cY5zVX7Eqncgyx7ZpaW1NIzMy9HC5HHNUkiBAY4GD0rS1DIKDHcg1nhGjlwPmzzjPStab901fcljUKOOlTchyTg44qCInAx/Cec1LvPO5QMnrSle4nsP3KQQ2AQPu1Gi4jyTnPFKcAu+M5Hc0JjevGQOevtSBEUpKTrJxgdqvuy+Wu3GDyTVG4B37gB070sbs0Q3EcdcGm1dITRa37jjOPpUO47fl5JHfpTElYMMDvgCpHw0nBIwaErCZYg3NCPMAz3xVgWrF12rnApLNMcjvW9pyLJKMDP4UNXd0ZSnyow3053R9qFjt7d6mt/DN3cEAIVB9K9D0rSTMMlOK2nsvs8eAuCB6V2U8O2uY4qmMadkcj4c8FxWx86+bdg521oeMrb7NomobLkqjW4cRggqRnH4GrNzfyIcdgawPF+qQ6hpOpBIY7f8AdKrYbl8HtVy5IxaW5nF1Kk1KR5LYkmzkQYwe/qc1ZIxJEo67xkVTtJB9jlJHyg4AFPR2VonY5G70rOUfeZ7kX7p010ihyV+91571n+duuoyU3bQeP5VZvJMOwP3s44NUI2IcNk7jjiuOEerEldF+6mmGhqmP4849Kj0kZ28ZwOT6VooiNokwKGSQuAMDpUFnZzKo+TGf0qm/cOW9pMhnjOGY8kt2qoLYOVDDvW7FauVIOTt65qncWTIAecg5qIzaL5lsWYnSG2+TgdMYrHvHHmMDjDY6VbLN9n7/AHsnNUbnB+dwMk5AFVDsxRRNF/qzz17Vd8NukWrEnkE8gelZsed+SCQ3fvVqyQ/aXdM8datuyuJ66HX67AkcYkHfnjvXPO6sqk8ZPQ1szzm70heMsq4Nc7MWCrvBB45rCVnsTTTWjGXSJ9pT1J4pqrmckfNlqa64fLMWIOQamWWOG1BTLTOTnjGBVI1Fv7kRxhATt9BWOy75FIYbScdafKWkf5iQ2T+VIY/mGRzgfjWyVgWgjsok4XJAIqzEx+wNvGAcVDFHiUseeKslSIAgGVyMg0NoTKFp/wAfU4B+b1I5HFdl4XsILmZftLHaqiuStn3anKqjJUfNiu68NriTGzGRzXTNe8m/I8+Dag7d2dl4M06BfEk1xHH+7ijwufU966jVZsuF6kms3w3F9nhZ+55NPmfzLsL1PrXdD3KXL3OCo+ad2Wb11jEBIGTwKo3l4sELMSMAd6drZ2Qw8/dYZ9q43xpqvkWTLG2GYYqKtTlbKpU+dpGD4m8QSTyPHExC5OSK5CeYqGZskdfcmkklaSV+eCOtV52BYr0wOK85+9K7PcpU1BWQPJvbc3YcYqfTScOw5JGKqSbR5S5HA7Vd0wptlB/h6emaU9IGsUMRy1y4Ixg4zT1jy+3nls0Rbg0ozlWbcKfG4US4+9jGfSob7D6EIILN2HNV7zKwsExytTqwKLu9ciq13iSIEDnPAzWkF7wnsWopfs6KCT0FbWg38Y1a2EQ/ebxj2rnJPnQNghwOc10fgi0s2162k1KUwRD5s4647VMoJ6vcmo7RZjSt5d1eo/O25Zfl6damiO07uMEnj0ps8CrqF4kbEotzIwbuyk5H6U3zCz5UjAPOeKU9Xob0/hRPbtulfCBV2MeeuacBxgLgDpx1oi2lnYHPy4xTwSDx9zOTWLepRrgNLaWRIB2kjrWzbQBFGc4IpNI0kz2dszFlCbpNmOMGr0yBRgHtVJe7c8uc/eaRAqoAR1GalLLuCnvTIkLIe5pky4fhenSh6IncsgIF4z7cVKArRkAHp0qmHY9qmhmwzDPQciiDuJoy79AuwDj1qxp8vmbogR0yaq3kheUAZ4BJFFhIIZQ2OM4Oaq9p6luN4jJgpd4mGcHAHpTQdgNSXIH22Rgep61HJxtz/FwKma1KjsV7iT5Qx6HGangZe4weuDUV1Ax2rkbc80hViVK9+OamWmpS1JN2WJBPrxUcj7XjA5OcU5wRgx4HPWmA7plOOhNSn1GJkgMT+PtT0PJAPIHao5CSG+X8qkU/vMjpSe1kUUNTiBVXHXPpWOCMvk8kflXQXYzGBg+uKwJICk2/oOcirpbWZomRqSrDb/vYqdX+YA4waixiSM9z1qUACXtnGK0lqVYaZAsgXHDAnrUhAMhPPHTPemTYVc9WUEgd6bE++NSRhiASDStpcFuPnA3KCf4efamoAqgDkZ4pJzjbgHgUyHO0BR9aa2Gx8akuMdavxQ7gWzz7Uy3hOVITPf610Wi6U9zIu1MDPOe1CTlsY1JqKuyLTrB7nYEU4xiu38O+HdswZsnjpVvSdLS3jVFUZHWu20SwKbG4xxXoYXC88rs8mviW9ETaTYpaFfMhIVhjJFWtU0uOWB2jGGAzj1rVIBGD0qlql9FZwPvPzY6V7fJFRt0PM5m3oeN665ill5wQawdVktx4D1KRoFMwdVEvcDNHirUTPdSmM/KGPHrWRrcJXwc9006bmkAEI6/Wvm5u9SyPdpQtGLfdHC2botjKOCR/jVqHlFU7cA55qtaqq28+V6t271YgdCAi8ncAfWtJ7u3c9OGkTVuSPMdSw5J49agLmIoyjcNvOKtaiq/aGIHQ4zUFyMRpCn3gBn2rji72Gjo9HSSbTbhoAGkBB257Vf0mRmfbj5h2PWq3hW6hs9J1AtGzS7AFI5waq6Tdu1zISjBuTVKMeU4Zpub0NmZcKeBnJ6VQch2K8elSSXu4EONpNQlshSpwGHHvWGzGk0tSO4swbY7Dy3oKxLuJ45tvOOxxXSqN8XLYGelUpovNb5OQDxmrTvsOMmtzEhBVxlskDrVm13G4kxkDvSXUZiUHYTyc1Jp7CQsygAY7inJPluaXRp6BNvuJbdsgMMDPc1X1aAw3JRifTFRiZrW6WTgbSD9as645mmWUcKyg1npYVnz37mRPhZzu5GcVWll2nb+QqeRt82AR8o71WdT5yE4Oa0h5mgijdGd5Ge1QlSVGeR061JIoAYEjNRRHZwRn5uOK1XdASoDE5eQjGBxVi2O+33kgndjrVWdy1yQcbScCpgpjsBg4YvnI70NXRLKmlgrrtzIWO0YAXsK9A0W4ZrmOGJCXY8n0ri4FHLqBknqBXpHgm3VY/OcfO2BmtlN1JJdrHHUgqUGd3aqIbcg8nFVYztmZ+Pah5cA4bjFZlxdqhbB5rslNKyPMjG7H6zOzW7bjk5zXlfi+8eS5wD8gXBruLy7MkbAsMV5hqsxlnkJYn5u9clSTkz0sJTsyg7Og3ADaePcU3GZWyT+PekYck87cd6eMsqtjqM1J3pAnLLx0GRmr1ou2KUkDnFUyFjZckdMVYsy7Rt8uYyeSTWdTVFLQSLL+YCSOSBg0yYmOGQ/ePt3qeFNgwvQ561DLlSccj2FJO7KtoMhYyRKzjD4zjPSo5iWlixjntViNflbC9sYqBkzMrMc9AB6VaauS72sX9OgNzdIhUY3YJrRs45hrcPkrudZQoUCqmnstuRLIcEVPpmozw69C9uVDvONm7sc1nq9iJX1INXVrbX7+GZNjpKwII5BqoiO5JHyknnmrviCaWfxBqk0+BIbg7znOT3NUQwDoqk89T1ptdjek3yK5cRV8/arEjGCD0JNTAgtImDwew9aqxbdzuWz82AKsuWM6IRjpz71hJalnVarrEmii3jgZXBtwDx9325rGTXrolWcK2eeRUHxItjaJCyzGV0t1Jx6ntWPhzDGDkERqMfhW3I+RO/U8+moN26nQx+IHDEYGfSpv7dZnxIi4NcjHlYQ7ZJ6cCrkgBEYzkjOc9KmUfM29nHsdjHfRypuBwRR9p/1jL3GM1y0EjiJtrFcVdt70MJN/BrG1mS6S6F0yjzn55x0p7TALzgE9OayIZizBsZzxVqQF8E5yaqQuWw37Y5kBzkZ5q75vmeWT69PSsaUMjMpGTwamt52E4U8jqfyqru4SjpobTzKsbk9TmoEuVYqjEbzVK4ZpUTb1xk1XikKPliOtZ6goGsHB+X61G8oRmJ7DGMVEsgY5HQjH0ofgE7Sc8Ula4WJS2446gkVLgHnnn0quGAwuOc1Ij/vGXB46GlIENumGzOQD7VnugeAnuauXRygLZxVCeQeWRGDx2q6acloO9inKAJkC5Kg5PtTNw85ggy2KezgAcEHPp2pihBIXCnn1ra3c0TbHyr35yQRTwgKgADdSMcttz1pmGJfaTu5xmpGRzsBLEo64PWrEMW4AL1H61VMZLjzW3MOMgVtaZYvMYwoOD096prRJEOXVmr4f003MybiTzg16poOjCOMLGnNV/BfhlvIVmXLY5J7V6Lp9lFaJgYL9zXq4LCtrmkjw8XieZ2Ry8lt5DAOMEV0ejTJJaqBjK9azPE5QEFCM4wcVlabe+SCCcfjXYpRpTsctueJ2dzcRwRF3I47V5R438SFGmw3zHgY7VvatqoW3kJfgD1rxnX7s32oth+CeOa58bily8sTpweHUpXZWuJWkiy3Vj3ouVgXwzc+bJmfzBtXHaq1zIUUiort0/sGUMWaRnBGDwBXiR+JHt22Ofs1zFMSDjeOo606ORFnRFBJ3YJx0pYyUgcBuQRkU6MBmQ7ssWyTXVe7Z0WsrGxeODdHsoJwKqo/mu5H3RxzU9yBJcSlT65qpaEIxGMBhnNcsV7o0d54Ajtvsl39tfbE6HJAz9KijEUckgVdvXFU9HeeWxmtrQkOQGGwcnnpUjfa4CXuIWxjnIxg07uUTz5x/eN3K9zH5j8dDT3Q2kIMp68Cn2sgdg7jIH3R71D4lnBjWPGXIySB0qIpWZbvdImRlaEbecHmoVJBPr9ax4p5IkYJkc1ehnNwoyDvH5UtYofKWphuAz64x7VHZwiFpG7HpTipXa/U5wDVi3Xcru4zjsPWnJ2VxIydQ+YZzjJ61Ytm+0WeyQ/6sHn1FVbxZGYlh8hNQwu8TkLnDcYqY7GzWhGU2zOdxx0qENjceuKmdHy57Z4qEhgXwpII5rSOo9yvcMRuwcmpbKNiysyk5P5U/7K0jjapJI4rqdA0eUAPOg45ArRaqyIqTUFdnPGwczHIODknNF4gislUnIzmuq1a1ePJQDI7CuT1JnCxqFBGTwalXvZkwlzq4W3oox81ekeGZgtmoJB+navOraNgVAwFJBOa6zRZjzEHwSR9K2pyUWZYiPMjqL7U0iVxu6CsX7d5uWJ55pbmxMjM5kDKDjjvVGS32AgNn1x2qpSbZzQhFIkmuA0DHivOdQmX7U5Hruz1zXaXuTA0aHG4cmuFuYhDJICc/N3pR1ep1Uk09Cw6BoIwf4id3tSxrxhANq8dKiRg0arggVctVURktnOcVEnZHTsV5I8n5hx/Wrdqu21fHIJ5IpI48kgjDngAVagjWCzcNyWYnAqJO6HzWIQQUDdMr+VR7QQcc981Jbg7TuADdvpVi3tmYrtU5Pas72ZTlZDbW1kkQKoGT+tXn0OTcqhOg545zXR+HtPHmxGVBvB6ela+vWhttWXbgKy5x61pGDs5HHUxHvcqPPbvSJ1jyWUc45ro/BHg+xkuZLvXr8W0cPzwgMAWftye1TXMRbO7oDnJrOurqJZF+0p50CMH2Z64pwmotXFKU5xsnY5/xcyx+JtSQZIklEnT+8ATVKNQZAXOMdvStLxhJHP4tne3hKLNFGVQnJzjFVCcPskUZjOC3vVVHrod1D+HH0GyOMq0ZJPXBqVJmPPVzz/8AqpsTK7YZcD2qW3ybmPGMGRVx7Vg+xtsWvGFjc3TWpk8zdJEjHOelRf2fILRd4OVGGJrb8T6kLXWJYWjwse1QAenHOKrvrFssOGzg9c1d3y8vmebFPSaXQzbfS5XtunBb6VFPaSRsS2M5NaE+sBogsOQDiqn2ovJ+8NKbsbx5nqViCsJ5yBzimL/qSRwCM1Ym2k4U/LUZ+VHbI4FQndGlyCCZgygfU1rRuWwxPGKwl2O+B1AyO3NWYJ5FOGPAODVzjfYlq5pSAFSw+8OaqyFkkJLYJHFXbaWJk2kjJ65qnNMjzNnGUXaMdDzUomJoI6i3xn5jgGq8wBcqnYZb0qpE4+8SSSakEh+YcAk9fUVDjqUo2LdsQOF9qsF8p9TzVKD7w575zVnf+9xjgc4pWuRIApYKSMlT97pU0DHcQagaQtHHwRlqnUEMAO4onsSmJMokQmQ55xg1AYV2rg/Wp7jHlgAdT61EpAA459KIbDK8kMbLzyc9KrSRlWABzn0FXHPz556cYqEOfMBZc8daptopFd0BlHJx+tCpkjjmg/cyB1qVEDEbQScZ61WthtvoWLGy+0XaLj5e+K7vR7BRdW4RMgEdq5TQI2Lx7R8xr1zwxpgESPIOeDXXh6TqOyPPxVXlO6sI47HTU3kKqruY1y2p675t0TEdq9sVH4514IkdlbtyeWxXJrMV5Y8kV6mIxHK/Zw6HmUqN/el1Ogu74yIdzVzN7rIgduRjpVS+1J8EAkD2Ncjqt6XJ5zg15tWtd6s7qOHvuamua95sLqDgetcakplnDZ6HP1plzK53ndldvIFJYJhPM9fWsZSurnfTpqGiFumld2JGBnpnkVPqFvLHorTPGRGWABIwGNQPIoJ5qzq88p8OxKxYI7nae3FRHdGu1jC5FpkD7xBHrSxqXkUMxBBBpggZbfc7/O2Pwp0OWnBz3Aro9DZXtqac0ipcP83cjJqOST5wFPBGCMUl4qvdSYwSG4Jo2hgRgZBx16VzpLcaO38DXX2CPzIgTMuBwuflrv8AUNWsL+Ai5jRHCYyB973NcJ8PDOL0pAVSTyyNxHQYql4leW3m2lyODnnrW0anJS9Tyq1JVK1hJ5IjfSJCRsU9qTUJYZHw2DgdfSuceZg+Q21uvFQtdSCTrkdzXJ7Nt3Oz2ZsmJQdwAxUyTRQgR4G5uc1kG8+VBvGQMn2qs88jSZB7U1BvcFHmOheYHy1B/Kp7OVWVuenp61yyXjRSE7icDmr+mXJ2sxxjNOcGk2LlL11JukPselQeSnmBict1zUF1PuckfdPpSrI25RwR6msUmkU46DpR85wOAaiwN2O3WpFJmdlUdDVlIdkwBGeKtId7F/RbdC4ducVtTXqW0TfOM46CsDzPKjYq2Mnjis+6uGdlIOeOa1jJpWRhKHO7sdPqkkssh3nuODWRPM4EbuxYE46570sibWdk4JNOMZdYAwA57frVqzdzS3KidHyygE4688ZrY0yRjMVXuAD7VjKQCBjmtPT5hCHYdQPzqIvWwVFodJBHM6hQxxmmajNHaDZkbj1rNh1hkt2KEZz1rBvr557jcxLDvW0n0RhCm5O7NO8vEVMluoNcpdDzpGck9evtVm5mYoApzxjJquELIueg6e9EbrVnTGKRJbzKpIMYOO5q685aJCQEXPAFZr5Djg/MenpV+3UOikdhxk1FRLcosWpVS0jrkgbVB71IsbPbKBxnioJ3ZyqqAAq9u9a+lWzSwRJzj1NYzvoL4dRLDTmlnOF4H6V0FnYJEqgDL+uKuWdusCYA7UssixqTntVxit2clSq5aIt6V8l0uMYziqHjjWwurxxQ7WZAMg1Vl1VLRWlQ5YdK4u8unur1p3JLFsn61pzWjyip0bz52ak19PcplXI55HpWdeXpUYKluQP1qSzYEyDPGKCiCQbsAbgcmsF8Wp1tKIuuRMuvPKQVKW0aqp9SM5rOiwOW7njmtfxc2NStpRtJltV5U+hI5rJtlOQ/HQ8elay7mtD4Ex8GFaTJY5PGe1TRNtO4n5weKrzGRWB2gkr93NS22CybgA+4Z56Vm1fU2uN8TSsuohGbczKhII6ZFUrlh5BZm+6CSPSpdbjMuuXBd92AByMdqz9UfZZuU5Jwo9+a6YRu4o402oXLkUge3iZCQMDrUm7DBsk+ozUMhIUZ5PAPtxSoAEbIJAOTUtLc1Wi1LjS/uz6E0zcWhZSeSp/CqpuFdGVUK475zU2/92Seu2o5LFRalqitCSspK5PHOak87gljgk1BGw3HB4zzSOd2QpGc5rZxu9SS/FMAcZy1RyMQNvOTgHNVInyX/vL39KmL7YtznLFsc1PLZiL0TYK849qezYcEHrVFZsyAAEY4NTuxfafToaycNSlqXIpipHB/KrKOQwPWsyKU8DOT0qdbkrIgboeD6Vm4u+gmi47kPEpGcsARnp71dicb2HHB55rNRxJMpB4HJJ7VaLrHzgFmqJ9FYztYfcNuxtPQ1FGAxyRkZqvPOTC5C4YdKjSZkK8jGMk1UYtIEr7GgAckkcdPpVeYBVOewFCXYZCMfeOTUrICmRyaGrbiWhSGG+7wAKswIfMzjjioYAAWGORV1sDpVJWBu50XhiOI3kI/i6nAr1lLtLay4xwuc15D4Q51MMTwtdP4z16OwsVgibMrjnHYV6GEqezg5Hl4mm51FFGNe60s2qTTSkEZ4qpd66CwK4ye1cbLfs05IPXrUCTEOeTjPFcznJts7lh4o3bvUnmfjgHjisu5ckdcd81HuATk89c1VuJlCZJzjvWSjeVzdRSVkNaUNE+B1HarEPywqoJyBVGH7z8cEVaZxgFx29etaSXQdupCzFtwIxz3q/rfmpo2nRO2QWJRc9sVnzFSAQeKua48i2WkxlMHBbOePTiqitUKW6KF6MwKB1Hp34qO3X92mQFXOcZ70+5P7sYGPnxUUTqAsYI3DnB+tVG9jobsi/cRDz5OeAcDPamGVVJjRh5gIBP+FPkZmu23dd3THaq2B9olldR8hBAHvWaV9yTp9E1W40oSy2ZzNtPPtWbqWo3F5cF7rOWHWo7FnMcwXj5MY9M1I1tcm3eQxlhwATUa7PYwkoqdyg+5gccVC3zOF3EAdea0JrKRLFHlyhb7vvWWV4DZ5zyTVwdy7lpB8gwOg/GmB2MwGfqc0lw5hiznKt0NMij3vF23cA00tLiurjZIxlmVutXrFv8ARpNmCd2Oah1C2CXQhU/KByR2q9p1qRCQATzilUa5RJjGHIJGRUpDYxyABV0WgwNp+bvmp0sAeSeOvFc3MNyRn6HFJ8zOMhW610t3bomHUZBXNVo4BHDtTA56CtIFZLUg4BQYP0ra6k2crvFI5+5b5SuR64qlMhZkwxAHOAK1zFGZN2eaXy42dcDlR2qNtjVSRhCPndJkAfw+tD5eVDjAHp9K2PsykuSvNPSyXzdxUY28Vok+oOojF8okgAfjUsCuSR0ODzittIYgvIG6lgSMq7DHpU8ugSqGJDbu8Cgq2STzjrVZ4HExyDxx9a6nEa7RkAAZ61HN9nKHO3kVdrXdyY1DjJVO/kcDsafIipGOGHpW/b2NvPeBmwEWodWtYywW3Bf8elUmac+tjnG3CQk8DaevrU9q7gHbnFW5tOmnZI1445rRtdKEcW3Iwq8mk5JofOluQWkDTBWfoByBxmum0pFiiUNwRwKo20aQrtJBJ5xV7zoIY4zITyeMCsZbmc5XNO4uRDGSxx6ViXl6ZAw6L2xU2t3KSQDy87V6nBrn57lE+UuTxxxTk7uyJpw0uGoSArhjhRisov12kHnIq5MVc5cueOoHNUztwCFYY6DHWqjtc6Fo7FrcUQkYO70qm94z4AUnDHNXIXDJGWXBx0pGQIzbUz8pJ9xSi0nZg2P1hi5sd+DtgAHPT5ieap2xCg5568VZ1iXclj8qriNjtI7Z4qnbs2YwBgtkn0q5ao2o/AiaUl7iIJ6YbtxUkceyRSSD83rSIoMnzHk8ZNLvT7TAWPG8A1nvojTZFTWWJ1R3B+8FU/lVG7iZ44I9hOXB9cVparKJrqd0UBw/T/ZxTFblSwOR+lbxk4pPsctrxsMnYAnjocYqO23lwWOF6YpZcZztI69e9Oj4GSucgGjZF9R9xjYcKBUatiB2Xk7afKuYQzcE8YoaPjaOgHapVrFIzkIZQcH1x061MibGHYjnBpkTLyG4welSuDkbck1u2QBABOBndShdzKpHIyfpUacsc9QSKfvCx8k5PGal3AVXOEHXB/OpmZwwwQFwcioI+Qh6ZPSpwo3EZ5zUyGtSeIgEBk5/+tTHkHmooHf1ppBG9t5YHoKUDMsAPJwTUWW42XYmCsc88dKtxSI2AQTk9D2rPRwZGIGf6VLESJC4OQOMVhJBa5PdsgXC5xnkYqnIWI2jJB6YqR34Yg98c0jbxEduM44NVFWRGwRgqhGeg5IrQtJMwANwOmPWqVuhMZyRx1q0IyIl2ngHPFEl0JbHSR7C5BABNNiLGQhsZ9fSrMI81ec5yTipLexklDkYI9hRboRzJGx4YIjl8yQ7VAJNc34gv21DVJpt2YhlV71uTW72mlySSPjamAPU1yiRkW7sx2lj0rW9oWRFNJycyuVyTjuasQR4G5zjPSmF1VAFGGqs0r9c5NJam+5Yu5gx2r261TkOV255py5K8jJz0qKVBkMxIH86uKS0GTWqBIy2SeKbPKHO0cd/pT7dR5bMCTgVFt3t6Zo+02w9BhJl25YrjsK0NUA82xG18pAGO48cntVVSu046jjitPWm3SWwbduFqOvpk9KG9SftIxJtwSJQQx8zJNEceLsO6gMThWHORT5dv2SLPysf8OlLaFWeMjGR+lWnZG7Vy5cllumJI++frVa1TKSsfvbxmlnOJA0h+cPmrCOghfcO4rJ3itAsb/hKe1tdT8y7iEsIXJRhndT5NVmla4MZRInbjcBxXM3c5ilj2g8jGfSrioqQBTlmL5INRLSKMJUlKdzQvXluwgknh2oOAKz2sk24E8Y59KjEIOTkdaaCFZsqML39alX6M0VGy3Los4dyeZMpCjpjrUZhiE4KyZHX6Ukmx1XAxuXrUDoBg44Axmkm3uwVPzJ5EtvOMgkY8VftXjjhyHOSx71iywom7dnB4FaVngWUS7QDuJLd6VR+6HstSWWeJc4cgn3qVbkdA7ewzVG8EfAUc9cetR28oeX7mAvTPeoUfduh+zRf+3iM5LcepNH9q5LAOMHtmsuYgwsevzdqRVzuAUYI4rRRW4eyTLv9qqFY5UjOM0kOrBizIRx6VmyqVhfYoLgcDFT2dplEyoBZcmrfKldidJXJv7W3BiW7+9POqNu+b0wOKzXRljYA8560kZYlgSPcVXKrD9ii/cartTI+uQpqAauPKyNwBXd92onABRWPbFUZG2oSOCTjBqoRT0B0kaz6meCdxxjtSw6nvU4DA4z0rJyfNb04yakjfBbGAe1N01YapRRfk1QnAUPn0xUSalIwwNwx1JqizYAYEct0NTBdzcYJIyTRypIPZRuXINQkSSSSTeFAyM1I+qTEZSNyucY3dqr71ZWQAjjA+tNziNu+QanfoL2MTSa+dVHJ80sF259as3l3cBhtHA9TWTaRq9xECM4OSavzMhyM+o5rCe6RUaMVqWxr12LKS3McTKcZ3DJz7Vk3FzNKciKIsevWpnAWPAGc8E1AThzuHG0kYpxd9RqlFbIUXEqnGxATVYz3BaIblwSSeKlYEHf146GoYo/nGTwQc4rSNlqNwRLLPLy5K4TgAL+tRJNO1weTgJkEeuaVskEL25pEISGZiW7D61SSS2BwRLqF1JeBfNKt5SbAQMcA5pLQ4YZ6YqrgSwvg8EE4qzbsA5H3gR27cUSVo2GkloiQEtyB35xU1tAZ7iGLHzOcioAQHKBuQPzqzpdx9m1S3lI+WI8g+h4rMU78rsdifC+hWASS/u2kuXUPtVht5HSq9zpujsqiFhzz94GsTxFqUF3qBaGCRYOkSs2SB9e9Z5eMR5a3BwM/erTmXRHBGjUteTZqXujQMAsMox9az59MliPygsAPzqMyW3kp/o7jIBzk0rSW5cHbKOdvDEc1LdtDaMZFK5tLliigYUfpVoWsmM7eO2alla33Jjzxk5zmgPbrgieYZ9eaXM2ki4poxGiKyhlXByafKHjCtt6gdPerS+S0jYumIOeCKGijLFhdjj1Fbc3cV9Cnxk8Hb3OKH2uoyPl7VbitQY2zcpn6Y605LUiL5pYjjpQ5JBe5URDnYo7damKkEH04PvU9tbyh92+IgA96e1m78MEIHON1S5q+rHcrjJQH1qRY2Ehblvl29KsrBIjEBUP/AAKrMEsqhh5MeMY+9zWfN2Bsq21vIykhSD06VIbOZvlyw75FXkmlWMkRKf8AgVLHdyF8GHtjO6ou73JcnsZcltL0KtjrmpoIpTHgg5PHNX5blli/1JIA/vUw3fyZ8l8/UU020S2xPs5+6i0FJB8pBGKnguNxJMTg9expJbtQeI5CfQCnJk6lW3kljIJDDryR1rVttS8m3J25Jqk+oRKpBjk+hWomv7eO3cusgI77O1CVyWu6JtS1Ge7URDhMZrHLkKd3Srb31uQpBb5l7rTWubJ4wc9v7pq5X6oqFl0KAck9B07jrUTcnPGc8Vef7Ew/1mD6dMVEVtm+7MPehPyNLlc8KCoGR29arXbE7euOn0rSMMBwyzAEjpVaaCNpseapx8xwauElcbasOi+S2Kd8c1VIzt7YHSrbsphPQ5WqaZY4zxTj1Yroauckrk5OCPStnVY9kybs/wDHuuOcnvWYiEHgbhmtDVHz5eM5EQGPzokxRXvIybxwbeJVI4b86SBdjoAMMSM470lzH5awkL/Fk0LMDLGw6lgtaJaaG/qW5iRdK5A27iBmnxZCvx8uelOKl7hcr8oYk0kmJEYgYIP51i30GjO1ppfMiZScDnC9a3NMVjpSSzg+Y5wMjBxVNyDJEWXJGMe1ahnaS2+dtxzhSewHapqzvTULGKpNVee/yInI27QOR6VTtt3nyBuRkkd6lZmEm4n5e9MgYifco6g9qiKsmdHQkeQ7Bng44oIZ9q9scikuYcl0MhG0A8dqLdnZdyjqOpo0tdCQl2yttGD1/KtC2IFrEoyeCf1rN6qc9c5rRgYGJFx2wTUVPhSC1ircjEm8YyOBRNIkCh2GSeOOuakl27z3C9AajlVTl25UHJFC1tcHtoRRMssTEDCk05gUYg9NvBBpV2LECBgdQMdaVSrBiMHI6ZqmxxIoyMEEn5eateaNvAGduD7VUJzCQOB1p0K7i277uOKclfUCuGxz6nvSyfO7SABdp+gqEFioDDJB6VI/zwgZxk4/WtbWY29Cld3xhbIQEDu3Wo45hdRxtnCuRgfjTNTsWwwZ85B5HelhjW3jtIxkiMg5rpShypx3OSM6jm+bYuSKqlm7A8k1BIsYl3D7w5HNTKryZKg7SRTljG8qyEAD71ZJ2Op7CH5ssByOQMcU1MQxO+Cc9qluZFRGRSQ+3NMtyzKykAZXmktriYiy7lVmJUsMjHarM+8xxlMZ+vaoIYysOJTubkA+lPaQoFXPyjGaT30CN2i5YBnuELsSwyeBVm5fAySvXnNV9MZWlkIPCLjH1qeRWMijA2g1zT+PUsbLlkG04B54qN8AncT7EVLIxVWyMDpUA3HGTxnOKIgIZB5Tdc1CHCuFLdOefepXVcHLbRtOMVWi6gYziMHPvmtYpWAllH+rKjnOTz2pjsArBuMnNSM/zAjnAyajmOYDlQQc800IbkrDsGMbuafbxtGSGcb8k4HHB7VBMw2kDPmMQSB3q/Fazs4kjtZ3Zh18o8VTvYhtLcZGQGBHOTyajiOL1m3MTjIB7VY+yzxfK1pOvcnyz1qjE6R30wlYxkKPvDHf3qUr3sLni7WZanLO8TdcHpU5OVyBioF2NJHyAOtTsAQ21gRnris5dEWiN4/3pJJ5HAFIyhl6kLu7HvTnZRIOedvaoywiYKxyS/FNXB2LD7iQM544pWXOGz83TjpTd2Zm2g5C9KkYkDB4Y1nsUigqgsQAD1qOSPcCCv3qcvDs5yeuCKaG2SDad2R0roV7iaQsax8FxjAxRMiyDKgAHnPrSh8biwGNuR7e1GWmgTblcDoR0o1vcQsSJ5q5BCkZAzUyRr/ebpkDPNJECJRkjcoxzUgwrgg8kEfQVEmCsRRwlWYq7t77qsxIGyu5gRyTmoYiwL9wWHAqcMGlYnr6ZqZNhZIVsNlUZ12kd+tMEbpK4EzNj36Go4/kLySHoeMd6S2dfLb5tzk5zSs1sTZNiXDyKqK0r1E8soGBIT+FTyyFoAh3Nk55HNVGYsFSMDO7BzWkVfcfKuqLEElwUP775s4PFTL9pIBEq5PHSqpL/KEIyGIJqxC+F5I3Adu1KXcXLHsMu7q4iXhgW9PWgS3n2F3l8tRxwaivFYquwZJcde1S3bLNZSwhsZ6+1PSy0IcERG6nO3GwqFpY7mQoT5ceB0JqszIUKxnBVcY6U9SSoXPUVdilCJNJcvKAxiQj2FOjcYOYEBNMhVQpGDgkDPvTnJOD05qX2QOnEVHUtzAAAOxqsXXzJW2MMLjr61fikUEqw4xjpUEa4SUE57ilGVr3E6aK0su2IKYiAF65plqu4/cOOvWrepKBAwPcDpTLZtsYOMEZH1q1L3boSpq4sLfMpC4A7E0/UrlZySgKjaFHrxUe4jYMk/yqrMdjkEc+1CV2bU6abuNumJihyPrz1pIcLKOQFJGM024/1cKtwvNPjb99EAMg4H0rZbGctG0X/MPnlQfmOaltlK5DDgnGahgA893Gc4PFAkI6nvXNJdEUttR2poYZ40Rgc4OauqVFrnIOTms+5PnTRkHLLjFXXwiorYxjPFRL4YoViuiYJkOT6DNTJvVQdvNMMg+XAPNKJDkqPzod2PYeu5e+WI5psYVI2AYg5z70kmfMY846ZqLaWO4Hj0oSuMa/MiYYjnmtdSqDBwAQKx1AZ0IJBBrYddzkEDCqMZ9amr0QmRXy7YxtAIJHNMd8qxAGAOhFNG9iA7ZUtwAOlE2Sjqp5JqUraAtSN0Zl8zgAcECkjT5duOTSuHyoBwpIzQxAbdk56VdxlWf92VQ4yGoMreYIwhI6k+lE3zyr83196G5QHn0rVbagyB5Cr5/hBxx61PasDEHA5Yk4NV1kxJiNQSOo680603/Zoy+c9MVcloRd81jJ12acXqJGdsfGe31rYtLe1fa87kIFycU6ZEOflVuDnPNVEfN2U6qUGABwK0c+eCilaxhGlKFWUm7p/gaUtwogSO3jCqSfmPU1TlclW+bnoKEbO0EjaBk0x0Z3kAYCPsRWUYpHVewmP9IO7+7RBiNmAXjOaZtBKqpJKr1qaBBkneG47Vb2AkjIclzxzkj3pGbnO0HHVaRUBDbG4PNB4VUXLH1JqOobF3SY1RLh0+8xBOecVZabMij16VW04EwSttILEZFSK2GQY78EVhPWTuOyS0HMflZTkKTUCvkvgDgZqS4lfsBjpVfo7Yzk04rQBrEuxDcHacUKoRSDxkAZpYz8p3YyOKdawvPOqKpd2ICooyST0AFaA3YRA7lI7eJndmCqqjJJ/Cr+rxab4chQeJLn/S2G4adakNN/wM9E/Hmr2q6vb+DIprOxu44PEO3E98ymRbXP/LOIAcyY6ntXnmqWkWpXs9/ZzCa2MoUzMu1yOPnYHnJ5Nd2GwqlaVXRf11PDxuZy1hQNceKNX1KdLTwvpsOnhztQQx+bO31Ygn8q3LL4e+NdTY3Go3FzGijLmecrj8M16h4efQ/BGi27+HdJ1LULm7QFdRmg2huP4SegzWjr2pHw/Eq3LRXGq3CCV0JJjhB7fWumcuRfukl8jyuSU9arbZ5Za/DW5VNy6tceZ97dEHIHtnNST+ENehT5LtbqPH+rul3A+3Na2q+J7m7AWed+McJ8o/Ss2bWbhvL/AHsjFRwSeawcqst3f1RrGMI7aehzlxZLayiK7il02Y8LImZIT+HUD6VNdpPZCOO7UBZf9XMhzHIPZvX2610S6tBcoEvEDKeGyORVHEWnSy2iqLzSp8ebbSdOe6n+EjsRXPKDqbqz/P8Ar7vQ7qWMnS+J3RjueSe2OtVipnltiG+7KWA9aNQT+zb0xJI0lnNzbyv1H+w3+0P161LYb9sRZMZyetYuLgrnsQqRqJNE1u5LTse7AAelTB95G7uaVI0WMlTgs350NwV9M4IrnbTZulYzl4uWQnHP5U6QmMMwXc2OD6e9NlAS4PJIJ/KmiRyOV69/UV0WvqJsVctEpP8AEu6pN7CUbR93n61DFtDY9V9etSF9hbGPmGBQ0IGZndtvygkH9asqCxAJwDzmq6DMmOgxUoZt7AgBR90g+1RJdgJYWUghex6VK6gMXUD0NQ27YdQQMEAk0+Vgqt/vZzWbWoyvLuaYwr0POR6U+2jjRncDDE4NRxjEjkHPy9e45qa1+Y/N0q5aKxKXcW6JjSMk4JPFVHPzDGBg8/WrOpbTBEM/KGB+lVhtMuTzjpTp7XKbJE5VCeM/qalVgi4XgN61AGCJGpPzYz9Oat/u/sy/KSc0paC3IUdmnVWwfTNMwp3qRglsU7hZQzDgDjFMSb90Sx+83FNLsIrzfLIvy44wAO1SpjqOcDvUEzbbxN2c4wMdKmhUYmTjJGQPWtHsHoPJ64/1eKemCgOegyarwFACF6kHg1LHgYC4HHIqWgJUYsemcDOelGwv5Z37RjnjrS24Jbcx68YolBD8HjPWs+tkMhvcLCy8sxqC3UIrbckjmi+kPyhGzzyfSi23A/LzmtkrQEtyTKhW52jGfpVNnJILdCetaJQHcWH3v0rOdd86hcCnBo2pWs2xbwIyQg8gg8GpbUBXXAwo6e1QXwKiMgZx2qW2ZNgIyOmR71f2Uc8n7zJWcpcScYGf0poLSBcketNlJMkgI4XmpYxlkXGW254HSpemo+YmjfMiDbjI61euYwPvHAxwMVnW77HUvzgelXLlyzBz0Hb0FYTXvICPcCpGDkEDNNXlzjsfSmmXzCfLGFzzUqOA3HT3otYomY+YPmPQ1DKoFvuBxlgOnWkD5VyeSemO1RRSeaNhHyg4Ge1JRaDYRMGVQOoOK1f+Wh6k4xgVlxoVuCTj73A9q0oQTKzZ79DU1RIa4xgY53DimEbZGPrwRUj580MeuflzUcjlnO4cEckGoQyMFvl9M/pUTZ2789Gzj2pWxuUbucce9EmeOgOOQK1WgELEN/vAmmklFY5yM9qc6gOSv1NNt1QAltzAHJrRbAQqP4sYOCM461bUD7NH6gZzUEk0bxPgYVVJ54pY2dbcE8gLkU5JsEMfcZGwcADgVW3+WHZhgBM5FWNqsZHQkHHIPrVWYHyZCOTt/LitIdiXtclhIe3ibaPmTP504nbGAD+HrUcfFrEFbLKgFKrMSw4yfWm1qEfhJNoEbM+NwGBTIiixHJqMB1by5HL8ZyadEgHLfWi1hp9SWEuYgcAEY4HpmkWRzeNFswi87qaSwkcqcAccVJEVYFycnHU1L01B36GnaZW1IBOSx6VAJf3sYZSG5zk1Pa8WcbdCTn9ajKoZQxwSBwDXMrXdymEx2xAqMjvTIyJgNpBAoAZlJPAJ7dDQ5EZIXGDVLsIinj3KfmO71FdHoLXejaP/AGvZxrPqM5e2sUP3lYD55eePlGeT3rmXBZWKNk9sVs6xJdpMbWx0+S4t7a0W1bnHzHDy9O5HH0relHmaTOHMK3JT5V1OZuoibu5OqWV0dP8AvpKh3tED/GxHDEnk1q/DTwxba34006GUM1k8u6Rem5ByQR2zWdqkl9cXRhuba90+EnzVs2IEQU9NuOvbrXoPwa1HRtA1G91LWblIGiiwilSc574FepGUkrN79tj51pN3O/8Ail4mtLVxZQMFS2TAVeAuOleUS3738YmluC8j8tznPpUHxF1a31vUZLjTHka1fLbpF2lie+PSuf06QrEr7g7ghdhOCuO9HLzrme4c3K7LY133mE/OVfoD6VWiS82sInV8HhWzk/Q0yedYUdpWI2/Mxx61Yng1K1sbO6uPs9st4hkgglk/eMg/jKj7oPvUa2K5kxrpPEC0gG0rnnqKtRTLHErM+85x9Af8DXPXOr3SOYmQhweSxyPw9qrS6q0D5aKUpINgfHGfTPSj2UmrgqsVodXrOmtqWjSKpHmA7gR2YdD/AErD0TUDcWwidcPFlX9iOK7TQxugiMuCxTDe9cHqtsdD8a3Ntn93MBICvfNY1KftItdtf8zuwdZ05pPZnQIx+zrgnrzimr/CR7mliz5QBU5xmmowydw6eh6V5Pc+iRm3k4jndSgwDmkt5zLE4ZQoz27in3xCXjMSMMO55pHbbEpAGenFdStyrQjW+4+QFArR7QAOcjORUaPuYKwO9RuxT85UqcEgA5z+lLvDOO3XrSCwiShJMMwwMDnvU05LQs0ON3Rc1FHBbtcFrhWYjpzx+NWrjaQuxeBxUyaurE3bbRmWNneQ3fmzkopBDKWBz9MVpkFtwAIHcmo48k7Uzk+tPuRmHylYAk5JoqTc5XZNGl7KNk7kG0xBsdOxqaF/lGDtwMHPrUd1lbRl7nA59aLZ1cuv9zAOKT1VzROzsS37bkQevWqZYpIuc4zz71LeguEClkO7P1qB/lbk98jJqoKysPcsbycYU88VOfljwuaiBPl8AAAY96dG7Mo3jHOPXNQwGux80Ar2xmoLrC3UUQ6ZJJHsKsuAzliSB296hmAaTk5I6Gqi9RNEEoIkQc4AyTmpg4EfGNx6EnpULAmRQx3L+oprneRjtxxWlrjuWIYsru+UnPNSkEMdp7d6qxyneowQPUdM1PyW6c9qiSd9RE0TDcF6EDmjkIF9aaELZbjGKcQFC4H1PvUFFO7CiMHADCpLXhRg84NQz8svIBJ5BqVZdjAKAa1fw2JW7HyZCgH71Z8KN9rQtnByRV6QAyoxP4VHIAhYkfKO9EHZWKv7tiG5yZ1HfBphV2dFTjBHI+tOkcb0IyPl6nvT4XAmXnPNaLSxjPVE9xEu9xu46H3pY2cSrjHCnGKZKckkkFc0+OQM6buMCs3exTQyPf5qEn5STjNWtSmCREA4yOSO1JCAzDB+UCquqx+ZCy+vU4qVaU1cOjM/StUjurn7PAHYk8Pjj3reQkH5uf61j+HLWOzjd5M7xnYB3Y1rQMd4+U465HPNaYlQ52obHNg5VZQvV3Ec7FdsfL3yKrgHduXOB1qad2IOBkMTyagjnVmMauNy9ayina513JYTlwrHjP51pQ8l2PT1JrLLj9eTWhExKFVB5Gc4yKzqoLhJkOpJxnimSEqu0DII5NLNksFHAFUb0SFjHECR3pQjdoJOyuWEwGXDZINPIywJOPr3qpawyJODIpztwo9KmLZYh84q2tdBQbau0RuwDM3Y8cU3d+6duRnikRlAAJ60yZtsTHPBNWl0KuMgj+VweQVxz3qxIdsar16KKjtyHhkLHgAdO5qdgsYVAvfrTk9RorTEorbep796qSt+6cHIZhz7Vbkk3SlRxiq8pRlcnJPTmtIGctRUUCPywCQAPm9aarBWAcdTil3KrYOdvGKeI0kGc4OT1p+oJ2ViNmBldycLuA/DFTBwI/mOBmkuGiwNmTg4o2KIwSST1pN3Q0Oi4J342tnmm4SInnC4706KTzABgAgdDVe7gLyI27Ax060Ja2Ym3a6N2ORfsiAd1GKgjwWOSeB6UQ7RaxxjhdoANNieOEyOxycVzJb2Lbsrivu27Rk5HFQzfKG7mp42lfT7e4njRFmY7Qr5IA9RUcvAyeeevpV2cXZmdKrGorxHadhpbUEDLyKpz9a0pV1y6u7g6VFbxxSTzIZ7h9inIwwB9gKy7WQQ3ls5GViYSEeuDWjdyXjLcRWumrdbZJD+8J2RCTB/Ouija7/U83MrvlMy4uL291WSe/ELSMiov2di0YVRgYz9K7vRtPg0X4ba3r19Fuu9TiOnaehGTg53Pj+v+z71wwkuHvmN41kJSoAjtm4jAGBn0NdD4l+IUGoHRNHi0m4e0sYNgjjcKJHx1B+orujdvbY8iTSW50h+Gt/r/hLwve30kkTwW7Lc3BcKYoQMr8vevMNUS20+d1SQyRqTsc9WH0rr/EfjXW9R8FWuno72ioTHLED2HQMa4G2ieacNdjftGVHrWsVdXvp2MpWvaxUkaa7m3OzBAQQh5B9M11Ok6Hd6pPc6jfFza29o0s10TxGVX5UXPXPHA9azZmRCJNiqFPQ96yrjUL7VpTZRSlbBMlkRjg+pq2pTWmnmZq0N9Sn589xMrbd/y8rmr9lcvdQ/ZSztGHVvLYZAx6mprO0WKVdgC+qn0q/FHHBOTjBkPft/+uprTjayRVKEt7nXaQcKDk9uo7VzvxajEfibRZEPzPbAZ+hrc0zLBFzlgwPFYPxkY/8ACb6XZ5+e3tYw3sTzWFNXn8n+R1J25fVfmXIgBHG3zDIGT602UBSu05OefUVHvdfLXI2gU8H96M4IIGPWvFs73Pq4lPUERpmcgFgBjNNkGY0VhznnFLdktdkAc+pplwmRs80qx9K3jskyXpdokggyjs7/ACniiSKNOhzk5HtQCdjBTuXNRyhzIueCvpSV29wHjG9myC1SMCQOuKiRQZNqg5PGKklyoPPHHeh7hsCq/kMyttwcYofKiFScMSFPqaWMgrg88nPvVXUjJIIEhU4Dbjg85oirysTJ2V0XSVkcrjIU0y2G2S4UDGGyMfSq+nxvC0nmk43565xVqH5jKeVJPWlJct0hxfNZheAKUdeSegzVaUhCNy5dume1WZ2LKoH94YqCQbZMyDOO3pRDbUscjOxcngDG30p8ZJGcZwMkCoRKWb5F+WrELkocLgmiSsSM3KYwWJwe56io4wGYyep/SnyqGKgjjpUT70ZQO3b1poERzkJcsB04AHrT/MQLhR83aop2R5TnhwOfY0qFDHk9SOvpWltEFx0T5zg4A7VYj4ywOSTkGqsLE53AbQSPrVmFjg8DHvUzQLUnTGfT8KHBwT14pm8NuCjPGaJGYxDBGTxzWVtR7FG5IEse4gZpyHDFm5PYetR3CkKj8YH45qRYy4G9sd810aWI6snI39RhTxn0pl4junloR1HPtU7cRgLyD3qI8FhzkAkD1rKL1uN7WKl0dpjIGWC4xTrYA3CkgAEgY/Go5yVaPuSv5UltuMgDDowHFdCXukS3LtyVRHwOhxRbnfHuGMiieIvuVv4mJNQx71QgfdGRWVk0VqPsGdsmRs/MeBVrUHzkYORgfWq2n4V1Y9z3qbUNpcsV3NnIPpUyX7wSelivbxSA/PgBj2NX4jsOB9Kr2u5kUnA/HpTmkbPbAHrSn7zsOKshZUY45GPSq6KqqHAG88Ej0qwzcqQMHv703aCnH3aE7IrcgRUlmVNx3HnitJd4gxGSdvoeTVCP5GwowfWtKHKKF53delTVYW7kMDSuGMp5ByB6Ukb5dmIyc/lUpwueDn1qDIA3Y6moWoEry73ycAjIqFSQTkfNj8qWVfmX064qNs78ggHvVJAiGQFXXd3BziqrsTGqk53E9ugHerLs3mjePlz0pjhGnZlzgKccVvHTciab2Jrc/uSoB4Ipt0zjBUDHQCpLIDYTuGAeKbLgkKxH3s1H2jToVJD5YUsNxbPSoSrqqZK7WJJBq2AMsTzgHp61RYDy4VXJzzyetbw1M5E8xIk3YwB0+lNjYOoIbKE9RSuAGznAApEXO3HI5OOlHQYEH5VBwM5OPSpi5IRRnkGoWBTou3HU9aVgZAGztCHHHehoB6qsRIJyAveh2JwVyARnntUsUYYfvCOmMetVltma4ZvMbA7DoaSs9wba2J7i8Wzs1kkZirMF9eTVqwdZ7V2cDhirYORTniQWu10DLjkEU2B4YNP/AHcXlorktk5LGsm4uNktbmM1UVS7fuWHqI42jwMJ1Cdeaifq249TimWtz9qXfsIGeBTpJFLbufwoalezKoKCjeGzEfHmEZ4xxirtqk+sQnT7eSQCfAaJXI3snQk/SqgAJZhj7vWoYpDbS+cG2oOGx1+ta0ZWZhjqXtKd10Ni+n0vTtCs9NSSCW8imbctvEPun+/J3INVNMgWTUbUiPzJFlUhM4L8jjPvU11p6Nai4tVURkZIA6Gq2mmSC5jkRtjRMHVu4Oa7ItSu+p4LXR7HpHxC8OJoz6hczaNDZW0yJ5Jhm3APjnPqfWvJ57lbVchhn1NbfjnX/EXiS6eZZo5BtHGdpyBjp0rze7gvRKBfQ3OQecrxXVRoqWtzmrVGuhcvLua7YhZPlbjA71t6PBDptm6OczSgFmH8NYmlxefJiKMhU7Ed63ra3aOAiUd8gjtW1WyXIYUruXMRySKsu/7oBz17e9Q2lnqGvTT3VmoeztCrOWfaME4B9evFa2m+E7/xLaXd1BLDDplsDukY8yuCBsUDnuK9X8N/DbS9Pgm+2TS3iyW8ciqn7sHJBJP+yPT2rlnWjTVlrI6Y05S32Kfwz0trqdru8jWKwt4zNMSPuqoyTmvH7vUJPE/jrUtXYExyTMU9Av8ACPyAr1T4ueN9O0jwWnhrw1Mr6jqP/H28f/LKIH7mfU4/KvNfDWn/AGS2GeWIyT71lUl7Kk5veR34Ok61Zdo/0jX3hAoYHDdPanxZkcZAGB0zULs27Hap0wJFB4+XrXjtaH0qKU5JupEywwOuOtVbG1l+1y3F1kQhCBk/ePbFXbpf37nJGRioo3AjbPKtwK2jJqOnUyqU+dpt7DLaTeGLcru4qRmLOMDBBz+FEQUIyqpGOaay7IgVbjJ60OzZUVpqSg7JN6/e9c9KzbuKSXVHkdZCjIqRhD37k+9aCrtXOMyOMgH1qW5tzbxwGVw0sgBYKfumnTnyO5hiKSrJRvYeyiKQxkgkAD6HvUEpJkiAJGxsn3pLYjbjBbBzmmlnaQBV5qEtTdJJWJ2AwMHAJ5p1unyyBnGPWjYzKobgYpswYfdA25OanfQq4TtiEHGec1UZ2UZJPHXvVm4UhIxyRxUFxiN9vrxmrgDHlfkJTpjGBUjSgxso+93xUSs3mhUJA2inxo537wMDuO9DXcTFZiCrAZIOePpTGPmyBs4IHSk87F3sU8KM1BbSrJcyDhscZA6U1F2uSpXdhs8X70MhAbqx9aSdwFXI49RRcMftmwg4A5NMYYA3D3ArVdLh3sTwSb0Y44AxipCTyq8gioIyPKcjjtjHWrCN8yEggkYzUSAkjDDGORipJmzGMcEUKeAPbmi5YeWCOvpWW7KKUuCMueM8AU1o5JoCsbbSvqeoobaQenLflUkIyoOQcn9K2vZEtX0H2kTRxBZGJ980yZijben171O+5eevtVG6YR3CDJLMOfelH3mHwobM5MyjaflHUUsJJukcAnJxtpJ3KTgknG0cU6xUPcK2DgHgGtdo3Ie5bnLJJyehqK3kyjNkZJJNLcndOSBwec0+YARRjAGf1rLpYq4W+DcKOo64NO1UsIyEUkk4NRRwbbiNs84yQO1Wrt9zAYBAPepfxJoCFMxqFXJ4wTU0PyhCy9T3p0RH8WOR0pqyFs54AqG7jsFx8qHPO6mq/wC7Cg8+lNkcOoAOSDk1Cq7WBOdwqktNR3JFIbO3Ga05VMghkyRIF42/TvWZFndjHU9fSrBvGLGG2KtKuAQemKicW3oDdiWRmGBIBn2NRs21QcZA64p7tuJyBnNQgMq8+vWkkO4ow8YK7gDyc0m5chs0sysFyvQnnNRsyhMkc4qkrgMlfgYxk5NRsdsbEjqMfjSkZYHOBjJptwhaADdyxzmtFbRCLNmNsJ4HrUMwAIK5ODnNOMjx2f7tMnpzULsRArP8vHahJ3uHMths8oELMw6g9KrNlkhCggYGOaW4JFvLnGMcUsany4s5yBWyVlczesrDnO2NiMHjv3pqEhVUZ3etSzEFMHvwBUcanAB5zzQti+o2dtgAZupx9anVuAONpHINVJVWRsNuJXoPerCgrHjHzUSSshJ6lgEMQQvHQUIyjcCPSmxHkrnBBpyx7p0XqC3NZPQsvSkYwMjOD9KjdVWLaSOeadMDk56CokyViL/3ayitBvXQEBVVReEXoKjk3eZyBg9KVsqhzk5PSmZKjaw6mrXclJR0RK7BGKNkDb1FQhcRANgqx5x3p2C7uc5A4qOPL53Dbg9PQU0S9SfR9Uk0qSRJ1MlmThl9Aa7zS7Pw/d6e11HHJcs3SGN+entXnM0Re3OM56fhVe3F7pkpn0u4aJhzjPyn8K6YtT62Z5eJwjT5qa0PXI7GKz0jNhoc8cvlMDJPtABLdSx7helUtQ0ifV50S6u7SCTO4sH38bRgHAx09K5OL4j37GOLXLaSVYl2b4W4Oe5HerY8S+E79VFzfXNsQOjocjjHam6VTe33annuSjpLT8DQvtH03SoljtJprm4mbBdtqKDjhgvX8awdNayvtatLSbc1kr/6VLHkAL/dBHr0z2rah1LwAgVptZmO08bIiTiqWn/EPwxoeqXTW2mHUbXH+jps8shv9r1FdEIVHfR/kYylC61R0/g3w/qc91DHpmnOlhFcmeOESFcL0ClvToc0/wAeeK9N8F6NLp8eoDWvFM6NCFRy0Nkpz+bDpXD+I/ip4u8RxG100Jo2nsMeXa/KSp9W61y2n6QsEwknPmSk5Zm5z702qdLWo7vsb0qNWtpBWXcq+H9OaS4Nzdjc+STuPeuuQiJH6gAdqpW23MgVehOOKtrtw4zn1rz8TVlVleR7uFoRoU+WJWF7vkAiTdzgjv8AWr8Gd7MT0GCagtVUAlVHzHBPrUsALPJyeW4rnnbZHRBNbsgvM+bz6bjz1qo6I0aiTcAWyNvard626VhjBwM1Gp2gDsOTWkHZIclcPu5cMRng5qMNuVQRwD+dOcnLZA5OKbgLt596aAWaZw8IiTLu23J7VdukMVwY5B84xkntxVSJvLYSLgnr9DUsjyTTmSTkk5PqeKmSIV+bUfCw8oggBuce1SkiLa2Mnr0qugBAwTjGaQSAZySTnpUuNyyxHKshx0xUU58uIntuzUS53EAjPWkuyTbbTwRTUdR3siadvlTJPY5qGVdsyDqG55pbhiY0ZuWyBz3qNWMkihhxzjNOKsgZIHUvtAypOAfSpozwcmqbAqxKnpxViOUGMADtg0SjpoIZMcybkAyRgmoIVETSMFwx6+5q2QE+X15qJU+Vi3U1SelhWVytIu+XOfmIpzKMAHgjmmvlZHZjweg96WQkYJHPRa07ATxruj+7yKlkVmjYptEuOAR0pkLqEAByTREzKzcYB6ZrJ3uBOJCi4ZRuxzUNw4wpHWpFIc5xkkc5qtPzcRDHQHNKK1B6IinQIN2BzzREzKSqgKuMhs067X5VHOSeQKSFdyEE7TWt/dE1qTSSnKjGQfWmt+8cNtHyqRSJlSBnce5NK7KI2xwcc5qbW2G1cozktOpH3QM06wmPnp83Q4P50yU4mww/hxxUmnQhZQRxk10O3LqYu9yzIzM74/hPNKrgxKzAkg1YkRRIwCjr6VIiL5bDavX0rFocWVIJDubg+1WWYEscZ5pqqvmDgfe9KsqqndkDr6VEo9Skyq7ZGWOBjj1oicbGB6kcGrcqL5f3R09KERcD5V6elK2g72KK7UGE+9Uarn5s5x1FXrhFEy4UdfSkgReflHU9qpLS47laEBnHYd6RLfy5JnhBV5B1A5z61dhRM/dXr6U4D/TgO2DxS1vYl2ZWsEZLWNbg/P3NPZ1I4OQDU14o3YwMZpbZFwPlH5VNr+8NaaEDDaQC2eO/ao2K7SXGauTIufuj8qrxqpZflHQ9qaiDlYrJsXOenGBTZosAvk4POKVVGV4H3quyqvlr8o/Kra5WCd0QEFraIPkDqBmq8h3xY6dsVoXCjEIwOnpUMqrkfKPvelTFDb6GPc5aOQZOPWpGbaVKHcAOATVy5jTyXGxcY9PemTIodcKB07V0JXRk3ZlN5CWAYFSPWrCdAAOg69qmuUU9VX8qSEDcBgYpNXjcpPUoAAzZLfMDVlhlS6tk5qcImXO1c49KcirtI2jH0okCepXgBKb2JJ9+1T2m4XCNn5c5xipoEXao2rj6VYskXzn+UdD2rOezLTIrhmw7KeaRG3LH2GBVi6VQX+Ufd9Kcqr5a/KOnpWVtB9bFR2wELEADPTvUEmHkGeR6itAIpQZVT+FV2Rd2Nq9D2qooVytDGEik5PLZzmol3o20H5ic5NaZVfs5+UdR2psSKW5Vfyql1Eik7KNyE5x+VJHztDc57Yqfaufujqe1SIi+fH8o6DtTtZBe7sUvJBlJ4wXI/SmS2UMpO+FCR7c5q+qruPyj/WHtVh0UO2FHUdqOZrZkcsZaNHPrpNoE3eUo44OM0WunxJISsSEqg7V0OxfI+6v5VDCi7n+Vfujt71ftZtO7I9hTurIzraLa7EEY9PSrSjJxjHpmpoUXJ+Ud+1SyKuwcDp6VnLVmkUktChaKDCWORnpzVrjZlQQwHNPt0TyB8q9D2qZUXyJPlH5VM1qXF3RVsGVYTgnBJ6mlt+D947s8e1WbdEFrgKuM+lSQIu8fKvftUSW5UWZt2we4Jxg7fzqJsNHwccVeuEUzNlR09KiVFI5UdPStIx0QXIFXdBzk+h9Ki2/dJzxzitCJFFtwo6ntUUargfKOh7U0tWTcpyvIlpJJCm50BcLnr7U3RJ7m/jSSaNV8xTtK5PT1q5Kq/Z2+UdD29ql0dFUxKqgAK2AB04rXlXspO2p59erONdJPQjhPyH0HFI+0OvHB9KuwIvl42jGfSmSIu8/KPyrntqeinoVc7m3I3IXIPrUFw24ouTlz3q7tXDfKOnpTZETzYPlX73pVRjZictCKZMIoIOMgVAQzsMHABrVuVXb90feHaoERd/3R+VKO1x3KbuSDuxyTx61JCD5QHtT2Vcn5R37VPCq7T8o/Km1oK5XDqygHrULS/KjN1PqetaEirkfKOvp7VRMaGKLKLw3pThBMTlbUqNIWnbKHHckdKapJVTIMc8VbdR9ofgdajCrhflHftWqRPMMiJjcKCS3JJNWIyW5PJFTW6LkfKOh7VIFUA4UflWckUmRgjyyw698VG3+uBzxir0aLh/lHT0pkiL5i/KvX0rNLUdzNupB5gXIBH6UyJtxIOMip71F85vlHbtUOnqDyQM+tdCh7lzP2nvWHZIBzQ4zEVJ69M1dZF8x/lHHtUTqMsMDioRdzJvFKynB7ZziprN2O0qcjANTXar544H5VJYouPur27e9bNe6jFu0j/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Ziploc&reg;-style bags are commonly used in the United States&nbsp;for packing drugs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Steven E Aks, DO.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5014=[""].join("\n");
var outline_f4_57_5014=null;
var title_f4_57_5015="Acute cholecystitis with pericholecystic fluid";
var content_f4_57_5015=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Acute cholecystitis with pericholecystic fluid seen on ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 491px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Longitudinal view of the gallbladder showing small shadowing stones in the dependent part of the gallbladder (green arrow). The ultrasound also shows a thickened wall in both the longitudinal projection (white arrow) and transverse projection (B).",
"    <br>",
"     (B) A small amount of pericholecystic fluid is noted (yellow arrow).",
"     <br>",
"      (C) The Doppler study shows an increase in blood flow to the wall (red arrow) reminiscent of the hyperemia of an inflammatory process. These findings are consistent with acute calculous cholecystitis.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5015=[""].join("\n");
var outline_f4_57_5015=null;
var title_f4_57_5016="Primary infantile glaucoma";
var content_f4_57_5016=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Primary infantile glaucoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Scott E Olitsky, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5016/contributors\">",
"     James D Reynolds, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Evelyn A Paysse, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5016/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/57/5016/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glaucoma is a group of eye diseases that are traditionally characterized by elevated intraocular pressure (IOP). Increased IOP leads to optic nerve damage and consequent visual loss. Peripheral vision loss occurs first, but if glaucoma is untreated, central vision loss and complete blindness can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"     1",
"    </a>",
"    ]. In infants and toddlers, additional damage to the visual system, including large refractive error, astigmatism, strabismus, and amblyopia, may occur. Early diagnosis and referral are crucial to ensure optimal visual outcome.",
"   </p>",
"   <p>",
"    Primary glaucoma may have onset at birth, in the first few years of life, or later in life. A distinction sometimes is made between glaucoma that is present at birth (true congenital glaucoma) and glaucoma that has onset in the first two to three years of life (infantile glaucoma) because the prognosis differs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. The later the onset, the less severe the structural anomaly, and the more likely the glaucoma will respond to treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical features, diagnosis, and treatment of primary infantile glaucoma will be presented here. Other causes of glaucoma in children and glaucoma in adults are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=see_link\">",
"     \"Overview of glaucoma in infants and children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infantile glaucoma occurs in 1:10,000 live births. It is a major cause of blindness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/4\">",
"     4",
"    </a>",
"    ]. Primary infantile glaucoma is bilateral in more than two-thirds of affected patients, but may be asymmetric in onset [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/5\">",
"     5",
"    </a>",
"    ]. The onset of signs and symptoms occurs at birth in 40 percent of affected patients and before one year of age in 86 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/6\">",
"     6",
"    </a>",
"    ]; however, the age of recognition ranges from birth until late childhood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INHERITANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infantile glaucoma is usually a sporadic disease. However, a number of reports have indicated that between 10 and 27 percent of cases are inherited. Inheritance is autosomal-recessive in some cases and multifactorial in others; the penetrance is variable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/4,7-9\">",
"     4,7-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The molecular defect in the majority of familial cases is in the cytochrome P4501B1 gene (",
"    <em>",
"     CYP1B1",
"    </em>",
"    ) on chromosome 2p21 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/10\">",
"     10",
"    </a>",
"    ]. The protein product of this gene is thought to affect a signaling pathway during the terminal stages of angle development [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/11\">",
"     11",
"    </a>",
"    ]. A second locus for primary infantile glaucoma has been mapped to chromosome 1p36 [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary infantile glaucoma is caused by abnormal fetal development of the angle structures (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 1",
"    </a>",
"    ), leading to impaired drainage of the aqueous fluid and elevated intraocular pressure (IOP) (",
"    <a class=\"graphic graphic_figure graphicRef71433 \" href=\"UTD.htm?14/26/14753\">",
"     figure 2",
"    </a>",
"    ). Elevated IOP causes damage to the optic nerve. In addition, in children younger than two to three years of age (who have more elastic ocular collagen), elevated IOP causes enlargement of the cornea and distention, enlargement, and thinning of the sclera.",
"   </p>",
"   <p>",
"    The underlying cause of angle dysgenesis is not known. Proposed theories center on neural crest cell migration and development, as neural crest cells are critical in the development of the trabecular meshwork [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. Some angle abnormalities that have been observed on gonioscopy include an open angle with no recess, obstruction of the trabecular meshwork by the iris or ciliary body, an absent or rudimentary scleral spur, and fewer and smaller openings in the trabecular meshwork [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1,4,8,15\">",
"     1,4,8,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical infant with primary infantile glaucoma presents with chronic or intermittent tearing (ie, epiphora), photophobia, and some degree of blepharospasm. Parents or pediatric healthcare providers also may notice a large cornea or asymmetry in the corneal diameters.",
"   </p>",
"   <p>",
"    Unilateral or asymmetric cases tend to present early, as small differences in corneal diameter are detected easily on gross inspection. However, when the disease is bilateral, increased corneal size may not be recognized or may be viewed as attractive, delaying presentation to medical attention until symptoms develop. Another potential cause of delay in diagnosis is the attribution of tearing to the more common nasolacrimal duct obstruction. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Findings on physical examination include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Corneal enlargement",
"     </li>",
"     <li>",
"      Corneal clouding, conjunctival injection, tearing, discharge, and blepharospasm, which are caused by corneal edema",
"     </li>",
"     <li>",
"      Optic nerve cupping",
"     </li>",
"     <li>",
"      Ocular enlargement (buphthalmos)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Younger children are more likely to present with corneal edema and haze, older children with corneal enlargement and buphthalmos [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/16\">",
"     16",
"    </a>",
"    ]. It is important to note that the older the age of onset, the fewer the signs and symptoms. Onset after age four may be insidious with increased optic nerve cupping as the only sign.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Corneal enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased intraocular pressure (IOP) causes stretching of the cornea and increased corneal diameter in children younger than three years of age (",
"    <a class=\"graphic graphic_picture graphicRef50389 \" href=\"UTD.htm?27/25/28049\">",
"     picture 1",
"    </a>",
"    ). The normal newborn corneal diameter ranges from 9.5 to 10.5 mm. At one year of age, a diameter of 11.0 mm is typical, with the cornea reaching adult size (12.0 mm) by two or three years. As a general rule, a corneal diameter that is more than 1 mm greater than average is cause for concern, and more than 2 mm is definitely abnormal [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, a corneal diameter of 12.0 mm or more in an infant younger than one year of age should prompt urgent referral to an ophthalmologist [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corneal enlargement has little effect on the epithelium and stroma, but injures the endothelium and basement membrane (Descemet's membrane). Corneal endothelium has little to no ability to divide after birth; it does not replicate and is a relatively static cell layer. As corneal stretching progresses, it causes breaks (called Haab's striae) in the basement membrane (",
"    <a class=\"graphic graphic_picture graphicRef62274 \" href=\"UTD.htm?30/8/30848\">",
"     picture 2",
"    </a>",
"    ). The breaks in the basement membrane leave permanent scars, which may be linear or arcuate, and are typically horizontally oriented. Haab's striae, which may be difficult to see without a slit lamp, are an important diagnostic feature found to occur in 25 and 60 percent of patients who presented at birth and six months of age, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/19,20\">",
"     19,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to scarring, corneal enlargement can cause astigmatism if the enlargement is irregular [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"     1",
"    </a>",
"    ]. In one series of 102 eyes from 59 patients with primary infantile glaucoma, 24 percent had at least two diopters of astigmatism [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link&amp;anchor=H6#H6\">",
"     \"Refractive errors in children\", section on 'Astigmatism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Corneal edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epithelial and stromal edema results from the absorption of aqueous fluid through Haab's striae. Corneal edema is manifest as clouding and occurs less frequently after the barrier function of the corneal endothelium matures (ie, after six months of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/8,16\">",
"     8,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Corneal edema causes many of the symptoms of infantile glaucoma. It is irritating, painful, and produces light scattering. The irritation causes tearing (epiphora), ocular discharge, conjunctival injection, and blepharospasm. Corneal clouding may result in unilateral or bilateral pattern deprivation, contributing to the development of amblyopia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of amblyopia\", section on 'Deprivational amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Optic nerve cupping",
"    </span>",
"    &nbsp;&mdash;&nbsp;The size of the cup, or central depression, in the head of the optic nerve is characterized by the ratio between the cup diameter and the disc diameter. Thus, a cup that has a diameter that is 50 percent of the disc diameter would be 0.5. In normal infants, the optic nerves are symmetric with little cupping.",
"   </p>",
"   <p>",
"    Elevated IOP damages the optic nerve, which takes on a hollowed-out appearance on funduscopic examination. This appearance is described as \"cupping.\" Cupping increases as axons are damaged by elevated IOP. Axons at the superior and inferior poles of the disc are preferentially affected, increasing cupping primarily in the vertical diameter (",
"    <a class=\"graphic graphic_picture graphicRef71467 \" href=\"UTD.htm?20/19/20799\">",
"     picture 3",
"    </a>",
"    ). Asymmetry of cupping from eye to eye may be a sign of infantile glaucoma.",
"   </p>",
"   <p>",
"    At a given IOP elevation, cupping increases more rapidly in infants than in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/22\">",
"     22",
"    </a>",
"    ]. However, in contrast to adults, infants with glaucoma may have a reduction in optic nerve cupping when IOP is controlled. The reversal of cupping seen in these cases is due to a change in the displacement of the axons within the optic nerve, not an improvement in the loss of viable nerve fibers which occurs in glaucomatous vision loss and is not reversible. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=see_link\">",
"     \"Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ocular enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased IOP causes stretching of the sclera in children younger than three years of age. Stretching of the sclera increases the size of the globe, also called buphthalmos or \"ox eye.\" The increased anterior-posterior diameter of the eye causes secondary axial myopia. In one series of 102 eyes from 59 patients with primary infantile glaucoma, almost two-thirds had at least three diopters of myopia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=see_link&amp;anchor=H4#H4\">",
"     \"Refractive errors in children\", section on 'Myopia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Myopic or astigmatic anisometropia (unequal refractive error between the eyes) occurs in approximately one-third of children with primary infantile glaucoma (either unilateral or bilateral) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/21\">",
"     21",
"    </a>",
"    ]. Anisometropia occurs in bilateral cases because the eyes are rarely symmetrically affected. Anisometropia, if left untreated, can cause amblyopia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of amblyopia\", section on 'Anisometropic amblyopia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A rare consequence of ocular enlargement may be subluxation of the lens. Zonules of collagen fibers hold the lens in place behind the iris (",
"    <a class=\"graphic graphic_figure graphicRef71234 \" href=\"UTD.htm?10/60/11201\">",
"     figure 1",
"    </a>",
"    ). As the globe increases in size, the zonules are stretched, and the lens may dislocate. If it dislocates into the anterior chamber, acute angle closure glaucoma, in which the iris root completely occludes the trabecular meshwork, can develop (",
"    <a class=\"graphic graphic_figure graphicRef59454 \" href=\"UTD.htm?39/50/40738\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"     1",
"    </a>",
"    ]. Acute angle closure glaucoma requires urgent intervention to prevent permanent visual loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=see_link\">",
"     \"Ectopia lentis (dislocated lens) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of infantile glaucoma is based upon a constellation of findings that includes enlarged cornea, corneal edema, and optic nerve cupping. Infants with these findings should be referred for urgent ophthalmologic evaluation. Referral should not be delayed pending progression (eg, of optic nerve cupping), as such delay can result in permanent visual loss.",
"   </p>",
"   <p>",
"    Most patients with infantile glaucoma can be diagnosed in the ophthalmologist's office, although some require an examination under anesthesia. The diagnosis usually is based upon the clinical features described above. The measurement of intraocular pressure, which some authors are able to reliably assess while the child is sleeping or feeding, is often not a vital part of the diagnostic process. However, it is helpful in following the treatment response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of infantile glaucoma depends upon the cardinal sign(s)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    symptom(s). When the constellation of tearing, blepharospasm, photophobia, and enlarged cornea occur together, infantile glaucoma should be the first consideration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Tearing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tearing (ie, epiphora) in infants can be caused by nasolacrimal duct obstruction, infectious or allergic conjunctivitis, corneal abrasions, and various metabolic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"     1",
"    </a>",
"    ]. Nasolacrimal duct (NLD) obstruction is the most common cause, occurring in 6 percent of all normal newborns [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/23\">",
"     23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=see_link\">",
"     \"Approach to the child with persistent tearing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29350?source=see_link\">",
"     \"Nasolacrimal duct obstruction (dacryostenosis) in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The distinction between these disorders can usually be made on the basis of clinical findings. Unlike patients with infantile glaucoma, children with NLD obstruction do not have blepharospasm or photophobia. Nasal discharge is another finding that helps to distinguish glaucoma from NLD (during episodes of tearing, the nose runs in patients with glaucoma, but not in those with NLD obstruction). Among the other causes of tearing, infantile glaucoma is the only one in which enlarged cornea, corneal clouding, and optic disc cupping occur.",
"   </p>",
"   <p>",
"    Children with cystinosis may have corneal deposits that cause photophobia, tearing, and blepharospasm (in addition to corneal clouding). Children with cystinosis also have extraocular manifestation (eg, growth failure, rickets). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=see_link\">",
"     \"Cystinosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristic ocular findings of tyrosinemia are corneal ulcers or dendritic keratitis, which cause photophobia, pain, excessive lacrimation, and conjunctival injection. Patients with tyrosinemia also have characteristic skin lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=see_link&amp;anchor=H12#H12\">",
"     \"Disorders of tyrosine metabolism\", section on 'Hereditary tyrosinemia type 2'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Corneal clouding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cloudy corneas can be caused by congenital hereditary endothelial dystrophy (CHED), mucopolysaccharidoses, sclerocornea, and trauma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital hereditary endothelial dystrophy (CHED) presents with corneal edema at birth. The corneal edema produces epiphora and photophobia. However, the cornea is of normal size, the intraocular pressure is normal, and the optic nerve and angle are normal (albeit difficult to visualize).",
"     </li>",
"     <li>",
"      Corneal clouding from structural changes in the stroma (",
"      <a class=\"graphic graphic_picture graphicRef52924 \" href=\"UTD.htm?15/2/15392\">",
"       picture 4",
"      </a>",
"      ) is a characteristic feature of mucopolysaccharidosis (MPS) type 1. Affected infants appear normal at birth; during the first year, they develop the characteristic coarse facial features, wide nasal bridge, and flattened midface. Other signs include hepatosplenomegaly, umbilical or inguinal hernias, and typical skeletal abnormalities. These infants typically present between six months and two years of age with developmental delay, recurrent respiratory infections, and chronic nasal discharge. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sclerocornea is a congenital malformation of the cornea in which the limits of the cornea and sclera are indistinct (",
"      <a class=\"graphic graphic_picture graphicRef63889 \" href=\"UTD.htm?21/19/21809\">",
"       picture 5",
"      </a>",
"      ). The cornea is hazy because its collagen fibrils are irregularly arranged. Additional ocular anomalies (eg, aniridia, cataracts, coloboma) usually are present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Corneal enlargement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary megalocornea (",
"    <a class=\"graphic graphic_picture graphicRef53764 \" href=\"UTD.htm?33/42/34467\">",
"     picture 6",
"    </a>",
"    ) also may be confused with infantile glaucoma. Megalocornea usually is inherited as an X-linked recessive trait; as a result, it almost always occurs in males. In patients with primary megalocornea, the intraocular pressure is normal; corneal edema, epiphora, and photophobia are absent; and the optic nerve is normal.",
"   </p>",
"   <p>",
"    Unilateral high myopia, proptosis, lid retraction, microphthalmos, enophthalmos, or ptosis can give the appearance of an enlarged cornea because one eye is larger, more prominent, or more visible than the other [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Cupping",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to glaucoma, cupping of the optic nerve can be physiologic (",
"    <a class=\"graphic graphic_picture graphicRef71031 \" href=\"UTD.htm?7/28/7616\">",
"     picture 7",
"    </a>",
"    ) or due to optic nerve anomaly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=see_link&amp;anchor=H19#H19\">",
"     \"Congenital anomalies and acquired abnormalities of the optic nerve\", section on 'Cupping'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of infantile glaucoma therapy is preservation of vision rather than control of intraocular pressure (IOP), although IOP is used to monitor treatment success [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/24\">",
"     24",
"    </a>",
"    ]. Treatment is almost always surgical, although medications have an adjunctive role.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical intervention is the mainstay of therapy for primary infantile glaucoma and most pediatric glaucomas. The first-line procedures include goniotomy and trabeculotomy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Goniotomy &ndash; Internal goniotomy involves cutting into the abnormal trabecular meshwork, which causes the iris to drop back, deepening the angle recess [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Goniotomy is limited by the need for adequate visualization, which may be impeded by corneal clouding. This limitation may be overcome with the development of endoscopic technology that provides direct visualization of the anterior chamber angle [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Trabeculotomy &ndash; Trabeculotomy is the procedure of choice when corneal clouding precludes visualization of angle structures [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/28\">",
"       28",
"      </a>",
"      ]. It involves the insertion of a trabeculotome into Schlemm's canal to create an opening in the abnormal trabecular meshwork [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Goniotomy and trabeculotomy are successful (IOP &lt;20 mmHg) in 80 to 90 percent of cases of primary infantile glaucoma when patients present between 1 and 24 months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/4\">",
"     4",
"    </a>",
"    ]. A second procedure at a different site is necessary in 20 to 30 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/24\">",
"     24",
"    </a>",
"    ]. The success rate is decreased when patients present before two months of age (ranging from 55 to 60 percent) or after 24 months of age (76 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/2,4,31-34\">",
"     2,4,31-34",
"    </a>",
"    ]. The visual prognosis for children treated with these procedures is good: 52 to 79 percent have visual acuity of",
"    <span class=\"nowrap\">",
"     20/60",
"    </span>",
"    or better [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/32,33,35\">",
"     32,33,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Complications of goniotomy and trabeculotomy include hemorrhage, inflammation, cataract formation, uveal or vitreous incarceration, endophthalmitis, retinal or choroidal detachment, and hypotony (abnormally low IOP).",
"   </p>",
"   <p>",
"    Second-line surgical therapies include trabeculectomy, implantation of drainage devices, and cyclodestructive procedures.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Trabeculectomy &ndash; Trabeculectomy, or filtering surgery, usually is attempted if goniotomy or trabeculotomy fail. This procedure involves creation of an artificial drainage pathway through the sclera to allow excess aqueous humor to leak out of the eye through a conjunctival filtering \"bleb\". The long-term success rate of trabeculectomy in children is usually cited as 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/36\">",
"       36",
"      </a>",
"      ]; success has been found to increase with the use of antifibrotic agents such as topical mitomycin-C and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/4/34880?source=see_link\">",
"       fluorouracil",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/24,37,38\">",
"       24,37,38",
"      </a>",
"      ]. Antifibrotic agents should be used with caution, as they increase the risk of leakage and late-onset endophthalmitis [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/38\">",
"       38",
"      </a>",
"      ]. Severe complications (eg, infection, bleb leak, collapse of the anterior chamber) are more common after trabeculectomy than trabeculotomy or goniotomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=see_link&amp;anchor=H14#H14\">",
"       \"Bacterial endophthalmitis\", section on 'Bleb-related endophthalmitis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Drainage devices &ndash; Glaucoma drainage devices consist of a small tube that is placed inside the eye, leading to a \"reservoir\" placed under the conjunctiva. The tube must be placed well into the anterior chamber so that retraction of the tube does not occur as the eye grows. Compared to other methods of surgical treatment, drainage devices have a higher risk of early and persistent hypotony. Success rates (IOP &lt;20 mmHg) of 60 to 65 percent have been reported in patients who were followed for two years [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/24\">",
"       24",
"      </a>",
"      ]. Complications include vitreous hemorrhage, malignant glaucoma, retinal detachment, erosion or recession of the implant, endophthalmitis, corneal edema, and cataract formation [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/39-44\">",
"       39-44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Cyclodestructive procedures &ndash; Cyclodestructive procedures aim to decrease aqueous fluid production by destroying the ciliary processes. Cyclodestructive procedures are usually recommended when other methods of control have failed or when the vision is extremely poor [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/45\">",
"       45",
"      </a>",
"      ]. Cyclodestruction is performed with cryotherapy or laser application and has a success rate (IOP &lt;20 mmHg) of approximately 50 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/46-48\">",
"       46-48",
"      </a>",
"      ]. Complications include hypotony, retinal or choroidal detachment, and inflammation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Medical therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of topical or oral preparations of pressure-lowering agents has a limited role in primary infantile glaucoma because nearly all cases require surgery. Surgery is required because of the rapidity of ocular damage and the difficulties inherent in monitoring the disease parameters (eg, IOP, visual acuity) in young children. However, medical therapy may be used postoperatively to prevent or postpone the need for a second surgical procedure.",
"   </p>",
"   <p>",
"    Medications used in the treatment of glaucoma include beta blockers, alpha-2-adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogs, miotics, and sympathomimetics [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beta blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/11/32944?source=see_link\">",
"       betaxolol",
"      </a>",
"      , carteolol,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?1/63/2036?source=see_link\">",
"       levobunolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/60/30660?source=see_link\">",
"       metipranolol",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/30/34272?source=see_link\">",
"       timolol",
"      </a>",
"      ) work by decreasing aqueous production. Side effects include bronchospasm, apnea, and bradycardia.",
"     </li>",
"     <li>",
"      Alpha-2-adrenergic agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/28/36291?source=see_link\">",
"       apraclonidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?31/30/32228?source=see_link\">",
"       brimonidine",
"      </a>",
"      ) work by decreasing aqueous production. Side effects include central nervous system depression and ocular injection [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5016/abstract/49-51\">",
"       49-51",
"      </a>",
"      ]. These agents are rarely used in young children and should be avoided in children younger than the age of two years, as sudden death has been reported with their use.",
"     </li>",
"     <li>",
"      Carbonic anhydrase inhibitors (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?27/57/28566?source=see_link\">",
"       acetazolamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/35/29235?source=see_link\">",
"       brinzolamide",
"      </a>",
"      , dichlorphenamide,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?18/63/19443?source=see_link\">",
"       dorzolamide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/43/41652?source=see_link\">",
"       methazolamide",
"      </a>",
"      ) also work by decreasing aqueous production. Side effects include paresthesias, loss of appetite, nausea, diarrhea, polyuria, and metabolic acidosis.",
"     </li>",
"     <li>",
"      Prostaglandin analogs (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44115?source=see_link\">",
"       bimatoprost",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/42/41635?source=see_link\">",
"       latanoprost",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/52/22339?source=see_link\">",
"       travoprost",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27203?source=see_link\">",
"       unoprostone",
"      </a>",
"      ) improve aqueous outflow. Side effects include iris and eyelid pigmentation, eyelash growth, and cystoid macular edema.",
"     </li>",
"     <li>",
"      Miotics (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/52/30531?source=see_link\">",
"       carbachol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/26/37283?source=see_link\">",
"       echothiophate",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?34/8/34944?source=see_link\">",
"       pilocarpine",
"      </a>",
"      ) improve aqueous outflow through the trabecular meshwork. Side effects include headache, myopia, and prolonged paralysis (with echothiophate after pharmacologic depolarizing agents were used during anesthesia).",
"     </li>",
"     <li>",
"      Sympathomimetics (eg,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?15/52/16195?source=see_link\">",
"       dipivefrin",
"      </a>",
"      , epinephrine) improve aqueous outflow. Side effects include eye pain, headache, macular edema, and conjunctival deposits.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glaucoma is a group of eye diseases that are characterized by elevated intraocular pressure (IOP). Increased IOP leads to optic nerve damage and consequent visual loss. Early diagnosis and referral are crucial to ensuring optimal visual outcome. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary glaucoma may have onset at birth, in the first few years of life, or later in life. The later the onset, the less severe the structural anomaly, and the more likely the glaucoma will respond to treatment. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The typical infant with primary infantile glaucoma presents with chronic or intermittent tearing (ie, epiphora), photophobia, and some degree of blepharospasm. Parents or pediatric healthcare providers also may notice a large cornea or asymmetry in the corneal diameters. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Findings on physical examination include corneal enlargement (",
"      <a class=\"graphic graphic_picture graphicRef50389 \" href=\"UTD.htm?27/25/28049\">",
"       picture 1",
"      </a>",
"      ), corneal clouding, conjunctival injection, tearing, discharge, blepharospasm, optic nerve cupping (",
"      <a class=\"graphic graphic_picture graphicRef71467 \" href=\"UTD.htm?20/19/20799\">",
"       picture 3",
"      </a>",
"      ), and ocular enlargement (buphthalmos). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of infantile glaucoma is based upon a constellation of findings that includes enlarged cornea, corneal edema, and optic nerve cupping. Infants with these findings should be referred for urgent ophthalmologic evaluation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The differential diagnosis of infantile glaucoma depends upon the cardinal sign(s)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      symptom(s). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of infantile glaucoma therapy is preservation of vision rather than control of IOP, although IOP is used to monitor treatment success. Treatment is almost always surgical, although medications have an adjunctive role. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/1\">",
"      Kipp MA. Childhood glaucoma. Pediatr Clin North Am 2003; 50:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/2\">",
"      Russell-Eggitt IM, Rice NS, Jay B, Wyse RK. Relapse following goniotomy for congenital glaucoma due to trabecular dysgenesis. Eye (Lond) 1992; 6 ( Pt 2):197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/3\">",
"      Morin JD. Primary infantile glaucoma: influence of age at onset. Can J Ophthalmol 1983; 18:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/4\">",
"      deLuise VP, Anderson DR. Primary infantile glaucoma (congenital glaucoma). Surv Ophthalmol 1983; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/5\">",
"      Moller PM. Goniotomy and congenital glaucoma. Acta Ophthalmol (Copenh) 1977; 55:436.",
"     </a>",
"    </li>",
"    <li>",
"     Yanoff M, Fine BS. Glaucoma. In: Ocular Pathology, 2nd ed, JB Lippincott, Philadelphia 1982. p.74.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/7\">",
"      McGinnity FG, Page AB, Bryars JH. Primary congenital glaucoma: twenty years experience. Ir J Med Sci 1987; 156:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/8\">",
"      Walton DS. Primary congenital open angle glaucoma: a study of the anterior segment abnormalities. Trans Am Ophthalmol Soc 1979; 77:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/9\">",
"      Demenais F, Bona&iuml;ti C, Briard ML, et al. Congenital glaucoma: genetic models. Hum Genet 1979; 46:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/10\">",
"      Pl&aacute;silov&aacute; M, Fer&aacute;kov&aacute; E, K&aacute;dasi L, et al. Linkage of autosomal recessive primary congenital glaucoma to the GLC3A locus in Roms (Gypsies) from Slovakia. Hum Hered 1998; 48:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/11\">",
"      Sarfarazi M, Stoilov I. Molecular genetics of primary congenital glaucoma. Eye (Lond) 2000; 14 ( Pt 3B):422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/12\">",
"      Akarsu AN, Turacli ME, Aktan SG, et al. A second locus (GLC3B) for primary congenital glaucoma (Buphthalmos) maps to the 1p36 region. Hum Mol Genet 1996; 5:1199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/13\">",
"      Kupfer C, Kaiser-Kupfer MI. Observations on the development of the anterior chamber angle with reference to the pathogenesis of congenital glaucomas. Am J Ophthalmol 1979; 88:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/14\">",
"      Tripathi BJ, Tripathi RC. Neural crest origin of human trabecular meshwork and its implications for the pathogenesis of glaucoma. Am J Ophthalmol 1989; 107:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/15\">",
"      Anderson DR. The development of the trabecular meshwork and its abnormality in primary infantile glaucoma. Trans Am Ophthalmol Soc 1981; 79:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/16\">",
"      Morin JD, Merin S, Sheppard RW. Primary congenital glaucoma--a survey. Can J Ophthalmol 1974; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/17\">",
"      Chew E, Morin JD. Glaucoma in children. Pediatr Clin North Am 1983; 30:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/18\">",
"      Seidman DJ, Nelson LB, Calhoun JH, et al. Signs and symptoms in the presentation of primary infantile glaucoma. Pediatrics 1986; 77:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/19\">",
"      Morin JD, Coughlin WR. Corneal changes in primary congenital glaucoma. Trans Am Ophthalmol Soc 1980; 78:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/20\">",
"      Morin JD, Bryars JH. Causes of loss of vision in congenital glaucoma. Arch Ophthalmol 1980; 98:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/21\">",
"      Robin AL, Quigley HA, Pollack IP, et al. An analysis of visual acuity, visual fields, and disk cupping in childhood glaucoma. Am J Ophthalmol 1979; 88:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/22\">",
"      Shaffer RN, Hetherington J Jr. The glaucomatous disc in infants. A suggested hypothesis for disc cupping. Trans Am Acad Ophthalmol Otolaryngol 1969; 73:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/23\">",
"      Petersen RA, Robb RM. The natural course of congenital obstruction of the nasolacrimal duct. J Pediatr Ophthalmol Strabismus 1978; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/24\">",
"      Beck AD. Diagnosis and management of pediatric glaucoma. Ophthalmol Clin North Am 2001; 14:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/25\">",
"      Barkan O. Technique of goniotomy. Arch Ophthalmol 1938; 19:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/26\">",
"      Barkan O. Operation for congenital glaucoma. Am J Ophthalmol 1942; 25:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/27\">",
"      Joos KM, Alward WL, Folberg R. Experimental endoscopic goniotomy. A potential treatment for primary infantile glaucoma. Ophthalmology 1993; 100:1066.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/28\">",
"      Hoskins HD Jr, Shaffer RN, Hetherington J. Goniotomy vs trabeculotomy. J Pediatr Ophthalmol Strabismus 1984; 21:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/29\">",
"      BURIAN HM. A case of Marfan's syndrome with bilateral glaucoma. With description of a new type of operation for developmental glaucoma (trabeculotomy ab externo). Am J Ophthalmol 1960; 50:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/30\">",
"      SMITH R. A new technique for opening the canal of Schlemm. Preliminary report. Br J Ophthalmol 1960; 44:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/31\">",
"      Dannheim R, Haas H. [Visual acuity and intraocular pressure after surgery in congenital glaucoma (author's transl)]. Klin Monbl Augenheilkd 1980; 177:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/32\">",
"      Broughton WL, Parks MM. An analysis of treatment of congenital glaucoma by goniotomy. Am J Ophthalmol 1981; 91:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/33\">",
"      Morgan KS, Black B, Ellis FD, Helveston EM. Treatment of congenital glaucoma. Am J Ophthalmol 1981; 92:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/34\">",
"      Akimoto M, Tanihara H, Negi A, Nagata M. Surgical results of trabeculotomy ab externo for developmental glaucoma. Arch Ophthalmol 1994; 112:1540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/35\">",
"      Biglan AW, Hiles DA. The visual results following infantile glaucoma surgery. J Pediatr Ophthalmol Strabismus 1979; 16:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/36\">",
"      Beauchamp GR, Parks MM. Filtering surgery in children: barriers to success. Ophthalmology 1979; 86:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/37\">",
"      Beck AD, Wilson WR, Lynch MG, et al. Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol 1998; 126:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/38\">",
"      Sidoti PA, Belmonte SJ, Liebmann JM, Ritch R. Trabeculectomy with mitomycin-C in the treatment of pediatric glaucomas. Ophthalmology 2000; 107:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/39\">",
"      Cunliffe IA, Molteno AC. Long-term follow-up of Molteno drains used in the treatment of glaucoma presenting in childhood. Eye (Lond) 1998; 12 ( Pt 3a):379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/40\">",
"      Melamed S, Cahane M, Gutman I, Blumenthal M. Postoperative complications after Molteno implant surgery. Am J Ophthalmol 1991; 111:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/41\">",
"      Munoz M, Tomey KF, Traverso C, et al. Clinical experience with the Molteno implant in advanced infantile glaucoma. J Pediatr Ophthalmol Strabismus 1991; 28:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/42\">",
"      Coleman AL, Smyth RJ, Wilson MR, Tam M. Initial clinical experience with the Ahmed Glaucoma Valve implant in pediatric patients. Arch Ophthalmol 1997; 115:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/43\">",
"      Molteno AC, Ancker E, Van Biljon G. Surgical technique for advanced juvenile glaucoma. Arch Ophthalmol 1984; 102:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/44\">",
"      Netland PA, Walton DS. Glaucoma drainage implants in pediatric patients. Ophthalmic Surg 1993; 24:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/45\">",
"      al Faran MF, Tomey KF, al Mutlaq FA. Cyclocryotherapy in selected cases of congenital glaucoma. Ophthalmic Surg 1990; 21:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/46\">",
"      Bock CJ, Freedman SF, Buckley EG, Shields MB. Transscleral diode laser cyclophotocoagulation for refractory pediatric glaucomas. J Pediatr Ophthalmol Strabismus 1997; 34:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/47\">",
"      Phelan MJ, Higginbotham EJ. Contact transscleral Nd:YAG laser cyclophotocoagulation for the treatment of refractory pediatric glaucoma. Ophthalmic Surg Lasers 1995; 26:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/48\">",
"      Plager DA, Neely DE. Intermediate-term results of endoscopic diode laser cyclophotocoagulation for pediatric glaucoma. J AAPOS 1999; 3:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/49\">",
"      Enyedi LB, Freedman SF. Safety and efficacy of brimonidine in children with glaucoma. J AAPOS 2001; 5:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/50\">",
"      Al-Shahwan S, Al-Torbak AA, Turkmani S, et al. Side-effect profile of brimonidine tartrate in children. Ophthalmology 2005; 112:2143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5016/abstract/51\">",
"      Levy Y, Zadok D. Systemic side effects of ophthalmic drops. Clin Pediatr (Phila) 2004; 43:99.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6273 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-189.41.181.191-2D925142A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5016=[""].join("\n");
var outline_f4_57_5016=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INHERITANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Corneal enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Corneal edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Optic nerve cupping",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ocular enlargement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Tearing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Corneal clouding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Corneal enlargement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Cupping",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Medical therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6273\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6273|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/60/11201\" title=\"figure 1\">",
"      Angle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/26/14753\" title=\"figure 2\">",
"      Impaired aqueous flow",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/50/40738\" title=\"figure 3\">",
"      Angle-closure glaucoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6273|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?27/25/28049\" title=\"picture 1\">",
"      Glaucoma corneal enlrgmnt",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?30/8/30848\" title=\"picture 2\">",
"      Glaucoma Haab striae",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?20/19/20799\" title=\"picture 3\">",
"      Glaucomatous optic disc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?15/2/15392\" title=\"picture 4\">",
"      Corneal clouding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/19/21809\" title=\"picture 5\">",
"      Sclerocornea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/42/34467\" title=\"picture 6\">",
"      Megalocornea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/28/7616\" title=\"picture 7\">",
"      Normal physiologic cupping",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/58/7079?source=related_link\">",
"      Approach to the child with persistent tearing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/18/24873?source=related_link\">",
"      Bacterial endophthalmitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/47/6906?source=related_link\">",
"      Congenital anomalies and acquired abnormalities of the optic nerve",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/18/12584?source=related_link\">",
"      Cystinosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/4/23624?source=related_link\">",
"      Disorders of tyrosine metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/37/41557?source=related_link\">",
"      Ectopia lentis (dislocated lens) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/42/29350?source=related_link\">",
"      Nasolacrimal duct obstruction (dacryostenosis) in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15289?source=related_link\">",
"      Open-angle glaucoma: Epidemiology, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/61/8153?source=related_link\">",
"      Overview of amblyopia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/31/41463?source=related_link\">",
"      Overview of glaucoma in infants and children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/61/28628?source=related_link\">",
"      Refractive errors in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_57_5017="Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis";
var content_f4_57_5017=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Catatonia in adults: Epidemiology, clinical features, assessment, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5017/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5017/contributors\">",
"     M Justin Coffey, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5017/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5017/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5017/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5017/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5017/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/57/5017/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H6713675\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catatonia is a behavioral syndrome marked by an inability to move normally, and is associated with many underlying psychiatric, neurologic, and general medical disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1\">",
"     1",
"    </a>",
"    ]. Within psychiatric nosology, catatonia is recognized as a descriptive modifier of mood episodes (analogous to psychosis), a subtype of schizophrenia, and a disorder due to a general medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Recognizing catatonia is important because it may be caused or exacerbated by treatment of the underlying disorder (eg, antipsychotic drugs used for mood or psychotic disorders may worsen catatonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews the epidemiology, pathogenesis, clinical features, assessment, and diagnosis of catatonia, as well as the disorders that can progress to catatonia. The treatment and prognosis of catatonia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43928?source=see_link\">",
"     \"Catatonia in adults: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6713689\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The estimated incidence of catatonia has been studied primarily in acutely ill psychiatric inpatients. The incidence is approximately 10 percent, but estimates range from 5 to 20 percent, based upon prospective studies conducted for one to twelve months at individual psychiatric units [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,5-13\">",
"     2,5-13",
"    </a>",
"    ]. The range is probably due in part to differences in study methods, including how catatonia was defined. The syndrome may go unrecognized, leading to the false conclusion that it is rare. In a Dutch study of 139 acutely psychotic inpatients, the treatment team diagnosed catatonia nine times less often than the research team (2 versus 18 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is not clear if there are any sociodemographic risk factors for catatonia. Catatonia seems to occur most commonly in patients with mood disorders compared with other disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4567399\">",
"     'Underlying disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6713696\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathophysiology of catatonia is unknown. Neurobiologic correlates of catatonia have been identified, but it is not clear if these findings represent etiologic causes or sequelae of the disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neurobiologic studies have led to a hypothesis that catatonia involves pathways that connect the basal ganglia with the cortex and thalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/15\">",
"     15",
"    </a>",
"    ]. Neuropathologic studies of patients with catatonic schizophrenia have found alterations in the basal ganglia (caudate nucleus, nucleus accumbens, and pallidum) and thalamus [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/16\">",
"     16",
"    </a>",
"    ]. Neuroimaging studies suggest that catatonia may possibly involve functional alterations in the prefrontal, orbitofrontal, and parietal cortices [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. In addition, neuropsychologic tests of remitted catatonic patients found a deficit in visual-spatial abilities that may involve right parietal cortex function [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. Neurotransmitter studies suggest that catatonia may be associated with decreased activity at gamma-aminobutyric acid A and dopamine D2 receptors, and increased activity at N-methyl-D-aspartate receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/18,20\">",
"     18,20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients may possibly have a genetic predisposition to catatonia. Preliminary evidence suggests that genes on chromosomes 15 and 22 may be linked to the periodic form of catatonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14470957\">",
"     'Other forms'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6713703\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core feature of catatonia is a motor disturbance in which patients are unable to move normally despite full physical capacity in the limbs and trunk [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1\">",
"     1",
"    </a>",
"    ]. Starting, stopping, and planning movement can be impaired, and motor behavior may be repetitive, purposeless, impervious to external stimuli, and contrary to intent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Small prospective studies of catatonia and case series have found that catatonia is marked by heterogeneous signs that are observed or elicited (",
"    <a class=\"graphic graphic_table graphicRef53391 \" href=\"UTD.htm?34/31/35324\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66229 \" href=\"UTD.htm?7/25/7580\">",
"     table 2",
"    </a>",
"    ); the most common are [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,2,10,25\">",
"     1,2,10,25",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immobility (hypokinesis or akinesis)",
"     </li>",
"     <li>",
"      Mutism",
"     </li>",
"     <li>",
"      Stupor (decreased alertness and response to stimuli)",
"     </li>",
"     <li>",
"      Negativism (resistance to all instructions or all attempts to be moved)",
"     </li>",
"     <li>",
"      Waxy flexibility",
"     </li>",
"     <li>",
"      Posturing (catalepsy)",
"     </li>",
"     <li>",
"      Excessive motor activity (excitement)",
"     </li>",
"     <li>",
"      Staring",
"     </li>",
"     <li>",
"      Echophenomena (repeating another person&rsquo;s words or movements)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Onset of catatonia can be either acute or insidious [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Following remission, some patients cannot recall their experience during the episode, whereas others describe an awareness of their activity and the inability to communicate [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Catatonia occurs in patients who are severely ill with an underlying psychiatric or general medical disorder, and is thus analogous to delirium [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,27\">",
"     2,27",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4567399\">",
"     'Underlying disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14470929\">",
"    <span class=\"h2\">",
"     Subtypes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several subtypes of catatonia, based upon the specific nature of the movement disturbance and other associated features [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,28,29\">",
"     1,28,29",
"    </a>",
"    ]. The three principal forms in order of incidence are retarded, excited, and malignant. While a factor-analytic study of 314 psychotic patients supported separation of retarded and excited catatonia as subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/30\">",
"     30",
"    </a>",
"    ], patients can exhibit signs of both subtypes concurrently [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/31\">",
"     31",
"    </a>",
"    ]. Subtypes are not necessarily stable during a catatonic episode, and patients may transition from retarded to excited catatonia or vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In addition, retarded and excited catatonia can each progress to malignant catatonia; alternatively, malignant catatonia can occur de novo. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14470936\">",
"    <span class=\"h3\">",
"     Retarded catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The retarded form of catatonia is characterized by mutism, inhibited movement, posturing, negativism, and staring [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Postures may be mundane (eg, sitting or standing in the same position for hours) or unusual (eg, head raised above the bed as if on a pillow). Response to voice and noxious stimuli is decreased. Although speech and spontaneous movements are reduced, some patients appear to be alert and aware of the environment. In more severe cases, eating and drinking may cease and stupor and incontinence may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14470950\">",
"    <span class=\"h3\">",
"     Malignant catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malignant catatonia (also called lethal catatonia) is a life-threatening condition that is characterized by fever (less likely in older patients), autonomic instability (labile or elevated blood pressure, tachycardia, tachypnea, and diaphoresis), delirium, and rigidity [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,15\">",
"     1,15",
"    </a>",
"    ]. The syndrome is typically fulminant and progresses rapidly within a few days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/34\">",
"     34",
"    </a>",
"    ]. Common but nonspecific laboratory findings include leukocytosis, elevated creatine kinase, and low serum iron [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/15,35\">",
"     15,35",
"    </a>",
"    ]. Signs of malignant catatonia overlap with signs of the neuroleptic malignant syndrome (NMS). (See",
"    <a class=\"local\" href=\"#H6713738\">",
"     'Differential diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H86152124\">",
"    <span class=\"h3\">",
"     Excited catatonia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Excited catatonia is characterized by excessive and purposeless motor activity in both the upper and lower limbs (hyperkinesis), restlessness, stereotypy, impulsivity, frenzy, and combativeness, [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,9\">",
"     1,9",
"    </a>",
"    ]. Delirium may occur in severe cases, and the excess motor activity may cause self-injury or harm to others.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14470957\">",
"    <span class=\"h3\">",
"     Other forms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other, infrequent forms of catatonia may occur [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1\">",
"     1",
"    </a>",
"    ]. One example is periodic catatonia, which is marked by waxing and waning of catatonic signs [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/28\">",
"     28",
"    </a>",
"    ] or periods of retarded catatonia alternating with excited catatonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85675547\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of catatonia can be observed or elicited (",
"    <a class=\"graphic graphic_table graphicRef53391 \" href=\"UTD.htm?34/31/35324\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66229 \" href=\"UTD.htm?7/25/7580\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/27\">",
"     27",
"    </a>",
"    ]. Clinicians may overlook these signs because of the severity of associated psychopathology (eg, psychosis). In addition, common signs of catatonia such as mutism, posturing, and rigidity may be absent; many catatonic patients speak and move about. Thus, patients exhibiting only one apparent catatonic sign should be examined for others.",
"   </p>",
"   <p>",
"    For patients with an underlying psychiatric disorder, the motor dysregulation of catatonia can be similar to the underlying psychopathology. As an example, the increased motor activity and impulsivity observed in mania may progress to excited catatonia. Mania uncomplicated by catatonia is marked by goal-directed activity and intact cognition. By contrast, activity in catatonia is often repetitive and not goal-directed. As another example, the psychomotor retardation, anergia, anhedonia, and anorexia observed in major depression may resemble retarded catatonia. The hypokinesis and refusal to eat or drink that characterize severe depression may be catatonic signs and patients suffering in this way should be assessed for other catatonic signs. Clinical features that often occur in depression not complicated by catatonia include suicidality, sleep disturbance, and feelings of worthlessness, guilt, helplessness, and hopelessness. In addition, catatonia can be distinguished by additional motor signs, such as posturing, rigidity, and negativism, as well as a positive response to the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    challenge test. (See",
"    <a class=\"local\" href=\"#H4567399\">",
"     'Underlying disorders'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4567794\">",
"     'Lorazepam challenge'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rating scales have been used for research purposes to systematically examine patients at the initial assessment and quantify progress during treatment, but their utility for routine clinical care is not well-established [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/25,36,37\">",
"     25,36,37",
"    </a>",
"    ]. The most widely used measure is the Bush-Francis Catatonia Rating Scale, which is a 23-item rating scale with good inter-rater reliability (0.93) and construct validity; the first 14 items can be used to screen for catatonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/38\">",
"     38",
"    </a>",
"    ]. Each item is defined, the procedure for rating each item is described, and the scale appears to be sensitive to clinical change [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/29\">",
"     29",
"    </a>",
"    ]. The Northoff Catatonia Scale is a reasonable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no specific diagnostic laboratory test for catatonia. However, malignant catatonia is associated with non-specific test results that include leukocytosis, increased creatine kinase, and low serum iron (",
"    <a class=\"graphic graphic_table graphicRef57370 \" href=\"UTD.htm?18/58/19371\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/35,40-42\">",
"     35,40-42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4567794\">",
"    <span class=\"h3\">",
"     Lorazepam challenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly every catatonic patient is initially treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    or another benzodiazepine (patients with malignant catatonia may be quickly switched to electroconvulsive therapy); the response to the first one or two doses can help make the diagnosis of catatonia. Case series suggest using an intravenous (IV) bolus of lorazepam 1 to 2 mg [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/31\">",
"     31",
"    </a>",
"    ]. IV administration allows for rapid, complete absorption, although intramuscular (IM) injections and oral administration have also been used [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/29,43\">",
"     29,43",
"    </a>",
"    ]. Intravenous benzodiazepines should be injected or infused slowly. In addition, clinicians should be cognizant of concomitant drugs that can cause sedation or respiratory depression, eg, opioids. Benzodiazepines cause varying degrees of motor incoordination and increase the risk of falls [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Partial, temporary relief of signs 5 to 10 minutes after IV administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    is consistent with a diagnosis of catatonia [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,28\">",
"     1,28",
"    </a>",
"    ]. If there is no change and the patient remains awake with stable vital signs, a second dose is given, and the patient is examined within 5 to 10 minutes, although observation can continue for longer periods. A negative response does not rule out catatonia, and occurs in approximately 20 percent or more of catatonic patients.",
"   </p>",
"   <p>",
"    Reasonable alternatives to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    are available. A randomized trial that compared a single dose of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/50/10022?source=see_link\">",
"     oxazepam",
"    </a>",
"    60 mg with a single dose of oral lorazepam 2 mg in 17 patients found that the benefit of each drug was comparable [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/44\">",
"     44",
"    </a>",
"    ]. In case reports, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/48/13064?source=see_link\">",
"     zolpidem",
"    </a>",
"    10 mg was useful [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/25,45-48\">",
"     25,45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of catatonia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43928?source=see_link\">",
"     \"Catatonia in adults: Treatment and prognosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4567399\">",
"    <span class=\"h2\">",
"     Underlying disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychiatric nosology does not conceptualize catatonia as a specific disease; rather, catatonia is a syndrome that occurs in the context of an underlying psychiatric or general medical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,3,15\">",
"     2,3,15",
"    </a>",
"    ]. The presence of catatonia reflects the severity of the patient&rsquo;s underlying illness. As an example, a study of 148 catatonic patients found that nearly 75 percent were concurrently psychotic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/36\">",
"     36",
"    </a>",
"    ]. Multiple underlying conditions may be present in the same catatonic patient [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/31,48,49\">",
"     31,48,49",
"    </a>",
"    ]. However, it is not known if comorbidity increases the risk of catatonia. None of the underlying disorders appear to be associated with a specific catatonic sign or subtype [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/8,31\">",
"     8,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Recognizing catatonia is important because it may be caused or exacerbated by treatment of the underlying disorder (eg, antipsychotic drugs used for mood or psychotic disorders may worsen catatonia) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43928?source=see_link&amp;anchor=H13927994#H13927994\">",
"     \"Catatonia in adults: Treatment and prognosis\", section on 'Avoid dopamine blocking drugs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Disorders that may involve catatonia include [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,50-52\">",
"     2,50-52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mood disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Bipolar I disorder",
"     </li>",
"     <li>",
"      Bipolar II disorder",
"     </li>",
"     <li>",
"      Unipolar major depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Schizophrenia-spectrum disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Schizophrenia",
"     </li>",
"     <li>",
"      Schizoaffective disorder",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other mental disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Autism or other pervasive developmental disorder",
"     </li>",
"     <li>",
"      Obsessive-compulsive disorder",
"     </li>",
"     <li>",
"      Substance use disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General medical disorders",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A review of case reports found that catatonia occurred in more than 100 general medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/31\">",
"     31",
"    </a>",
"    ], including infectious, metabolic, and neurologic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On acute inpatient psychiatric units, catatonia most frequently occurs in the context of a mood disorder, particularly bipolar disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/5,29,50\">",
"     5,29,50",
"    </a>",
"    ]. A study of 148 catatonic patients found that the underlying condition was a mood disorder in 46 percent of patients, schizophrenia-spectrum disorder in 26 percent, general medical condition in 20 percent, and another psychiatric disorder in 8 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/36\">",
"     36",
"    </a>",
"    ]. Reviews of other studies have found a similar distribution of underlying diagnoses [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,53\">",
"     2,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The underlying disorder may be unknown in some catatonic patients, in which case the initial clinical evaluation should include a [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/8,31,36\">",
"     8,31,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Psychiatric and general medical history",
"     </li>",
"     <li>",
"      Mental status and physical examination",
"     </li>",
"     <li>",
"      Laboratory tests &ndash; Tests should be guided by the symptoms, history, and findings on the physical examination. Patients with an established underlying disorder (eg, major depression with psychotic features) may not need any tests. There is no laboratory test specific for catatonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Catatonic stupor and mutism may preclude assessing the patient for symptoms of the underlying disorder. However, family and friends can compensate for the patient&rsquo;s inability to provide a history. After catatonia resolves, the patient should be re-evaluated for psychopathology or a general medical disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=see_link\">",
"     \"Schizophrenia: Clinical manifestations, course, assessment, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6713717\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A minimum of two to four signs for at least several hours is required to make the diagnosis of catatonia (",
"    <a class=\"graphic graphic_table graphicRef53391 \" href=\"UTD.htm?34/31/35324\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef66229 \" href=\"UTD.htm?7/25/7580\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,11,25,38\">",
"     1,11,25,38",
"    </a>",
"    ]. However, neither the number of catatonic features required for the diagnosis nor their duration is established, and no one sign is pathognomonic [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/53\">",
"     53",
"    </a>",
"    ]. The most helpful verification of catatonia is a positive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    challenge test. (See",
"    <a class=\"local\" href=\"#H4567794\">",
"     'Lorazepam challenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13003965\">",
"    <span class=\"h2\">",
"     Psychiatric nosology",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to psychiatric nosology, catatonia is a syndrome (rather than a specific disease) that is diagnosed in patients who are ill with an underlying psychiatric",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    general medical disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR), catatonia is recognized as a descriptive modifier of mood episodes (manic, major depressive, or mixed episode), a subtype of schizophrenia, and a disorder due to a general medical condition [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2\">",
"     2",
"    </a>",
"    ]. The specifier &ldquo;with catatonic features&rdquo; is applied to mood episodes that can occur in patients with bipolar I disorder, bipolar II disorder, or unipolar major depressive disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with a mood disorder or schizophrenia, DSM-IV-TR criteria for catatonia are met when the clinical picture is dominated by at least two of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Immobility (including posturing) or stupor",
"     </li>",
"     <li>",
"      Excessive motor activity that is purposeless and not influenced by external stimuli",
"     </li>",
"     <li>",
"      Mutism or negativism (motiveless resistance to instructions or maintenance of a rigid posture against attempts to be moved)",
"     </li>",
"     <li>",
"      Stereotyped movements, mannerisms, or grimacing",
"     </li>",
"     <li>",
"      Echolalia or echopraxia",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Only one of these criteria is required to meet DSM-IV-TR criteria for a catatonic disorder due to a general medical condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6713738\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Signs of catatonia can overlap with signs of other disorders; in particular, malignant catatonia may resemble the neuroleptic malignant syndrome (NMS) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/4,54\">",
"     4,54",
"    </a>",
"    ]. Both disorders present with fever, autonomic instability, rigidity, and delirium. Patients who present with these signs should be assessed with neuroimaging and a lumbar puncture to rule out central nervous system and systemic infection.",
"   </p>",
"   <p>",
"    The differential diagnosis of catatonia includes a number of conditions, some of which can cause catatonia (eg, delirium, stroke, and nonconvulsive status epilepticus) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Neuroleptic malignant syndrome",
"      </strong>",
"      &mdash; The neuroleptic malignant syndrome (NMS) and malignant catatonia are life-threatening disorders with similar clinical features. Both disorders can present with delirium, autonomic instability, fever, and rigidity [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/54,55\">",
"       54,55",
"      </a>",
"      ]. In addition, an elevated creatinine kinase and white blood count and low serum iron are common to NMS and malignant catatonia. A review of 292 cases of malignant catatonia found that the clinical features were indistinguishable from NMS in more than 20 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/56\">",
"       56",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link&amp;anchor=H8#H8\">",
"       \"Neuroleptic malignant syndrome\", section on 'Clinical manifestations'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Many authorities consider NMS a drug-induced form of malignant catatonia, based upon their overlapping clinical features as well as similarities in the hypothesized pathophysiology for each disorder [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,4,8,10,15,20,25,55,57\">",
"       1,4,8,10,15,20,25,55,57",
"      </a>",
"      ]. In addition, discontinuing antipsychotics and starting benzodiazepines can be helpful for both NMS and malignant catatonia, and electroconvulsive therapy can benefit patients with either disorder even after failed pharmacotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/1,54\">",
"       1,54",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      It is not established that NMS is a subtype of catatonia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/17,36\">",
"       17,36",
"      </a>",
"      ]. Malignant catatonia can present with signs (eg, impulsivity, posturing, and repetitive stereotypic movements) that are not generally observed in NMS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/36,58,59\">",
"       36,58,59",
"      </a>",
"      ], affective symptoms that can occur in catatonia do not seem to be as prominent in NMS [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/17\">",
"       17",
"      </a>",
"      ], and laboratory abnormalities that occur in NMS may not occur as consistently in patients with malignant catatonia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/36\">",
"       36",
"      </a>",
"      ]. Some authorities hypothesize that NMS and malignant catatonia have overlapping but distinct pathophysiologic mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/17\">",
"       17",
"      </a>",
"      ]. Establishing the diagnosis of NMS can lead to treatment that differs in some respects from that of catatonia [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/54,56\">",
"       54,56",
"      </a>",
"      ], although some authorities recommend a common and consistent therapeutic approach [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link&amp;anchor=H23#H23\">",
"       \"Neuroleptic malignant syndrome\", section on 'Treatment'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Serotonin syndrome",
"      </strong>",
"      &ndash; Serotonin syndrome and malignant catatonia can both present with delirium, autonomic instability, hyperthermia, and rigidity. Distinguishing features of the serotonin syndrome include ingestion of a serotonergic drug such as an SSRI, and the prominence of hyperreflexia, myoclonus, nausea, vomiting, and diarrhea. Some authorities view the serotonin syndrome as a form of catatonia, due to similarities in presenting signs and response to specific treatments [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5017/abstract/60\">",
"       60",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=see_link\">",
"       \"Serotonin syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Malignant hyperthermia",
"      </strong>",
"      &ndash; Malignant hyperthermia and malignant catatonia can both present with autonomic instability, hyperthermia, and rigidity. Malignant hyperthermia is a rare genetic disorder that occurs in susceptible patients exposed to an inhalational anesthetic (eg, halothane) or a depolarizing muscle relaxant (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33510?source=see_link\">",
"       succinylcholine",
"      </a>",
"      ). The distinguishing feature of malignant hyperthermia is its clinical setting, and various procedures are used to diagnose it (muscle contracture testing, muscle biopsy, and genetic testing). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=see_link\">",
"       \"Malignant hyperthermia: Clinical diagnosis and management of acute crisis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Akinetic mutism",
"      </strong>",
"      &ndash; Akinetic mutism and catatonia may both manifest with immobility, mutism, and waxy flexibility. However, akinetic mutism does not include posturing, echolalia, or echopraxia, is not responsive to benzodiazepines, and the lesions to the prefrontal or premotor areas that cause the disorder should be detectable with neuroimaging. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link&amp;anchor=H19#H19\">",
"       \"Stupor and coma in adults\", section on 'Akinetic mutism'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Nonconvulsive status epilepticus",
"      </strong>",
"      &ndash; Nonconvulsive status epilepticus and catatonia can both present with stupor and respond positively to benzodiazepines. Nonconvulsive status epilepticus may be distinguished by the presence of subtle rhythmic twitching and ocular movement abnormalities, and is diagnosed by epileptic activity on the electroencephalogram (EEG). By contrast, catatonia is associated with either a normal EEG or diffuse, nonspecific changes (eg, slowing).",
"     </li>",
"     <li>",
"      <strong>",
"       Locked-in syndrome",
"      </strong>",
"      &ndash; Locked-in syndrome is characterized by immobility and mutism. However, no other signs of catatonia are present, neuroimaging typically reveals brainstem lesions, and locked-in patients usually attempt to communicate with eye movements and blinking, whereas catatonic patients are not motivated to communicate. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/63/34807?source=see_link\">",
"       \"Locked-in syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Stiff-person syndrome",
"      </strong>",
"      &ndash; Stiff-person syndrome is marked by rigidity and a positive response to a benzodiazepine, and autonomic instability may occur as well, all of which may occur in catatonia. However, stiff-person syndrome is generally accompanied by a fixed deformity of the spine and anti-glutamic acid decarboxylase antibodies, which are not observed in catatonia. In addition, catatonic signs such as mutism and posturing are not part of stiff-person syndrome. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=see_link\">",
"       \"Stiff-person syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Parkinson disease",
"      </strong>",
"      &ndash; Retarded catatonia and late-stage untreated Parkinson disease may both present with immobility, rigidity, and decreased speech output. In addition, major depression can occur in Parkinson disease and may underlie catatonia. However, catatonia often includes odd postures and a positive response to benzodiazepines, whereas distinguishing features of Parkinson disease include rest tremor, postural instability, and a positive response to levodopa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=see_link\">",
"       \"Clinical manifestations of Parkinson disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Stroke",
"      </strong>",
"      &ndash; Stroke can manifest with mutism, but focal neurologic signs and positive findings on neuroimaging are often present as well, and other signs of catatonia are absent. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=see_link\">",
"       \"Overview of the evaluation of stroke\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Delirium",
"      </strong>",
"      &ndash; Catatonia may include periods of delirium, and delirium may include some motor features of catatonia. Patients with delirium and catatonia may both present with stupor (decreased alertness and response to stimuli), hypokinesis or hyperkinesis, and limited speech output, but catatonia is usually accompanied by other distinguishing features, including posturing, rigidity, and negativism, as well as a positive response to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      challenge test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=see_link\">",
"       \"Diagnosis of delirium and confusional states\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Dementia",
"      </strong>",
"      &ndash; End-stage dementia and catatonia may both manifest with mutism and hypokinesis. However, catatonia is usually accompanied by other distinguishing features, including posturing, rigidity, negativism, and a positive response to the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      challenge test. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=see_link&amp;anchor=H5#H5\">",
"       \"Evaluation of cognitive impairment and dementia\", section on 'Dementia syndromes'",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      <strong>",
"       Elective mutism",
"      </strong>",
"      &ndash; Elective mutism is the failure to speak in an otherwise vigilant patient, who may selectively refuse to speak with some individuals and speak with others. The disorder is usually accompanied by a personality disorder, preexisting stressor, and no other signs of catatonia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6713745\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Catatonia is a behavioral syndrome marked by an inability to move normally despite full physical capacity to do so. It is associated with multiple psychiatric and general medical disorders. The most common underlying psychopathology is bipolar disorder, unipolar major depression, schizophrenia, schizoaffective disorder, or autism spectrum disorders. Recognizing catatonia is important because it may be caused or exacerbated by treatment of the underlying disorder (eg, antipsychotic drugs used for mood or psychotic disorders may worsen catatonia). (See",
"      <a class=\"local\" href=\"#H6713675\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4567399\">",
"       'Underlying disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The estimated incidence of catatonia in acutely ill psychiatric inpatients is approximately 10 percent. (See",
"      <a class=\"local\" href=\"#H6713689\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs of catatonia can be either observed or elicited; these are listed in the tables (",
"      <a class=\"graphic graphic_table graphicRef53391 \" href=\"UTD.htm?34/31/35324\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66229 \" href=\"UTD.htm?7/25/7580\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6713703\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The three principal subtypes of catatonia are retarded, excited, and malignant. Patients can exhibit signs of more than one subtype, and subtypes are not necessarily stable during a catatonic episode. (See",
"      <a class=\"local\" href=\"#H14470929\">",
"       'Subtypes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An intravenous (IV) bolus of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      1 to 2 mg can help diagnose catatonia. Partial, temporary relief of signs 5 to 10 minutes after IV administration of lorazepam is consistent with a diagnosis of catatonia. If there is no change, a second dose is given. A negative response does not rule out catatonia, and occurs in approximately 20 percent or more of catatonic patients. (See",
"      <a class=\"local\" href=\"#H4567794\">",
"       'Lorazepam challenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The initial clinical evaluation for determining the underlying disorder should include a history, mental status and physical examination, and laboratory tests guided by symptoms and findings on examination. (See",
"      <a class=\"local\" href=\"#H4567399\">",
"       'Underlying disorders'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most authorities require a minimum of two to four signs for at least several hours to make the diagnosis of catatonia (",
"      <a class=\"graphic graphic_table graphicRef53391 \" href=\"UTD.htm?34/31/35324\">",
"       table 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef66229 \" href=\"UTD.htm?7/25/7580\">",
"       table 2",
"      </a>",
"      ). However, neither the number of catatonic features required for the diagnosis, nor their duration is established. (See",
"      <a class=\"local\" href=\"#H6713717\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Signs of catatonia can overlap with signs of other disorders; in particular, malignant catatonia resembles the neuroleptic malignant syndrome (NMS). Both of these life-threatening disorders can present with delirium, autonomic instability, fever, and rigidity. The differential diagnosis of catatonia also includes the serotonin syndrome, malignant hyperthermia, akinetic mutism, nonconvulsive status epilepticus, locked-in syndrome, stiff-person syndrome, Parkinson disease, stroke, delirium, dementia, elective mutism, and conversion disorder. (See",
"      <a class=\"local\" href=\"#H6713738\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/1\">",
"      Fink M, Taylor MA. The catatonia syndrome: forgotten but not gone. Arch Gen Psychiatry 2009; 66:1173.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     The ICD-10 Classification of Mental and Behavioural Disorders: Clinical descriptions and diagnostic guidelines. World Health Organization. file://www.who.int/classifications/icd/en/bluebook.pdf (Accessed on May 04, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/4\">",
"      Lee JW. Neuroleptic-induced catatonia: clinical presentation, response to benzodiazepines, and relationship to neuroleptic malignant syndrome. J Clin Psychopharmacol 2010; 30:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/5\">",
"      Taylor MA, Fink M. Catatonia in psychiatric classification: a home of its own. Am J Psychiatry 2003; 160:1233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/6\">",
"      Francis A, Fink M, Appiani F, et al. Catatonia in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. J ECT 2010; 26:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/7\">",
"      van der Heijden FM, Tuinier S, Arts NJ, et al. Catatonia: disappeared or under-diagnosed? Psychopathology 2005; 38:3.",
"     </a>",
"    </li>",
"    <li>",
"     Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL.  (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/9\">",
"      Chalasani P, Healy D, Morriss R. Presentation and frequency of catatonia in new admissions to two acute psychiatric admission units in India and Wales. Psychol Med 2005; 35:1667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/10\">",
"      Zisselman MH, Jaffe RL. ECT in the treatment of a patient with catatonia: consent and complications. Am J Psychiatry 2010; 167:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/11\">",
"      Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990; 51:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/12\">",
"      Ungvari GS, Leung CM, Wong MK, Lau J. Benzodiazepines in the treatment of catatonic syndrome. Acta Psychiatr Scand 1994; 89:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/13\">",
"      Seethalakshmi R, Dhavale S, Suggu K, Dewan M. Catatonic syndrome: importance of detection and treatment with lorazepam. Ann Clin Psychiatry 2008; 20:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/14\">",
"      Dhossche DM, Stoppelbein L, Rout UK. Etiopathogenesis of catatonia: generalizations and working hypotheses. J ECT 2010; 26:253.",
"     </a>",
"    </li>",
"    <li>",
"     Mann SC, Caroff SN, Campbell EC, et al. Malignant catatonia. In: Current Clinical Neurology: Movement Disorder Emergencies: Diagnosis and Treatment, Frucht SI, Fahn S.  (Eds), Humana Press, Totowa, NJ 2005. p.53.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/16\">",
"      Northoff G. What catatonia can tell us about \"top-down modulation\": a neuropsychiatric hypothesis. Behav Brain Sci 2002; 25:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/17\">",
"      Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 2002; 109:1453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/18\">",
"      Northoff G. Brain imaging in catatonia: current findings and a pathophysiologic model. CNS Spectr 2000; 5:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/19\">",
"      Northoff G, Steinke R, Nagel DCzerwenka C, et al. Right lower prefronto-parietal cortical dysfunction in akinetic catatonia: a combined study of neuropsychology and regional cerebral blood flow. Psychol Med 2000; 30:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/20\">",
"      Carroll BT. The universal field hypothesis of catatonia and neuroleptic malignant syndrome. CNS Spectr 2000; 5:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/21\">",
"      Meyer J, Huberth A, Ortega G, et al. A missense mutation in a novel gene encoding a putative cation channel is associated with catatonic schizophrenia in a large pedigree. Mol Psychiatry 2001; 6:302.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/22\">",
"      St&ouml;ber G. Genetic predisposition and environmental causes in periodic and systematic catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/23\">",
"      St&ouml;ber G, Pfuhlmann B, N&uuml;rnberg G, et al. Towards the genetic basis of periodic catatonia: pedigree sample for genome scan I and II. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/24\">",
"      St&ouml;ber G, Seelow D, R&uuml;schendorf F, et al. Periodic catatonia: confirmation of linkage to chromosome 15 and further evidence for genetic heterogeneity. Hum Genet 2002; 111:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/25\">",
"      Francis A. Catatonia: diagnosis, classification, and treatment. Curr Psychiatry Rep 2010; 12:180.",
"     </a>",
"    </li>",
"    <li>",
"     Lewis S, Escalona PR, Keith SJ. Phenomenology of schizophrenia. In: Kaplan &amp; Sadock's Comprehensive Textbook of Psychiatry, Ninth Edition, Sadock BJ, Sadock VA, Ruiz P.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2009. Vol I, p.1433.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/27\">",
"      Fink M, Taylor MA. Catatonia: subtype or syndrome in DSM? Am J Psychiatry 2006; 163:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/28\">",
"      Fink M, Taylor MA. The many varieties of catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/29\">",
"      Bush G, Fink M, Petrides G, et al. Catatonia. II. Treatment with lorazepam and electroconvulsive therapy. Acta Psychiatr Scand 1996; 93:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/30\">",
"      Peralta V, Cuesta MJ, Serrano JF, Martinez-Larrea JA. Classification issues in catatonia. Eur Arch Psychiatry Clin Neurosci 2001; 251 Suppl 1:I14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/31\">",
"      Daniels J. Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/32\">",
"      Penland HR, Weder N, Tampi RR. The catatonic dilemma expanded. Ann Gen Psychiatry 2006; 5:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/33\">",
"      Fink M. Catatonia: a syndrome appears, disappears, and is rediscovered. Can J Psychiatry 2009; 54:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/34\">",
"      Trigo M, Crippa J, Hallak J, et al. The complexity of the differential diagnosis in psychiatry exemplified by a catatonic syndrome. Rev Psiquiatr Clin 2001; 28:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/35\">",
"      Northoff G, Wenke J, Pflug B. Increase of serum creatine phosphokinase in catatonia: an investigation in 32 acute catatonic patients. Psychol Med 1996; 26:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/36\">",
"      Rosebush PI, Mazurek MF. Catatonia and its treatment. Schizophr Bull 2010; 36:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/37\">",
"      Sienaert P, Rooseleer J, De Fruyt J. Measuring catatonia: a systematic review of rating scales. J Affect Disord 2011; 135:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/38\">",
"      Bush G, Fink M, Petrides G, et al. Catatonia. I. Rating scale and standardized examination. Acta Psychiatr Scand 1996; 93:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/39\">",
"      Northoff G, Koch A, Wenke J, et al. Catatonia as a psychomotor syndrome: a rating scale and extrapyramidal motor symptoms. Mov Disord 1999; 14:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/40\">",
"      Lee JW. Serum iron in catatonia and neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/41\">",
"      Carroll BT, Goforth HW. Serum iron in catatonia. Biol Psychiatry 1995; 38:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/42\">",
"      Singerman B, Raheja R. Malignant catatonia--a continuing reality. Ann Clin Psychiatry 1994; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/43\">",
"      Koek RJ, Mervis JR. Treatment-refractory catatonia, ECT, and parenteral lorazepam. Am J Psychiatry 1999; 156:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/44\">",
"      Schmider J, Standhart H, Deuschle M, et al. A double-blind comparison of lorazepam and oxazepam in psychomotor retardation and mutism. Biol Psychiatry 1999; 46:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/45\">",
"      Zaw ZF, Bates GD. Replication of zolpidem test for catatonia in an adolescent. Lancet 1997; 349:1914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/46\">",
"      Thomas P, Rascle C, Mastain B, et al. Test for catatonia with zolpidem. Lancet 1997; 349:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/47\">",
"      Cottencin O, Danel T, Goudemand M, et al. Catatonia recognition and treatment. Med Sci Monit 2009; 15:CS129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/48\">",
"      Cottencin O, Warembourg F, de Chouly de Lenclave MB, et al. Catatonia and consultation-liaison psychiatry study of 12 cases. Prog Neuropsychopharmacol Biol Psychiatry 2007; 31:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/49\">",
"      Carroll BT, Anfinson TJ, Kennedy JC, et al. Catatonic disorder due to general medical conditions. J Neuropsychiatry Clin Neurosci 1994; 6:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/50\">",
"      Taylor MA, Abrams R. Catatonia. Prevalence and importance in the manic phase of manic-depressive illness. Arch Gen Psychiatry 1977; 34:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/51\">",
"      Takaoka K, Takata T. Catatonia in high-functioning autism spectrum disorders: case report and review of literature. Psychol Rep 2007; 101:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/52\">",
"      Wing L, Shah A. A systematic examination of catatonia-like clinical pictures in autism spectrum disorders. Int Rev Neurobiol 2006; 72:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/53\">",
"      Ungvari GS, Caroff SN, Gerevich J. The catatonia conundrum: evidence of psychomotor phenomena as a symptom dimension in psychotic disorders. Schizophr Bull 2010; 36:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/54\">",
"      Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome. Am J Psychiatry 2007; 164:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/55\">",
"      Fricchione GL. Neuroleptic catatonia and its relationship to psychogenic catatonia. Biol Psychiatry 1985; 20:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/56\">",
"      Caroff SN, Mann SC, Keck PE Jr. Specific treatment of the neuroleptic malignant syndrome. Biol Psychiatry 1998; 44:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/57\">",
"      Fink M, Taylor MA. Neuroleptic malignant syndrome is malignant catatonia, warranting treatments efficacious for catatonia. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/58\">",
"      Castillo E, Rubin RT, Holsboer-Trachsler E. Clinical differentiation between lethal catatonia and neuroleptic malignant syndrome. Am J Psychiatry 1989; 146:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/59\">",
"      Fleischhacker WW, Unterweger B, Kane JM, Hinterhuber H. The neuroleptic malignant syndrome and its differentiation from lethal catatonia. Acta Psychiatr Scand 1990; 81:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5017/abstract/60\">",
"      Keck PE, Arnold LM. The serotonin syndrome. Psychiatr Ann 2000; 30:333.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14683 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-425BDFC11D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5017=[""].join("\n");
var outline_f4_57_5017=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6713745\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713675\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713689\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713696\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713703\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14470929\">",
"      Subtypes",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14470936\">",
"      - Retarded catatonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14470950\">",
"      - Malignant catatonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H86152124\">",
"      - Excited catatonia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14470957\">",
"      - Other forms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85675547\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4567794\">",
"      - Lorazepam challenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4567399\">",
"      Underlying disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713717\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13003965\">",
"      Psychiatric nosology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713738\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6713745\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14683\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14683|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/31/35324\" title=\"table 1\">",
"      Observed signs of catatonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/25/7580\" title=\"table 2\">",
"      Elicited signs of catatonia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/58/19371\" title=\"table 3\">",
"      Laboratory findings in catatonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/57/43928?source=related_link\">",
"      Catatonia in adults: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/13/14554?source=related_link\">",
"      Clinical manifestations of Parkinson disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/10/39081?source=related_link\">",
"      Diagnosis of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/25/28057?source=related_link\">",
"      Evaluation of cognitive impairment and dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/63/34807?source=related_link\">",
"      Locked-in syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/13/32984?source=related_link\">",
"      Malignant hyperthermia: Clinical diagnosis and management of acute crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/47/28410?source=related_link\">",
"      Overview of the evaluation of stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/47/34552?source=related_link\">",
"      Schizophrenia: Clinical manifestations, course, assessment, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/63/16376?source=related_link\">",
"      Serotonin syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/665?source=related_link\">",
"      Stiff-person syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_57_5018="Anticoagulant therapy in acute ST elevation myocardial infarction";
var content_f4_57_5018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulant therapy in acute ST elevation myocardial infarction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5018/contributors\">",
"     A Michael Lincoff, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Donald Cutlip, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Freek Verheugt, MD, FACC, FESC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Christopher P Cannon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?4/57/5018/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?4/57/5018/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rupture of an atherosclerotic plaque is the usual initiating event in an acute coronary syndrome (ACS). Persistent thrombotic occlusion at the site of plaque rupture results in acute myocardial infarction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=see_link\">",
"     \"The role of the vulnerable plaque in acute coronary syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thrombin activity at the site of plaque rupture may result in delayed or incomplete reperfusion of occluded vessels and contributes to reocclusion. Thrombin is a central mediator of clot formation through its activation of platelets, conversion of fibrinogen to fibrin, and activation of factor XIII, leading to fibrin cross-linking and clot stabilization (",
"    <a class=\"graphic graphic_figure graphicRef80270 \" href=\"UTD.htm?38/48/39694\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will review the evidence that parenteral anticoagulant therapy is beneficial in patients with an acute ST-elevation myocardial infarction (STEMI), and will provide recommendations for its use according to whether the patient receives fibrinolysis, primary percutaneous coronary intervention, or no reperfusion therapy. Information regarding anticoagulant agents in non-ST elevation ACS (unstable angina or non-ST elevation MI) and the role of antiplatelet therapy in STEMI are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=see_link\">",
"     \"Anticoagulant therapy in non-ST elevation acute coronary syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ANTICOAGULANT AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are three classes of anticoagulants (",
"    <a class=\"graphic graphic_figure graphicRef80270 \" href=\"UTD.htm?38/48/39694\">",
"     figure 1",
"    </a>",
"    ) that have been evaluated in the management of acute coronary syndromes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The heparins, including unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (UFH) and the low molecular weight heparins (LMWH), are indirect thrombin inhibitors that complex with antithrombin (AT, formerly known as AT III) and convert AT from a slow to a rapid inactivator of thrombin, factor Xa, and to a lesser extent, factors XIIa, XIa, and IXa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"       \"Overview of hemostasis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"       \"Therapeutic use of heparin and low molecular weight heparin\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      There are a number of intrinsic limitations to UFH therapy in patients with acute MI. The most important is that the heparin-antithrombin (AT, formerly called antithrombin III) complex cannot bind or inactivate thrombin bound within a clot [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/1\">",
"       1",
"      </a>",
"      ]. Such clot-bound thrombin acts as an important thrombogenic stimulus at a site of coronary thrombosis, particularly after clot disruption by fibrinolytic agents [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/2\">",
"       2",
"      </a>",
"      ]. An additional concern with the administration of UFH has been heparin-induced thrombocytopenia (HIT). The risk is much lower with LMWH than with UFH and is not seen with the direct thrombin inhibitors or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H36\">",
"       'Heparin-induced thrombocytopenia'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Low molecular weight heparin (LMW) heparin inactivates factor Xa, like UFH, but has a lesser effect on thrombin. As a result, LMW heparins do not prolong the aPTT in a predictable fashion. They have a number of advantages over UFH, including a more predictable anticoagulant effect and a reduced likelihood of inducing immune-mediated thrombocytopenia.",
"     </li>",
"     <li>",
"      The direct thrombin inhibitors (eg, hirudin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/45/4823?source=see_link\">",
"       lepirudin",
"      </a>",
"      ) bind to and inactivate one or more of the active sites on the thrombin molecule [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/3\">",
"       3",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"       \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The prototypic agent of this class, hirudin, is a peptide derived from the saliva of the medicinal leech. Hirudin selectively binds to and inhibits both the fibrinogen recognition and catalytic sites of thrombin. Peptide analogues of hirudin include bivalirudin (previously called hirulog), which also binds to the substrate recognition and catalytic sites of thrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/4\">",
"       4",
"      </a>",
"      ], and the arginine derivative",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"       argatroban",
"      </a>",
"      , which competitively inhibits the thrombin catalytic site. These drugs share a number of the following properties that make them attractive as potential therapeutic agents compared to UFH:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Antithrombin is not required as a cofactor.",
"     </li>",
"     <li>",
"      Clot-bound thrombin can be inhibited.",
"     </li>",
"     <li>",
"      Circulating inhibitors do not inhibit their function.",
"     </li>",
"     <li>",
"      There is no appreciable binding to plasma proteins.",
"     </li>",
"     <li>",
"      There is no activation of platelets and, in contrast, these drugs inhibit thrombin-mediated platelet activation.",
"     </li>",
"     <li>",
"      Thrombin bound to fibrin derivatives is susceptible to inactivation by direct thrombin inhibitors, but is protected from inhibition by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/2\">",
"       2",
"      </a>",
"      ]. This may be particularly important after fibrinolysis, when there is a procoagulant state.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The synthetic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      pentasaccharide",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      acts through antithrombin to exclusively neutralize factor Xa. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=see_link\">",
"       \"Therapeutic use of fondaparinux\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21645429\">",
"    <span class=\"h1\">",
"     FIBRINOLYTIC THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following information is used to formulate recommendations for the use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in STEMI patients treated with fibrinolytic therapy:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no randomized trials directly comparing",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      to placebo in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      plus a platelet P2Y12 receptor blocker (which is the recommended antiplatelet therapy). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H169940262#H169940262\">",
"       \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Fibrinolytic therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A 1996 meta-analysis of over 60,000 patients (in six trials) treated with fibrinolytic therapy (any agent) and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      (but not a P2Y12 receptor blocker) found that the addition of intravenous or high-dose subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      led to a small and marginally significant reduction in the short-term risk of death (8.6 versus 9.1 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/5\">",
"       5",
"      </a>",
"      ]. In addition, the rate of major bleeding significantly increased in patients treated with heparin.",
"     </li>",
"     <li>",
"      Among patients treated with non-fibrin-specific fibrinolytic agents such as streptokinase or anistreplase, no significant benefit in the outcomes of infarct vessel patency, mortality, or reinfarction have been found between those receiving and not receiving UFH [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/6-8\">",
"       6-8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are conflicting data concerning the efficacy of UFH on infarct vessel patency in patients treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/41/11929?source=see_link\">",
"       alteplase",
"      </a>",
"      (which is fibrin-specific), with some studies suggesting a beneficial effect [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/6,9,10\">",
"       6,9,10",
"      </a>",
"      ] and others not [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. Comparison of these studies is difficult due to difference in dosing and timing of both the fibrinolytic agent and UFH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We believe there is weak evidence to support the use of unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients receiving fibrin specific fibrinolytic agents who are treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    plus a platelet P2Y12 receptor blocker. There is no evidence to support its use in patients receiving non-fibrin specific agents such as streptokinase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above discussion highlights the lack of rigorous evidence that can be used to support the use of UFH in the setting of fibrinolytic therapy in patients who receive dual antiplatelet therapy. Nevertheless, it is reasonable to use UFH for at least 48 hours after administration of fibrin-specific fibrinolytic agents. For those patients in whom UFH is chosen, data from many of the early trials have been used to identify the optimal dose of UFH in patients treated with fibrinolytic therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/13-18\">",
"     13-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data from the GUSTO-1, GUSTO-2, and GUSTO-V trials suggest that the optimal level of anticoagulation associated with the lowest rates of death and bleeding complications among patients receiving fibrinolytic therapy is an aPTT of 50 to 70 seconds [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. To achieve this target, we suggest an intravenous bolus of 60 to 100",
"    <span class=\"nowrap\">",
"     units/kg,",
"    </span>",
"    up to a maximum of 4000 units. The bolus should be followed by an intravenous drip of 12",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    per hour (goal aPTT time of 1.5 to 2 times control, or approximately 50 to 75 seconds).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Delayed subcutaneous heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no role for delayed subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the management of patients given fibrinolytic therapy. In the",
"    <span class=\"nowrap\">",
"     GISSI-2/International",
"    </span>",
"    and ISIS-3 trials, subcutaneous heparin given hours after thrombolysis did NOT reduce mortality and increased major bleeding complications in over 62,000 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/19-21\">",
"     19-21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21646980\">",
"    <span class=\"h2\">",
"     LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no trials comparing LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to placebo in patients treated with fibrin-specific agents. However, low molecular weight (LMW) heparin has been evaluated in clinical trials of patients with STEMI treated with streptokinase. The CREATE trial, the largest of these trials, randomly assigned 15,570 patients with an acute STEMI to reviparin or placebo every 12 hours for seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/22\">",
"     22",
"    </a>",
"    ]. Fibrinolytic agents (predominantly streptokinase) were administered to 73 percent of patients. At seven days, the rate of the primary composite outcome (death, myocardial reinfarction, or stroke) was significantly reduced with reviparin (9.6 versus 11.0 percent; hazard ratio 0.87, 95% CI 0.79-0.95) and this benefit persisted at 30 days. Reviparin treatment was significantly better when started within two hours after symptom onset. These findings were confirmed in a meta-analyses of four placebo controlled trials, of which CREATE was the largest [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21647036\">",
"    <span class=\"h2\">",
"     UFH versus LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of trials have compared the relative efficacy of UFH and LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ) in patients with STEMI treated with fibrinolytic agents that were usually fibrin-specific [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/23-28\">",
"     23-28",
"    </a>",
"    ]. The major initial trials were ASSENT-3, ASSENT-3 PLUS, and ExTRACT-TIMI 25. In the largest of these trials, ExTRACT-TIMI 25, the median duration of therapy was two days for UFH and seven days for enoxaparin.",
"   </p>",
"   <p>",
"    A 2007 meta-analysis of trials comparing UFH to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    in over 27,000 STEMI patients receiving fibrinolytic therapy included the above three trials as well as three smaller studies [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/29\">",
"     29",
"    </a>",
"    ]. The primary endpoints of death, MI, or major bleed at 30 days occurred significantly less often in patients receiving enoxaparin (11.1 versus 12.9 percent, odds ratio [OR] 0.84, 95% CI 0.73-0.97), with most of the benefit attributable to a reduction in MI. Major bleeding occurred significantly more often in patients receiving enoxaparin (2.6 versus 1.8 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21647326\">",
"    <span class=\"h2\">",
"     Direct thrombin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early trials, such as TIMI-9B, GUSTO-IIB, and HIT-4, compared hirudin to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in STEMI patients treated with either streptokinase or a fibrin-specific fibrinolytic. No significant difference in outcomes between the two drugs was found [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/30-32\">",
"     30-32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    (previously called hirulog) was compared to UFH in the HERO-2 mortality trial of 17,073 STEMI patients treated with streptokinase [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/33\">",
"     33",
"    </a>",
"    ]. The following findings were noted at 30 days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was no difference between the two groups in the primary endpoint of mortality (10.5 versus 10.9 percent with UFH, odds ratio 0.99).",
"     </li>",
"     <li>",
"      There was a small but significant reduction in reinfarction at 96 hours with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (1.6 versus 2.3 percent).",
"     </li>",
"     <li>",
"      There was a nonsignificant trend toward more episodes of severe bleeding (0.7 versus 0.5 percent, p = 0.07) and intracerebral bleeding (0.6 versus 0.4 percent, p = 0.09) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      ; there was also a significant increase in moderate and mild bleeding with bivalirudin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are only limited data assessing the role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20375?source=see_link\">",
"     argatroban",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/45/4823?source=see_link\">",
"     lepirudin",
"    </a>",
"    other direct thrombin inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/34\">",
"     34",
"    </a>",
"    ]. Neither of these drugs is used in acute STEMI due to the absence of large scale trials showing benefit and concerns of an increased rate of bleeding compared to other anticoagulants. They do have indications for patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    induced thrombocytopenia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link&amp;anchor=H45#H45\">",
"     \"Heparin-induced thrombocytopenia\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21650089\">",
"    <span class=\"h2\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in STEMI was evaluated in the OASIS-6 trial of over 12,000 patients who were randomly assigned to fondaparinux (2.5",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or placebo for up to eight days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/35\">",
"     35",
"    </a>",
"    ]. Patients could be managed with fibrinolytic therapy, primary PCI, or no reperfusion therapy and they were evaluated based on whether they had an indication for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . The results of this complicated trial are reported here; the implications for our recommendations are discussed in the relevant sections of this topic.",
"   </p>",
"   <p>",
"    There were two strata:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stratum 1 consisted of 5658 patients, without planned PCI, in whom",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was not indicated. These patients, most of whom received thrombolytic therapy with streptokinase (78%), were randomly assigned to subcutaneous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (initial dose intravenously and then 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      given subcutaneously) or placebo for up to eight days or hospital discharge, if earlier.",
"     </li>",
"     <li>",
"      Stratum 2 consisted of 6434 patients with an indication for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (eg, fibrinolytic therapy [with a fibrin-specific agent], primary PCI, or no reperfusion but eligible for heparin). These patients were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (initial dose intravenously and then 2.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      given subcutaneously) for up to eight days or hospital discharge or UFH 60",
"      <span class=\"nowrap\">",
"       U/kg",
"      </span>",
"      bolus followed by infusion of 12",
"      <span class=\"nowrap\">",
"       U/kg-hr",
"      </span>",
"      for 24 to 48 hours. Placebos were used to maintain blinding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     Fondaparinux",
"    </a>",
"    was compared to placebo in stratum 1 and to UFH for 24 to 48 hours in stratum 2. The following findings were noted with fondaparinux at 30 days:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For the entire trial population (Strata 1 and 2), a significant reduction in the primary endpoint of death or reinfarction was shown at 30 days (9.7 versus 11.2 percent, hazard ratio [HR] 0.86, 95% CI 0.77-0.96). This 1.5 percent absolute benefit was seen by nine days and persisted at 180 days. The reduction in events was significant for both endpoints (eg, mortality at 30 days, 7.8 versus 8.9 percent).",
"     </li>",
"     <li>",
"      There was a significant reduction in the primary endpoint of death or reinfarction in patients in stratum 1 (11.2 versus 14.0 percent with placebo, HR 0.79) but not in those in stratum 2 who required",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (8.3 versus 8.7 percent, HR 0.96). The benefit in stratum 1 at 30 days was not seen at two days. Thus, at least part of the benefit of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      in stratum 1 could be due to the longer duration of antithrombotic therapy (up to eight days for fondaparinux versus up to 48 hours for UFH) [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On subgroup analysis, patients in stratum 1 who received a non-fibrin specific agent had a significantly lower rate of the primary endpoint with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      compared to placebo (10.8 versus 13.8 percent); in patients in stratum 2 who received a fibrin-specific agent, there was no significant difference between fondaparinux and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The lack of benefit in stratum 2 reflected a balance between a significant benefit in patients not undergoing primary PCI (11.5 versus 13.8 percent, HR 0.82) and a trend toward worse outcomes in patients treated with primary PCI (6.1 versus 5.1 percent, HR 1.16). Among patients undergoing primary PCI,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      was also associated with an increase in guiding catheter thrombosis and in coronary complications (eg, abrupt closure, no reflow, dissection). (See",
"      <a class=\"local\" href=\"#H21650153\">",
"       'Fondaparinux'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In prespecified subgroup analyses, the benefits of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      were confined to those receiving fibrinolytic therapy or for individuals not undergoing reperfusion therapy. No benefit, and a trend toward harm, was seen in patients undergoing primary PCI [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21650153\">",
"       'Fondaparinux'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      There was an insignificantly lower rate of bleeding with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      compared to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (1.7 versus 2.5 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21648011\">",
"    <span class=\"h2\">",
"     Fibrinolytic summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;For STEMI patients treated with fibrinolytic therapy there is moderate quality evidence to support the use of anticoagulant therapy with UFH, LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    . In most cases we prefer LMW heparin. While we are concerned about the use of fondaparinux in patients treated with fibrinolytic therapy who may need subsequent percutaneous coronary intervention (PCI), it is a reasonable option in patients who are at high risk of bleeding or those who are unlikely to be referred for PCI. We suggest anticoagulation for at least 48 hours and up to eight days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PRIMARY PCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulant therapy is always given during percutaneous coronary intervention (PCI), with or without stenting, to prevent acute vessel closure due to thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, all STEMI patients undergoing primary PCI need to be anticoagulated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H23#H23\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Parenteral anticoagulant therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This section will summarize the evidence regarding the choice of agent as well as the optimal dose and timing of such therapy in patients undergoing primary PCI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21647888\">",
"    <span class=\"h2\">",
"     UFH versus enoxaparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The open label ATOLL trial randomly assigned 910 STEMI patients to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (intravenous bolus of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or UFH (initial intravenous bolus of 70-100 IU without or 50-70 IU with glycoprotein [GP]",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) before primary PCI (67 percent with radial access) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/40\">",
"     40",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    , thienopyridines, and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitors (80 percent) were given according to local practice.",
"   </p>",
"   <p>",
"    At 30 days, the following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There was a non-significant reduction in the rate of the primary outcome of death, complication of MI, procedure failure, or major bleeding with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (28 versus 34 percent; relative risk [RR] 0.83, 95% CI 0.68-1.01).",
"     </li>",
"     <li>",
"      The main secondary end point of death, recurrent MI or acute coronary syndrome, or urgent revascularization occurred significantly less often with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (7 versus 11 percent; RR 0.59, 95% CI 0.38-0.91).",
"     </li>",
"     <li>",
"      There was no significant difference in the rate of major bleeding between the two groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The strengths of this trial include early randomization (71 percent in the field by mobile emergency medical services) and treatment with currently accepted antiplatelet therapies. One important limitation is that radial access was used in a high percent of cases, making the conclusions less certain for patients who undergo a femoral approach [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two meta-analyses have concluded that the use of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (generally",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    ) compared to UFH leads to lower rates of mortality and major bleeding [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. The 2012 meta-analysis (which included ATOLL) evaluated outcomes in studies that compared enoxaparin to UFH in (mostly) ACS patients treated with PCI. This included seven studies (average follow-up of 2.4 months) of over 10,000 patients who underwent primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/43\">",
"     43",
"    </a>",
"    ]. In this population (most patients received intravenous enoxaparin); the risk (RR) of death was significantly decreased with enoxaparin (RR 0.52, 95% CI 0.42-0.64) as was the risk of major bleeding (RR 0.72, 95% CI 0.56-0.93). In nearly 9000 patients who underwent PCI after fibrinolysis, a mortality benefit for enoxaparin that nearly achieved significance was seen (RR 0.83, 95% CI 0.66-1.05), while the risk of major bleeding was similar.",
"   </p>",
"   <p>",
"    Limitations of these meta-analyses include absence of patient level data and variation in the timing, dose, and route of administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    across studies. Nevertheless, we believe the available data support a preference for enoxaparin over UFH in those STEMI patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    will not be used. &nbsp;&nbsp; &nbsp;&nbsp;",
"   </p>",
"   <p>",
"    For patients in whom",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    will not be chosen,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , using the dosing regimen in the ATOLL trial, is a reasonable alternative to UFH for patients undergoing PCI with a radial artery approach. When the femoral approach is used, intravenous enoxaparin may be a reasonable alternative to UFH, but we are uncertain as to the optimal dose; an intravenous bolus of 0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21647881\">",
"    <span class=\"h2\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    in primary PCI was evaluated in the HORIZONS AMI trial in which approximately 3600 patients with STEMI were randomly assigned to either bivalirudin (initial bolus of 0.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by an intravenous infusion of 1.75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per h that was discontinued after PCI) plus provisional glycoprotein (GP)",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor or to UFH plus planned GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor prior to primary PCI [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/44\">",
"     44",
"    </a>",
"    ]. Approximately 65 percent of patients received UFH prior to randomization. In the bivalirudin group, 7.5 percent of patients received GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor during PCI for no reflow or giant thrombus. Most patients received a thienopyridine (usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/9/34969?source=see_link\">",
"     clopidogrel",
"    </a>",
"    ) before catheterization. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H27#H27\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Evidence in the era of P2Y12 receptor blocker use'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The composite endpoint of major adverse cardiovascular events (death, re-infarction, target vessel revascularization, or stroke) occurred at nearly identical rates by 30 days in the two treatment arms: 5.4 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    versus 5.5 percent with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa.",
"    </span>",
"    However, major bleeding was significantly reduced by bivalirudin (4.9 versus 8.3 percent, p &lt;0.001). Death by 30 days due to cardiac causes occurred significantly less frequently with bivalirudin (1.8 versus 2.9 percent), as did all-cause mortality (2.1 versus 3.1 percent). The decrease in all cause mortality with bivalirudin remained significant at one and three years (3.4 versus 4.8 percent and 5.9 versus 7.7 percent, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/38,45\">",
"     38,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This study provides high quality evidence to suggest a preference for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    over the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    plus GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa.",
"    </span>",
"    Concerns about the trial included its open-label design and a statistically significant one percent increase in stent thrombosis seen within the first 24 hours, although not by 30 days. However, a recent study in non-ST elevation MI, ISAR-REACT 4, that was blinded, found similar results to HORIZONS-AMI in STEMI: similar rates of ischemic endpoints between bivalirudin alone versus UFH and GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibition, with a significant reduction in bleeding, thus supporting the findings in STEMI.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H689553778\">",
"    <span class=\"h3\">",
"     Switching from heparin to bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some medical centers use only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in the emergency department. The issue of whether the benefit of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    seen in the HORIZONS AMI trial (presented directly above) exists for patients switched from heparin to bivalirudin was evaluated in a subgroup analysis (called the HORIZONS-SWITCH analysis) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/46\">",
"     46",
"    </a>",
"    ]. In this analysis of the 2357 patients in HORIZONS-AMI treated with UFH before enrollment, switched patients also had significantly lower rates of bleeding compared to those who received heparin (7.6 versus 12.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21650153\">",
"    <span class=\"h2\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a result of OASIS-6, in which there was a trend toward worse outcomes with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in patients treated with primary PCI, we recommend not choosing fondaparinux for STEMI patients who will be treated with primary PCI. (See",
"    <a class=\"local\" href=\"#H21650089\">",
"     'Fondaparinux'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21647997\">",
"    <span class=\"h2\">",
"     PCI summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend anticoagulant therapy for all STEMI patients undergoing PCI, based on the evidence from such practice in the broad population of patients undergoing PCI (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=see_link&amp;anchor=H23#H23\">",
"     \"Antithrombotic therapy for percutaneous coronary intervention: General use\", section on 'Parenteral anticoagulant therapy'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    We recommend anticoagulation with either a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (with a glycoprotein",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    (with provisional GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor) as opposed to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ; we prefer bivalirudin, as it leads to a lower rate of bleeding compared with UFH plus GP",
"    <span class=\"nowrap\">",
"     IIb/IIIa",
"    </span>",
"    inhibitor.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    , using the dosing regimen (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    intravenously) in the ATOLL trial, appears to be as safe and effective as UFH for patients undergoing a radial artery approach. However, for patients undergoing a femoral artery approach, we are less confident of the relative efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    and enoxaparin based on the weaknesses in the meta-analysis presented above. (See",
"    <a class=\"local\" href=\"#H21647888\">",
"     'UFH versus enoxaparin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NO REPERFUSION THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21650953\">",
"    <span class=\"h2\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized trials have compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    to placebo among patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    but not reperfusion therapy. Two of the fibrinolytic trials provide conflicting results regarding the efficacy of off-protocol heparin administration among patients who received aspirin but were assigned to treatment without a fibrinolytic agent [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Interpretation of these conflicting findings is difficult, particularly since the nonrandomized use of heparin in these trials probably reflects underlying differences in baseline characteristics and risk factors among the patients treated.",
"   </p>",
"   <p>",
"    However, systemic anticoagulation should be used if there is evidence of high risk for systemic or venous thromboembolism (large anterior Q wave MI, severe left ventricular dysfunction, heart failure, history of systemic or pulmonary embolus, atrial fibrillation, or echocardiographic evidence of mitral or left ventricular thrombus).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    in this setting was evaluated in the subset of 3325 patients who did not undergo reperfusion therapy in the CREATE trial discussed in the preceding section [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/22\">",
"     22",
"    </a>",
"    ]. Reviparin was associated with a significant reduction in the incidence of death, myocardial reinfarction, or stroke compared to placebo (15.0 versus 18.3 percent).",
"   </p>",
"   <p>",
"    The TETAMI trial compared UFH to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    in 1224 patients who did not receive reperfusion therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/49\">",
"     49",
"    </a>",
"    ]. The patients were also randomly assigned to treatment with either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/2/13351?source=see_link\">",
"     tirofiban",
"    </a>",
"    or placebo. At 30 days, the incidence of the combined endpoint of death, reinfarction, or recurrent angina for patients treated with enoxaparin was not significantly different from UFH (15.7 versus 17.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21651549\">",
"    <span class=\"h2\">",
"     Bivalirudin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     Bivalirudin",
"    </a>",
"    has not been evaluated in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21650161\">",
"    <span class=\"h2\">",
"     Fondaparinux",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    in STEMI patients not treated with reperfusion was evaluated in a prespecified subgroup analysis of the OASIS-6 trial (see",
"    <a class=\"local\" href=\"#H21650089\">",
"     'Fondaparinux'",
"    </a>",
"    above). Among the 2867 patients in both strata who were not reperfused, fondaparinux lowered the rate of the primary efficacy outcome (death and MI at 30 days) compared to",
"    <span class=\"nowrap\">",
"     UFH/placebo",
"    </span>",
"    (12.2 versus 15.1 percent; hazard ratio [HR] 0.80, 95% CI 0.65-0.98) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/38\">",
"     38",
"    </a>",
"    ]. This subgroup analysis of OASIS-6 provides some support for the use of fondaparinux in patients who are not reperfused.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21648019\">",
"    <span class=\"h2\">",
"     No reperfusion summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is some evidence to support the use of an anticoagulant in STEMI patients not undergoing reperfusion. We believe UFH,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    are reasonable choices; we recommend not using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442407958\">",
"    <span class=\"h1\">",
"     ANTICOAGULANT REGIMENS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442407983\">",
"    <span class=\"h2\">",
"     Dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing schedules depend upon the clinical situation:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      UFH:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients receiving fibrinolysis we suggest an intravenous bolus of 60 to 100",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      (maximum of 4000 units) followed by 12",
"      <span class=\"nowrap\">",
"       units/kg/h",
"      </span>",
"      (maximum 1000",
"      <span class=\"nowrap\">",
"       units/h)",
"      </span>",
"      intravenously to achieve an activated partial thromboplastin time of 50 to 75 seconds.",
"     </li>",
"     <li>",
"      For patients undergoing primary PCI and treated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (plus a GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor), we suggest an intravenous bolus of 50 to 70",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      up to a maximum of 5000 units (target activated clotting time &gt; 250 seconds). The optimal dose of heparin in patients undergoing primary PCI who do not receive GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor is unknown. In the randomized trials in which the antiplatelet agent was not added, the goal of heparin therapy was an activated clotting time (ACT) of &gt;350 seconds.",
"     </li>",
"     <li>",
"      For patients treated with medical therapy (no reperfusion), we suggest an IV bolus of 50 to 70",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      up to a maximum of 5000 units, to be followed by an IV drip of 12",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      per hour, with a goal aPTT of 1.5 to 2 times control or approximately 50 to 75 seconds.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       Enoxaparin",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients receiving fibrinolysis and &lt;75 years, we use a loading dose of 30 mg IV bolus followed by 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneously every 12 hours (maximum of 100 mg for the first two doses). The first subcutaneous dose should be administered with the IV bolus. In patients &ge;75 years we use no loading dose and 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      subcutaneously every 12 hours (maximum of 75 mg for the first two doses).",
"     </li>",
"     <li>",
"      For patients undergoing primary PCI, we generally prefer either UFH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      . For patients undergoing primary PCI with a radial artery approach, an intravenous bolus of 0&middot;5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      (with an additional bolus of 0.25",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      if the procedure is prolonged by more than two hours) can be used.",
"     </li>",
"     <li>",
"      For patients who are not reperfused, we use no loading dose and administer 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 12 hours.",
"     </li>",
"     <li>",
"      In patients with a creatinine clearance &lt;30",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      using the Cockroft-Gault formula, irrespective of age, we suggest 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every 24 hours without a loading dose. This applies to all patients, irrespective of whether they received reperfusion or not.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      :",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients being managed medically, we suggest giving 2.5 mg intravenously, followed by 2.5 mg subcutaneously once daily.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      is not recommended for use in patients undergoing primary PCI. For patients undergoing PCI who were treated with fondaparinux, intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      should be given during the procedure to prevent catheter related thrombosis. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Classification of anticoagulant agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       Fondaparinux",
"      </a>",
"      should be avoided in patients with estimated creatinine clearance less than 30",
"      <span class=\"nowrap\">",
"       mL/min.",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       Bivalirudin",
"      </a>",
"      &mdash; We suggest an initial bolus of 0.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      followed by an intravenous infusion of 1.75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per hour. Administration of UFH or LMWH prior to arrival in the catheterization laboratory for primary PCI is not a contraindication to transitioning to bivalirudin during the procedure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H442407990\">",
"    <span class=\"h2\">",
"     Duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;The duration of anticoagulant therapy depends on the initial management strategy. Although the optimal treatment length has not been determined for these, the following represent commonly employed regimens in clinical practice:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients undergoing PCI, anticoagulant therapy is stopped at the end of the procedure in uncomplicated cases. However, in cases where a platelet P2Y12 receptor blocker has been given just before PCI and there is a concern about less than optimal antithrombotic effect, it is reasonable to continue a full infusion dose of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      for up to four hours after the procedure. This extended use of bivalirudin was used in the first randomized trial of Hirulog (bivalirudin) in patients with unstable angina and allowed for in HORIZONS-AMI trial [",
"      <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/4,44\">",
"       4,44",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21647881\">",
"       'Bivalirudin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients receiving fibrinolytic therapy or no reperfusion therapy, anticoagulant therapy is continued for at least two days; if LMWH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      are used, therapy should be continued, preferably for up to eight days or until hospital discharge, whichever occurs earlier.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Continuation of anticoagulation beyond the times suggested above should be undertaken only if:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The PCI is complicated and there is an ongoing risk or recurrent ischemia.",
"     </li>",
"     <li>",
"      There is evidence of high risk for systemic or venous thromboembolism (eg, anterior STEMI, severe left ventricular dysfunction, heart failure, history of systemic or pulmonary embolus, or echocardiographic evidence of left ventricular thrombus) or a preexistent rational for long term anticoagulation, such as patients with prosthetic heart valves or atrial fibrillation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     HEPARIN-INDUCED THROMBOCYTOPENIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of immune-mediated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    -induced thrombocytopenia (HIT) is approximately 2.5 to 3.0 percent in patients exposed to UFH for more than four days [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/50\">",
"     50",
"    </a>",
"    ]. The incidence is much lower (0.2 percent) in patients treated with UFH for less than four days. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with a history of HIT, or in who HIT develops or is suspected while on UFH therapy, the preferred anticoagulant is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , although other direct thrombin inhibitors are used in patients with HIT, because its efficacy has been established in patients with STEMI. LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    should also be avoided since it may cross-react with the heparin-induced antibodies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=see_link\">",
"     \"Heparin-induced thrombocytopenia\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H21647881\">",
"     'Bivalirudin'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Recommendations for monitoring the platelet count in patient on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H11#H11\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Platelet count monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21644171\">",
"    <span class=\"h1\">",
"     RECOMMENDATIONS OF OTHERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the use of anticoagulant therapy in patients with STEMI are available from the 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on the management of acute ST elevation MI (most recent update in 2009) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/51,52\">",
"     51,52",
"    </a>",
"    ], the European Society of Cardiology (2008) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/53\">",
"     53",
"    </a>",
"    ], and the American College of Chest Physicians (2008) [",
"    <a class=\"abstract\" href=\"UTD.htm?4/57/5018/abstract/39\">",
"     39",
"    </a>",
"    ]. The following are important points made by the first two of these bodies (the American College of Chest Physicians will release an updated version in late 2010 or early 2011):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From the",
"      <span class=\"nowrap\">",
"       ACC/AHA",
"      </span>",
"      guidelines:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients treated with fibrinolysis, a strong recommendation was made for anticoagulant therapy in all patients, with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      preferred to either UFH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      . Therapy was recommended for a minimum of 48 hours. UpToDate makes a weak recommendation.",
"     </li>",
"     <li>",
"      For patients undergoing primary PCI, anticoagulant was strongly recommended in all patients.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       Bivalirudin",
"      </a>",
"      was preferred to either UFH or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      For patients not undergoing reperfusion, no specific recommendation is made. However, the document acknowledges that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      is superior to placebo in these patients.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      From the ESC guidelines:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients treated with streptokinase, a weak recommendation for either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      was made; for patients treated with a fibrin-specific lytic agent, enoxaparin was preferred.",
"     </li>",
"     <li>",
"      For patients undergoing primary PCI,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      was strongly preferred to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      based on weak evidence.",
"     </li>",
"     <li>",
"      For patients not undergoing reperfusion, a strong recommendation was made for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , or UFH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;All patients with ST-elevation myocardial infarction (STEMI) should receive anticoagulation. Irrespective of the reperfusion strategy, anticoagulant therapy should be given as soon as possible after diagnosis. In addition, all patients with STEMI should receive dual antiplatelet therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=see_link&amp;anchor=H36#H36\">",
"     \"Antiplatelet agents in acute ST elevation myocardial infarction\", section on 'Summary and recommendations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The choice of anticoagulant agent depends upon the treatment strategy for each patient. The dosing and duration for these drugs (unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    [UFH], low molecular weight heparin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"     bivalirudin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"     fondaparinux",
"    </a>",
"    ) are presented above. (See",
"    <a class=\"local\" href=\"#H442407958\">",
"     'Anticoagulant regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For all patients treated with primary percutaneous coronary intervention, we recommend anticoagulant therapy (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Primary PCI'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend either",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (with provisional glycoprotein [GP]",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor in cases of ischemic complications or large thrombus burden) or a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (and planned GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor) in preference to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (with provisional GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor) in preference to a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      (with planned GP",
"      <span class=\"nowrap\">",
"       IIb/IIIa",
"      </span>",
"      inhibitor) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21647997\">",
"       'PCI summary'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      For patients in whom bivalirudin will not be chosen,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , using the dosing regimen in the ATOLL trial, is a reasonable alternative to UFH for patients undergoing PCI with a radial artery approach. When the femoral approach is used, intravenous enoxaparin may be a reasonable alternative to UFH, but we are uncertain as to the optimal dose; an intravenous bolus of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      is reasonable. (See",
"      <a class=\"local\" href=\"#H21647888\">",
"       'UFH versus enoxaparin'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients",
"      <strong>",
"      </strong>",
"      treated with fibrinolytic therapy, we suggest anticoagulant therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21648011\">",
"       'Fibrinolytic summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients not at high risk of bleeding, we suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      as opposed to UFH,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/48/18184?source=see_link\">",
"       bivalirudin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For those patients in whom PCI is possible or likely after fibrinolytic therapy, UFH is a reasonable choice.",
"     </li>",
"     <li>",
"      For patients at high risk of a bleeding complication and who are not likely to require PCI, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      as opposed to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      or UFH (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21650153\">",
"       'Fondaparinux'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H21648011\">",
"       'Fibrinolytic summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients not treated with reperfusion therapy, we suggest anticoagulant therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"       enoxaparin",
"      </a>",
"      , UFH, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/35/40503?source=see_link\">",
"       fondaparinux",
"      </a>",
"      , as opposed to no anticoagulant therapy, as soon as possible after presentation (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H21648019\">",
"       'No reperfusion summary'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/1\">",
"      Weitz JI, Hudoba M, Massel D, et al. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/2\">",
"      Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-antithrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation 1998; 97:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/3\">",
"      Lefkovits J, Topol EJ. Direct thrombin inhibitors in cardiovascular medicine. Circulation 1994; 90:1522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/4\">",
"      Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995; 333:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/5\">",
"      Collins R, MacMahon S, Flather M, et al. Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. BMJ 1996; 313:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/6\">",
"      The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993; 329:1615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/7\">",
"      O'Connor CM, Meese R, Carney R, et al. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1. J Am Coll Cardiol 1994; 23:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/8\">",
"      Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005; 112:3855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/9\">",
"      de Bono DP, Simoons ML, Tijssen J, et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992; 67:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/10\">",
"      Hsia J, Hamilton WP, Kleiman N, et al. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators. N Engl J Med 1990; 323:1433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/11\">",
"      Topol EJ, George BS, Kereiakes DJ, et al. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989; 79:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/12\">",
"      Thompson PL, Aylward PE, Federman J, et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation 1991; 83:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/13\">",
"      An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993; 329:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/14\">",
"      Wang TY, Chen AY, Alexander KP, et al. Excess heparin dosing among fibrinolytic-treated patients with ST-segment elevation myocardial infarction. Am J Med 2008; 121:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/15\">",
"      Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIa Investigators. Circulation 1994; 90:1631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/16\">",
"      Antman EM. Hirudin in acute myocardial infarction. Safety report from the Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9A Trial. Circulation 1994; 90:1624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/17\">",
"      Granger CB, Hirsch J, Califf RM, et al. Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation 1996; 93:870.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/18\">",
"      Nallamothu BK, Bates ER, Hochman JS, et al. Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab: results from the GUSTO-V trial. Eur Heart J 2005; 26:1506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/19\">",
"      GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet 1990; 336:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/20\">",
"      In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. The International Study Group. Lancet 1990; 336:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/21\">",
"      ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. Lancet 1992; 339:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/22\">",
"      Yusuf S, Mehta SR, Xie C, et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005; 293:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/23\">",
"      Ross AM, Molhoek P, Lundergan C, et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 2001; 104:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/24\">",
"      Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001; 358:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/25\">",
"      Van de Werf F. ASSENT-3: implications for future trial design and clinical practice. Eur Heart J 2002; 23:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/26\">",
"      Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation 2002; 105:1642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/27\">",
"      Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003; 108:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/28\">",
"      Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006; 354:1477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/29\">",
"      Murphy SA, Gibson CM, Morrow DA, et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007; 28:2077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/30\">",
"      Antman EM. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial. Circulation 1996; 94:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/31\">",
"      A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators. N Engl J Med 1996; 335:775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/32\">",
"      Neuhaus KL, Molhoek GP, Zeymer U, et al. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial. J Am Coll Cardiol 1999; 34:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/33\">",
"      White H, Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial. Lancet 2001; 358:1855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/34\">",
"      Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/35\">",
"      Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006; 295:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/36\">",
"      Califf RM. Fondaparinux in ST-segment elevation myocardial infarction: the drug, the strategy, the environment, or all of the above? JAMA 2006; 295:1579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/37\">",
"      Peters RJ, Joyner C, Bassand JP, et al. The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. Eur Heart J 2008; 29:324.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/38\">",
"      Oldgren J, Wallentin L, Afzal R, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. Eur Heart J 2008; 29:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/39\">",
"      Goodman SG, Menon V, Cannon CP, et al. Acute ST-segment elevation myocardial infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:708S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/40\">",
"      Montalescot G, Zeymer U, Silvain J, et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011; 378:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/41\">",
"      Stone GW, Ohman EM. Antithrombin alternatives in STEMI. Lancet 2011; 378:643.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/42\">",
"      Navarese EP, De Luca G, Castriota F, et al. Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. J Thromb Haemost 2011; 9:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/43\">",
"      Silvain J, Beygui F, Barth&eacute;l&eacute;my O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention: systematic review and meta-analysis. BMJ 2012; 344:e553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/44\">",
"      Stone GW, Witzenbichler B, Guagliumi G, et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008; 358:2218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/45\">",
"      Stone GW, Witzenbichler B, Guagliumi G, et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011; 377:2193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/46\">",
"      Dangas GD, Mehran R, Nikolsky E, et al. Effect of switching antithrombin agents for primary angioplasty in acute myocardial infarction: the HORIZONS-SWITCH analysis. J Am Coll Cardiol 2011; 57:2309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/47\">",
"      Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/48\">",
"      Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after onset of acute myocardial infarction. Lancet 1993; 342:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/49\">",
"      Cohen M, Gensini GF, Maritz F, et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003; 42:1348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/50\">",
"      Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106:2710.",
"     </a>",
"    </li>",
"    <li>",
"     www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007). www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/52\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?4/57/5018/abstract/53\">",
"      Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29:2909.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 92 Version 22.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5018=[""].join("\n");
var outline_f4_57_5018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H37\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION OF ANTICOAGULANT AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21645429\">",
"      FIBRINOLYTIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Delayed subcutaneous heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21646980\">",
"      LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21647036\">",
"      UFH versus LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21647326\">",
"      Direct thrombin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21650089\">",
"      Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21648011\">",
"      Fibrinolytic summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PRIMARY PCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21647888\">",
"      UFH versus enoxaparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21647881\">",
"      Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H689553778\">",
"      - Switching from heparin to bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21650153\">",
"      Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21647997\">",
"      PCI summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NO REPERFUSION THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21650953\">",
"      Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21651549\">",
"      Bivalirudin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21650161\">",
"      Fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21648019\">",
"      No reperfusion summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H442407958\">",
"      ANTICOAGULANT REGIMENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442407983\">",
"      Dose",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H442407990\">",
"      Duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      HEPARIN-INDUCED THROMBOCYTOPENIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21644171\">",
"      RECOMMENDATIONS OF OTHERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/92\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/92|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/48/39694\" title=\"figure 1\">",
"      Targets for antithrombotic therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/2/5162?source=related_link\">",
"      Anticoagulant therapy in non-ST elevation acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/49/35610?source=related_link\">",
"      Antiplatelet agents in acute ST elevation myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/8/27786?source=related_link\">",
"      Antithrombotic therapy for percutaneous coronary intervention: General use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40890?source=related_link\">",
"      Heparin-induced thrombocytopenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25721?source=related_link\">",
"      The role of the vulnerable plaque in acute coronary syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/23/44408?source=related_link\">",
"      Therapeutic use of fondaparinux",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f4_57_5019="Pacing for SA node dysfunction";
var content_f4_57_5019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F70519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F70519&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Indications for pacing for sinus node dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Pacemaker necessary",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pacemaker probably necessary",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pacemaker not necessary",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic bradycardia",
"       </td>",
"       <td>",
"        Symptomatic patients with sinus node dsfunction with",
"documented rates of &lt;40 bpm without a clear-cut association between",
"significant symptoms and the bradycardia",
"       </td>",
"       <td>",
"        Asymptomatic sinus node dysfunction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic sinus bradycardia due to long-term drug therapy of a type and dose for which there is no accepted alternative",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5019=[""].join("\n");
var outline_f4_57_5019=null;
var title_f4_57_5020="Perpetrator characteristics Munchausen by proxy";
var content_f4_57_5020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52225&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Usual Munchausen syndrome by proxy perpetrator characteristics (not to be considered a profile)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Usually the mother",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Presents initially as a \"normal\" or \"good\" caretaker",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Accomplished liar, deceiver, and manipulator; extremely believable,",
"convincing, and superb in ability to give plausible explanation for his",
"or her behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Knows what he or she is doing; not simply overanxious or overprotective",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May or may not have extensive health care knowledge",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Deny all or part of the maltreatment they have perpetrated, even when",
"there is extensive evidence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May change behavior when they are suspected or caught, but do not",
"usually stop it",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May or may not add or change health care providers",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May or may not have mental health pathology",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May have a personal history of symptom/illness falsification",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Appears to have good, or even excellent, perpetrator-victim dynamics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Often have no prior child protection agency involvement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Should be considered more dangerous once they believe they are suspected",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Use their victims to satisfy their internal needs through the attention",
"they receive from having a child with problems; their needs are much",
"more important",
"to them than the needs of the child; external gain may be present",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May seek attention from professionals and nonprofessionals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May change their",
"maltreatment methods",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Lasher, LJ. MBP overview and definitions. file://www.mbpexpert.com/definition.html.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5020=[""].join("\n");
var outline_f4_57_5020=null;
var title_f4_57_5021="Arterial catheter rapid flush test";
var content_f4_57_5021=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56073&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Arterial catheter rapid flush test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 161px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Intravascular pressure tracings obtained during the rapid flushing of a monitoring catheter. A. Optimal damping in which rapid flushing produces a rapid upstroke in pressure followed by recovery characterized by a fall in pressure to below baseline with less than three beats of ringing. B. Overdamped system in which no ringing is seen. C. Underdamped system in which there is excessive ringing.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Rippe, JM, Irwin, RS, Alpert, JS, Fink, MP (Eds), Intensive Care Medicine, 3rd ed, Little Brown, Boston, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5021=[""].join("\n");
var outline_f4_57_5021=null;
var title_f4_57_5022="Endarterectomy mild stenosis";
var content_f4_57_5022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F65469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F65469&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Carotid endarterectomy is not beneficial for symptomatic patients with a mild stenosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 241px; background-image: url(data:image/gif;base64,R0lGODlh+AHxAOYAAP///4CAgAAAAICZ//+AgAAz//8AAIiIiBEREXd3dzMzM1VVVe7u7qqqqszMzERERCIiIoig//+IiBFB/93d3WZmZv8REaq7/1V3/3eS/zNc/5mZmf9VVcDAwMzW//+qqv93d//AwP8zM//MzLu7uyJO/0Rp/+7x//8iIv9AQP9EREBAQMDN//+goP/u7kBm//9gYGBgYBAQEP8gIP9wcN3k///d3dDQ0PDw8P+wsP9mZmaF//+7u7vJ/6CgoDAwMP9QUP+ZmZmt///w8P8QEP/g4BBA/4CMvyBN//8wMP+QkL+AgFBz///Q0KCz/2CA/9DZ/5Cm/7DA/+Dm/8+AgH8gIAAs34BZv08MP4BwcK8AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAD4AfEAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6err7O3u7/Dx8vP09fb3+Pn6+/z9/v8AAwociKqBgAWEHBw0VUGAAAeRDgg4QFCUQYSNJFJUxkAAgoqLJDo8SAHAxUYnBylEqOBhKBILDy0Q0ACRxnwtP2aaWZNRSkY3gQpIAKCjzlgSiRoFqSipSQQQGED6CWBlKYNEZdK0ORGfQocbdm71GVPoxpBDbzldypRr1gQT/61uQODw40yHDygYVNDyAQOrMx3sbalA6l26PQU5aCkgr9EHAqRWHangq8MDIgUoAEDXIcKg9uASFtTyLkW6EKESmls3s4LBm+FeNkkSAgIHDO5CSAxAo+Wui0f+ZoDgI9wHdBFSgFw88qDHAiAcgLCQAeToNeEuQJAgt8PdKkdG9sgc4t3GejUTlszPae+hK42WLDTzwEm4BwA/NPgAAGTMC/FEiG0MwFSYeOy5p5hHAAg4oAAkgFYPdQ5QCEBLJMBk3FAbdCWIfIMIaJBDCjgFWQMXKXBbgzRREB0hoCn0UUthCeJecQDgx9lD9e3I3lISVQAAdRTwxACBsg3Fk/+LEMCYFpBlsWhfY/552F5aOca1UEOe9UadQwmclJR+gi2EX48OTrZZR+MdNYhTRSLoYJI0SThPh+IR1RJuDCoEAXLsAcBlgFulJCBcYVImSGcjJThRnI3iqRkDN25I0Z6o+fgcg05h6lxLDei4I4JvPsmgmF8OdZ+V+zjVAFR/lUXcQ5yqutB/ZK4KIFEnDohAgZMyWIhTPdLlXVgS9ceTnfL8N9mMD7F1l5CGzBpnWCmZSBN/cAk5U43DTlSsc6QJsEGQi1p64UO9GrvpR53ySNORv4r67SHoLnWRjO8lipCoV460gFQrWYYARXe1lOhIQuZq5kTWeQRqQow5Jqz/k0Q5QJeKkWk8aU6gMguPjJLRuCdbI0IUXmtVbfyTbAfTxpK53tXlZH4bG8uokAwwRpy6ewbH8Y+16hntda9luVHNFxfl86mEambrv6y2JcqRAsxndUFUOgNTk1t7w6ZH4IZtSq/LjKiZyma37fbbcMct99yxsFUMjlrx5ghVbSvIjFV5SwLwPH4nYvcshyuCtyFpLiJilH1j2UviiADO+FiMuDu4PIUjQnkwi9OHueOFQm5258lYLrreiWhe9ToRX4ZgaTSxVh2DzmZ2liBJUqQdd4QkOXCtwyMAGaV1pYUj0w2clxdnbgqafE26v/ddA64NNmk5sXelu7WcNbnB/5dUIwc5nnQRxShCzkLmgO1uxg7e71kVdd1EJ9UHHfIeKf+RA/djWl5UJ73+UW8kCBtJXs6TgOMkpx3dKlVWGDMRzfTLKA2hiFOIJMEqhWok9dvLu94zPOG8yCk46pHoTuMmiSBkWWnhoI2o9Lj+OIscEZwhUYiEnw7lx4IN2YCOMrWgJvmNOiTYi4v84hGthWheSALhIHIoMymNjVZG9N+QVrRC1bmQRdiLYdaeeBrnDNEl66hQXRzgnj31izYHqktJzuOQxBxqKJvr3gGgVLwZfkaL7rJRqtTnJh3xhI7but9mHke13YVDjR5xACIb4CdAZQZMOnKjIMSUFjrVhP86AhoURhb1KZpsDpK3yR/EhPVFFN7Ggm8apOoMSZNJTkeKrrsUGiEogAqga10QUchmkmIUEf4yXLwy5es2GR2jIK+PADDQG1PoIX65EmMePOaOSCBMFmHrYY4cR7e0WaWFdHOKXdFkNC2YlGSB0Xpg+xBdtGakKIaTd70Uof6EJc1r2kZl1oRPlLQVRmo9a5pjzOQu0+E8CvTMIQ9Vme14xqCGCOmSbMuSR3xXtexpFDLQ1KjCoFeU8zSPRFokBHMmhlGRjMZjrwFnORpqPYdAJGWCGB8CFZpR2SjsoQiY2KwoYrDdxS5pm6MpZCDQkj1ezKdaBGCjEibQUQpipVv/wShViSKSBqZzoXQDBWTKFlZb/CwWYy2rNShYP7XaAnWnYKtb50rXutr1rnjNq173yte++vWvgA2sYAdL2MIa9rCITaxiF8vYxjr2sZCNrGQnS9nKDjYCBYgAACYwgVFgNgOWDW0zMlCAAvRAEJjVLGcp4YECaIARnxWtbJNRgtLuALWZ3WxnJ9Ha1y4itrMN7jAu4FrOngAAqdUtADyggdKaoAbLNUFpC3CCCUwXA5ud7gU8IN0CPBcAQiitdUE7CNKawLrYPUF3S3ABQqh3uhEgLnYxkFniauC+AKBvAazbXsyWVrOkxcAEMmBdD2y2BMJNMH0jsGDk5na1JZjA/wl64FoARNjAhahtD3oriAifILw7aC2CgSsI0qq2AB6g7wVO4OHyFuC2gpBvfus7XQ1gdr4FuEBsa1sD0pY2A6TNQHg1m+DZ1mC6pX1tcjnL4ROUlsMu1i6HW4tkDciYxAAwMQCa6wHrHre57RWEB2q7Xw/IeMEynrFmVaxf7Wp5uQUowXmPW2RvUAABJBjEdajl0kAx48YdNu2SO+thCr/2wrg1wYy3G+cOTwC6gjC0g8lb4txyWcUslrAhSLsD+6o5zbGVro5fTIg3z5jUo7hznq/qED6TyM91JoVIVj0dBtyZki5RQFuZUdswc3rQy22ud6HL3emeoLkTAPOpt//b3QJg18fNpXSWLY3i97o2zIJo83elW4LmxtfZgnhvsnPs4Ol6wNTERfEoZi1IWyMA1xDRdaxVASFBLCArD8DMZnrTn8OyuACQXgRxFV2KejcI3/q2Ub/nfQqD5/uqvuz3dAzRgSMM4OIYz7jGN85xjkeBBSyAQjmckHEWRMLJ4hWCI0RtCodv5AERFyTFO8BwUBj83ldNOL8NEQAsXKHjQA86x5nwghcYobRGKDoThM70pjv96VBvOhKQgPEXDMAZN0f4AfZ9gIUP4ghHqPknDF7rWysk3rsGQACqMANUQAHkUYi63OdOd7o7gRAXxzqto2L2XKc972LfRGaotef/GW6vEAEIwAxgEIK2AV4Zg2d1Lw1fGEMM4AmBn0Xic5CCFBCABi3Y2uPDcQQrIMHkzwC2KLDMj8QDIAQE+LwBQt+WAVi97hxHPTGWsIQnXD0ZPj6tg1W7W0lAWRGs34frCdGC2beFBbjvuO6HEXvbD2D6xCAzjFVv/Ar/tgDSbn0ADNF82mf+E7GHvtWPYV/jDl+5zHUusZtd3etmt7TMlj94xQv+UnsXvQBgbezlXs32bTj2bff1WvrFX+WWWwE2YAV2YMCwfIUAAzBwfqBABUQwBAAwesOwYA0GbIVWYYiWYaYFZR4GYiI2af53YimWY5lGZ9MGYwBwZjSWZICm/2I7BnA+Bn5BNmQTOH7k53zTIAEGIAEAYAEWMApGCALsEABaAAQdeHvRt3HYFwpHVmXvx2QVhnLHN21SVmFUVmNX1n8upllc5mVbRm5iRmYTYGbghmbgpmaL1mb492YiNmdBiAjNRwOx94eA+Hk5EAwgYAAGwAOCYIRIqISUMAIGIAKM0IRPmAVEkAPQV4Ubt36lAGgWJmgPRmgSJmkliFmKpmIraGGPNgiShmVadmkw2GKFwGmeJofYxYKihlk0OG1Edmq52AsUSH5+GIiBSARAwIG+gAKGqAOJeIRJuIST4IiQuAiSuA6JpwQX+AkeGAq9Vmk7AGzxN2zRZWzIpv9s+pV/pfVsSWaGlYaG1dZdVkYI2gZd3OZtaSZuyuZfT4ZuTxYMvygJQwAERCCMgAh6svABj6iELgAAitiMADACImCIKmADDakChmgALmABFckBSViRHzACFGkAEQkAQWCIGOmEhuACH3mEBqmRHKCSjygCkNiSBoCRH6CQFYmEhcgBFgACGDkCSYgCupB4IZAEoGB91xcQ/xZwijBwwtCPk5ADwSiQBDADM2B+rdCSEoCVNrmIS4gCFuACPPCIAOCVPlkIyMgD0CgIXukCI6kDjgiU01gIhaiMgrCSAICVBmmIImCELGkAHyCJyGgDhWiIIFCIIDCSSJgLrmcAoHD/iZrIDyi3XyrXCCzHj0I4ClNpCCEQAi1AkKNgAxWpl1vZjGnpAoaYloMwmIbYkWLpiKEpAnYZl4QwAsg4kyNgl3hpABp5l8zYkh8gkxxZiIn5lirwlUE5fknQeKFglJhId1e4V04JCovXeTNgiDPQeTRAhKHAl2p5iAvJiGsZlpBIlsuoArzJmkA5lhYgkYIgnjZpkogwlwYZky65m5JIkX9pAHQpCMI5CDK5n7jgejAABH+onJxwic05d4/pV9H5CTlAAC2wmUMYjJtZoQZ6CchYkwAwl9+5hA4JkRLpkRXpAg9pAQ9ZkzLZkSmpkYP5kPBJCMAZkhSJAg8pAXYJ/wAoOZMnapMVOQL9WZenuQuuB3uxlwLXyAzZCJ2X+Qqd+Xmd96RJEJqG+KRP+oeDmA0uEJiNYJDmKaRL+nop4AxJqlcNmgtDYKEh8KAEAANtZw2mSZJB4Aj4yQv9WASM2QzMWXJ5VabCsHhSKZVXWlZOaQBF0AwImnELWld8Ggxq+qeByKZu5ZQpcKHRMKZqtajS4KeOuqmc2qme+qmASKmWaQgw4Hmiiqe/d1cBsAKJR3PZ0KigGquyOqtSeaq/sKqtOgiw53nTkKe4JwUsMAUCgasB4KoYOArEaqyCQACe56iBSgyHGn1Fd3RJR4VP95zkgKnHugkNSqR/mp1WKf8OU8ACUhB1iWoO2rqtmZCuh9CHnWqr42Cp4sCu6moJ9GoIsPqnvKoO8hoO91qvk/CvksCsBACv4NCv4CCwAAsJCgsJsAep6ICw39CwC9sIFBsJmmqw2+CrVYitxXCxFasIIPsIRAqx4xCtmOixxDCyIXsILIuxjFeosNChTGgAL+oOL9uyhJCzJFuqUwoD4SoKg4mIo8mIzyiW0miz8sCzOqt2X6oKRQB7VEmrBeoItUmXNHu00agIsomzT9u0l8C0ldACVEuwW3qQxkmzHwqSIZqSF5mRG7maIsq2IkmSSnuSKWmjusmbeguT9DmTfsmjzJiTO9mTP7mHYMutX0v/fQTQCFiplTQbnmJJnmZ5iKi5lm35lu95CHM5CLjpknrJnb4JmAYgmBVZmDaLmIibuOu6uMIQe4wAmq9ZtBZQmqeJtPwZmqwJia5ZkbC5t10rCLRJkre5t7m5m1rpm8C5mj9KnMZ5q67LupEgtqvQAm3KtXs7lt7JjOD5le5JuUZonr6puerJngDgnsFLCPIplse7jE6In0YIoD/Km/o5qtKLCdS7CpoqjMqZobmrA2r7kHQ7txZZojuaogTMonp5t4UQoxI5ozV6ozlqooFrhD06v3lZltB7v/gbvcHgrY8qhdGQpaV7tl26uhxMCfk7C0NgAMbIDG86k3HaCHP6/woUwBhZ0Wc858FNe8NgQnmwtsKzAAQwUKtmswDKsRtndyFpJ8TBhcQAQAFK7Hc7XA0gDIgDajYKgBH3tnUKV8UpPAhbbG8J4MU7h3g8LA0t/MJtQQJfwh1dJ3OIx6rFGsZuXBdlLHHxNAjJyg1ELKsamw0kMB+DLAkHY8ZxPMe5GsaDcMhc53WC0MfbcMWdmgI0QA7yliP79giAssSZvLNpDLadTMVoLA85YADP2g0koCJMpSKbvAgusjZADMaMHMuVMculLA9+GA5qUxdkpbiMrMKhXA4EW7ahagwM4EsMAGuc4MT16szOQMlUu6/UOMzBDMpvU8yxqgRNIAuU0v9AZQwK0Lyt44wOBGAAUfmpAEmMgRjInnA/sOQJ5YyB82wOEFoJTaAEgEjNptARr4EiqybP1nzNkTzQdQW7qfDJoVDPmcfQAaHN7pwJFQAB4HxPrUvQ02vQdAXCEY0JFBTPneDQYifShRUhKIIi4qzRwUzShCUSDaAABhXSKs3ILD1YTLUbCfDKzTzTYVzTgdURL90AFaDTwIzRj+DTgQUBQ50ACBDTO23UR83TwiUpCOBETw3VFivVwkUCZWzVV43Vi4DUgJUA/bEYv6wJYp1gae1XMdMgRI3WWn2/a81XQM07b72udKysYK3IdbywfLEBc+HU3JrXe40IkgywVO3/1XBd2CIb17PlAF290I7NunPNVxUg2ALN2IlQ2Xu1AHf91ZqdyyF7ANzRQBbdwaHtspMdWh/92WG72mDL2XqVRCcd0DKd2rQcsnrBAA3AzBeN29jcsi4N0ykN3MEdsjcdKq5tr7DdtLKNV0D9GkNd3MZd0Dqr1LrW1NRd3c+NV4m93cbd3XjF1Qeg2Itd3U7bshugAA/AOreN3uJNVzAhHKIQ35Nl327F1IANPJKN3uldsTm9zLrm24fgw40hFTos2mFs4H5hPZWn4PVKJyTiCDkdxQiwAZ7cxM0daxV+ZxhOyscNsBIO0oowPhtAHGz0yLmdwiaO4ogMyf9dscs8/+MEbgg3XAEI8Bl6zHOEncI3nuNnPHF8rdfXjHP+UcYqPuRhbOQPgORfrORQ7dlOkwAZvuIcLOU9Q+Ugzscbfn4MjuCvZuX3++UOHsRdLtdnXrH4LVtrDlltHlpv7lhxXllzzlh1ft9pvrB3Lll7nlh97uZ5DrB//liDbliF3liHTliJvliLLliN7ueB/syR7tyTTs6V3rKPDliZflibzqCXHrKd3lehruiffn6jPlinTqalrudCiAM+QOR7vXyuDuvAnXg3EAMy8AO0jtW2juu67t+CgAO4LgMxcAPALewyQOzGDuy3nus+gAPA3ew/8OzADgAd8APKbtzXnu3VLv8IHUDthTDrhf3t0B7ur97tgiDtuw7W6l7tro7txX7sPgDvy+7fzU7s5Z7a9x4D+Y7e217sqU5X/34DAb9X5G7dqX3wMY7uC1/rqy7oDz/SEa+uBa+qE2/p/l3xnp7xF3+sGq+oHU/PIV9nH89XJT9XJ6/qHM/wXL7yLN/wtNAB6w4LMp8LNT8Mz33zt6DztsDzyCDbzw30Iy8JQT/0Yi4Lh06sibf0TN/0Tv/0UB/1Ur+qdDz1Vn/1WO/0K1D1Wd/1Xq/1Rs+wXP/1ZO/1W1/2aN/1Z5/2bD/1Wz/zEzj2bT/3dF/3dn/3Vw/3ASr3eN/3fv/3gG/1eu8LPo/bhf//8oif+Iq/+Izf+I7/+JA/W4V3C2SNC8ExebUw310DDJNP+TAeC5eP2a+g+Z8vDGX3braAF7ggRJORUbRwa8Bw+u4NC6pvC6y/xLcA+8fA5KftComcCx3h+rOgEOaNC7yPC79/C8Fv+WN0DA/nH6L/Csl/C02OC9TR+9T/ctEv/aUvC9V/C9efDMf/Vt0PCz2z/eYPAWedC+NP/rhw/rpwJOsf+3yH+u5/CyRw4bjgSxYOCAcAg4SFhoeIiYqLigcQDBQIDYyUlZaHBw+Xm5yIJAgbnaKiFYKRgqOpqooPAgIVq7GJrq4UsreEFbSvuLcbEK4LvcOsrrDEsru2yKm6/7THzKK/wdHV1tfY2drb3N3e3+Dh4uPk5ebn6Onq6+zt7u/w8fLz9PX29/j5+vv8/f7/AAMKHEiwoMGDCBMqXMiwocOHECNKnEixosWLGOMdEKBgELBQGUNWYwBs0saOIlNqUyDgwEZNKmP22iAAAgVgJGTqZEZCAIKfthy0EvDAFgJawhpwVKDAAUtXDnbKbHX02EZXgq7WnMRygYAGCZBKHZsLq0cEDGhCA4BTqSumAkCSVRmpJgMAGxOwFbAML1EAT79ynEuYgs9BDnYNDkurgVJhAGi+vUs4pC5UXnc5HjqYZVQGnFFVlsng8Nm+LwF4dSwAMiGWckdbDItq43TaoyQSd/RcSCkE2aRNAxCKlAFLBCxZQz5qDDhG2oS0CnBwleXu6X7fTnLOvbv37+DDix9Pvrz58+jTq1/Pvr379/Djy59Pv779+/jz69/Pv7///wAGKOCABBZo4IEIJqjgggw26OCDEEYo4YQUVmjhhaIEAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The European Carotid Surgical Trial included 374 patients with a prior stroke, TIA, or retinal infarct who had a mild (0 to 29 percent) carotid stenosis. The incidence of disabling or fatal stroke or surgical death (left panel) or of any stroke that lasted more than seven days or surgical death (right panel) were higher in patients who had carotid endarterectomy compared to those on medical therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from European Carotid Surgery Trialist Collaborative Group. Lancet 1991; 337:1235.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5022=[""].join("\n");
var outline_f4_57_5022=null;
var title_f4_57_5023="AIDS case deaths 1985 2006";
var content_f4_57_5023=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F58099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F58099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 516px\">",
"   <div class=\"ttl\">",
"    Estimated number of AIDS cases and AIDS-related deaths among adults and adolescents in the United States and dependent areas, 1985-2006",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 496px; height: 330px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The upper curve represents estimated AIDS incidence (number of new cases); the lower one represents the estimated number of deaths of adults and adolescents with AIDS. The peak in 1993 was associated with the expansion of the AIDS surveillance case definition implemented in January 1993. The overall declines in new AIDS cases and deaths of persons with AIDS are due in part to the success of highly active antiretroviral therapies, introduced in 1996.",
"    <br>",
"     In recent years, AIDS incidence and deaths of persons with AIDS have leveled. The data have been adjusted for reporting delays.",
"     <br>",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Divisions of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. file://www.cdc.gov/hiv/topics/surveillance/resources/slides/epidemiology/index.htm.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f4_57_5023=[""].join("\n");
var outline_f4_57_5023=null;
